Bausch Health Companies (BHC) 10-Q 24 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 21, 2014
Document and Entity Information	'	'
Entity Registrant Name	'Valeant Pharmaceuticals International, Inc.	'
Entity Central Index Key	'0000885590	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	335,672,637

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$808.80	$600.30
Trade receivables, net	1,880.20	1,676.40
Inventories, net	932.7	883
Prepaid expenses and other current assets	465.6	343.4
Assets held for sale	10	15.9
Deferred tax assets, net	316.4	366.9
Total current assets	4,413.70	3,885.90
Property, plant and equipment, net	1,300.40	1,234.20
Intangible assets, net	11,620.40	12,848.20
Goodwill	9,467.80	9,752.10
Deferred tax assets, net	23.9	54.9
Other long-term assets, net	233.4	195.5
Total assets	27,059.60	27,970.80
Current liabilities:	'	'
Accounts payable	323.3	327
Accrued and other current liabilities	1,993.90	1,800.20
Acquisition-related contingent consideration	116.5	114.5
Current portion of long-term debt	690.6	204.8
Deferred tax liabilities, net	19	66
Total current liabilities	3,143.30	2,512.50
Acquisition-related contingent consideration	211.3	241.3
Long-term debt	15,584.30	17,162.90
Pension and other benefit liabilities	157.7	172
Liabilities for uncertain tax positions	113.8	169.1
Deferred tax liabilities, net	2,407	2,319.20
Other long-term liabilities	208.6	160.5
Total liabilities	21,826	22,737.50
Equity	'	'
Common shares, no par value, unlimited shares authorized, 334,004,879 and 333,036,637 issued and outstanding at September 30, 2014 and December 31, 2013, respectively	8,334.40	8,301.20
Additional paid-in capital	240.2	228.8
Accumulated deficit	-2,899.90	-3,278.50
Accumulated other comprehensive loss	-552	-132.8
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,122.70	5,118.70
Noncontrolling interest	110.9	114.6
Total equity	5,233.60	5,233.30
Total liabilities and equity	$27,059.60	$27,970.80

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Common shares, no par value (in dollars per share)	'	'
Common stock, shares issued	334,004,879	333,036,637
Common stock, shares outstanding	334,004,879	333,036,637

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (LOSS) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	'	'	'	'
Product sales	$2,022.90	$1,506.40	$5,868.10	$3,608.80
Other revenues	33.3	35.3	115.4	97
Total revenues	2,056.20	1,541.70	5,983.50	3,705.80
Expenses	'	'	'	'
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	545.8	560.8	1,619.50	1,128.90
Cost of other revenues	15	14.4	45.3	44.3
Selling, general and administrative	504.1	355.7	1,501.80	854.9
Research and development	59.1	49	186.9	97.3
Amortization and impairments of finite-lived intangible assets (see Note 9)	393.1	910.2	1,113.90	1,540
Restructuring, integration and other costs	61.7	243.1	337.4	345.7
In-process research and development impairments and other charges	19.9	124	40.3	128.8
Acquisition-related costs	1.6	8.6	3.7	24.4
Acquisition-related contingent consideration	4	-35	14.8	-33.5
Other (income) expense	-232	202.4	-275.7	208
Total expenses	1,372.30	2,433.20	4,587.90	4,338.80
Operating income (loss)	683.9	-891.5	1,395.60	-633
Interest income	0.8	2.8	3.8	5.4
Interest expense	-258.4	-249.3	-746.1	-581.4
Loss on extinguishment of debt	0	-8.2	-93.7	-29.6
Foreign exchange and other	-53	5.1	-63	-3.5
Gain on investments, net	3.4	0	5.9	5.8
Income (loss) before provision for (recovery of) income taxes	376.7	-1,141.10	502.5	-1,236.30
Provision for (recovery of) income taxes	100.3	-169.2	124.4	-247.7
Net income (loss)	276.4	-971.9	378.1	-988.6
Less: Net income (loss) attributable to noncontrolling interest	1	1.3	-0.5	1.3
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$275.40	($973.20)	$378.60	($989.90)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:	'	'	'	'
Basic (in dollars per share)	$0.82	($2.92)	$1.13	($3.13)
Diluted (in dollars per share)	$0.81	($2.92)	$1.11	($3.13)
Weighted-average common shares	'	'	'	'
Basic (in shares)	335.4	333.6	335.2	316.5
Diluted (in shares)	341.3	333.6	341.4	316.5

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income (loss)	$276.40	($971.90)	$378.10	($988.60)
Other comprehensive (loss) income	'	'	'	'
Foreign currency translation adjustment	-446.8	183	-440.4	-41.1
Unrealized gain on equity method investment, net of tax	4	0	22.5	0
Net unrealized holding (loss) gain on available-for-sale equity securities:	'	'	'	'
Arising in period	-0.9	0	1.8	3.6
Reclassification to net income (loss)	-1.8	0	-1.8	-4
Pension and postretirement benefit plan adjustments	-0.6	0	-1.8	0
Other comprehensive (loss) income	-446.1	183	-419.7	-41.5
Comprehensive loss	-169.7	-788.9	-41.6	-1,030.10
Less: Comprehensive income (loss) attributable to noncontrolling interest	2.2	0.7	-1	0.7
Comprehensive loss attributable to Valeant Pharmaceuticals International, Inc.	($171.90)	($789.60)	($40.60)	($1,030.80)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities	'	'	'	'
Net income (loss)	$276.40	($971.90)	$378.10	($988.60)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'	'	'
Depreciation and amortization, including impairments of finite-lived intangible assets	439.3	946	1,248.10	1,605.30
Amortization and write-off of debt discounts and debt issuance costs	34.6	27.6	58.1	70.5
In-process research and development impairments	19.9	124	20.3	128.8
Acquisition accounting adjustment on inventory sold	12.4	149.4	21.9	219.2
(Gain) loss on disposal of assets, net	-254.5	0.6	-254.5	0.6
Acquisition-related contingent consideration	4	-35	14.8	-33.5
Allowances for losses on accounts receivable and inventories	12	16.1	47.6	36.7
Deferred income taxes	74.6	-185.6	63.2	-286.2
(Reduction) additions to accrued legal settlements	-0.9	149.6	-48.2	155.2
Payments of accrued legal settlements	-0.2	-0.2	-1.2	-14.7
Share-based compensation	20.2	16	60.6	32.5
Tax benefits from stock options exercised	-15.9	-32.2	-17.1	-48.6
Foreign exchange loss (gain)	55.1	-5.4	62.4	3.4
Loss on extinguishment of debt	0	8.2	93.7	29.6
Payment of accreted interest on contingent consideration	-1.3	-3.3	-9.5	-6.2
Other	9.7	-4.9	15.8	-13.5
Changes in operating assets and liabilities:	'	'	'	'
Trade receivables	-121.4	54.8	-205.2	-106.2
Inventories	-41.5	-46.2	-122.8	-105.1
Prepaid expenses and other current assets	5.5	48	34.5	80.2
Accounts payable, accrued and other liabilities	90.7	-53.9	18.4	2.7
Net cash provided by operating activities	618.7	201.7	1,479	762.1
Cash Flows From Investing Activities	'	'	'	'
Acquisition of businesses, net of cash acquired	-606.8	-4,439.40	-981.1	-5,190.40
Acquisition of intangible assets and other assets	-74.3	-4.9	-105.8	-38.1
Purchases of property, plant and equipment	-39.6	-24.9	-211.2	-51.7
Proceeds from sales and maturities of marketable securities	0	0	0	17
Purchase of equity method investment	0	0	-75.9	0
Proceeds from sale of assets and businesses, net of costs to sell	1,477	0	1,479.80	27.4
Net cash provided by (used in) investing activities	756.3	-4,469.20	105.8	-5,235.80
Cash Flows From Financing Activities	'	'	'	'
Issuance of long-term debt, net of discount	555	7,165.10	965.6	7,505.10
Repayments of long-term debt	-1,629.80	-4,781.10	-2,184	-5,385.80
Short-term debt borrowings	6.1	4.8	12.5	23.4
Short-term debt repayments	-6	-25.2	-19.2	-37.5
Issuance of common stock, net	0	-1.3	0	2,269.90
Repurchases of common shares	0	0	0	-55.6
Settlement of stock options	0	0	-3.1	0
Proceeds from exercise of stock options	3.8	2.5	10.9	7.1
Tax benefits from stock options exercised	15.9	32.2	17.1	48.6
Payments of employee withholding tax upon vesting of share-based awards	-2	-14.4	-38.5	-35.9
Payments of contingent consideration	-14.4	-15.2	-96.6	-98.1
Payments of debt issuance costs	-10.2	-46.9	-21	-80.5
Other	-0.5	-2.1	-5.1	-2.1
Net cash (used in) provided by financing activities	-1,082.10	2,318.40	-1,361.40	4,158.60
Effect of exchange rate changes on cash and cash equivalents	-15.3	6	-14.9	-4.7
Net increase (decrease) in cash and cash equivalents	277.6	-1,943.10	208.5	-319.8
Cash and cash equivalents, beginning of period	531.2	2,539.40	600.3	916.1
Cash and cash equivalents, end of period	808.8	596.3	808.8	596.3
Non-Cash Investing and Financing Activities	'	'	'	'
Acquisition of businesses, contingent consideration obligations at fair value	-16	0	-65.1	-67.4
Acquisition of businesses, debt assumed	($4.50)	($4,222.10)	($8.50)	($4,264.70)

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
DESCRIPTION OF BUSINESS	'
	DESCRIPTION OF BUSINESS
	The Company is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.
	On August 5, 2013, the Company acquired Bausch & Lomb Holdings Incorporated (“B&L”), pursuant to an Agreement and Plan of Merger, as amended (the “Merger Agreement”) dated May 24, 2013, with B&L surviving as a wholly-owned subsidiary of Valeant Pharmaceuticals International (“Valeant”), a wholly-owned subsidiary of the Company (the “B&L Acquisition”).
	For further information regarding the B&L Acquisition, see note 3 titled “BUSINESS COMBINATIONS”.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying unaudited consolidated financial statements (the “unaudited consolidated financial statements”) have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Form 10-K”). The unaudited consolidated financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2013, except as described below under “Adoption of New Accounting Standards”. The unaudited consolidated financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented.
	Reclassifications
	Certain reclassifications have been made to prior year amounts to conform with the current year presentation. Such amounts include a reclassification of $52.8 million recognized in the third quarter of 2013 related to B&L's previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees from Restructuring, integration and other costs to Other (income) expense on the consolidated statement of income (loss) for the three-month and nine-month periods ended September 30, 2013. This reclassification had no effect on the Company’s previously reported results of operations, financial position or cash flow.
	Use of Estimates
	In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.
	On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.
	Adoption of New Accounting Standards
	In July 2013, the Financial Accounting Standard Board (“FASB”) issued guidance to eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits are netted against all available same-jurisdiction loss or other tax carryforward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. The guidance was effective for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance did not have a material impact on the Company’s financial position or results of operations.
	In April 2014, the FASB issued guidance which changes the criteria for reporting a discontinued operation while enhancing disclosures in this area. Under the new guidance, a disposal of a component of an entity or group of components of an entity that represents a strategic shift that has, or will have, a major effect on operations and financial results is a discontinued operation when any of the following occurs: (i) it meets the criteria to be classified as held for sale, (ii) it is disposed of by sale, or (iii) it is disposed of other than by sale. Also, a business that, on acquisition, meets the criteria to be classified as held for sale is reported in discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations, as well as disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation. The Company early adopted this guidance in the second quarter of 2014, and the Company applied this guidance to the divestitures described in note 4 titled “DIVESTITURES”.
	Patient Protection and Affordable Care Act - Annual Pharmaceutical Fee
	In July 2014, the Internal Revenue Service issued final regulations related to the branded pharmaceutical drug annual fee pursuant to the Patient Protection and Affordable Care Act. Under the final regulations, an entity’s obligation to pay the annual fee is triggered by qualifying sales in the current year, rather than the liability being triggered upon the first qualifying sale of the following year. The Company adopted this guidance in the third quarter of 2014, and it did not have a material impact on the Company’s financial position or results of operations.
	Recently Issued Accounting Standards, Not Adopted as of September 30, 2014
	In May 2014, the FASB and the International Accounting Standards Board issued converged guidance on recognizing revenue from contracts with customers. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue model to contracts within its scope, an entity will: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition to these provisions, the new standard provides implementation guidance on several other topics, including the accounting for certain revenue-related costs, as well as enhanced disclosure requirements. The new guidance requires entities to disclose both quantitative and qualitative information that enables users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early application is not permitted. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In August 2014, the FASB issued guidance which requires management to assess an entity’s ability to continue as a going concern and to provide related disclosures in certain circumstances. Under the new guidance, disclosures are required when conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year from the financial statement issuance date. The guidance is effective for annual periods ending after December 15, 2016, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance will not have any impact on the Company’s financial position and results of operations and, as this time, the Company does not expect any impact on its disclosures.

BUSINESS_COMBINATIONS

BUSINESS COMBINATIONS	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
BUSINESS COMBINATIONS	'
	BUSINESS COMBINATIONS
	The Company’s business strategy involves selective acquisitions with a focus on core geographies and therapeutic classes.
	(a) Business combinations in 2014 included the following:
	In the nine-month period ended September 30, 2014, the Company completed business combinations, which included the acquisition of the following businesses, for an aggregate purchase price of $1,046.6 million. The aggregate purchase price included contingent consideration payment obligations with an aggregate acquisition date fair value of $65.1 million.
	•	On July 7, 2014, the Company acquired all of the outstanding common stock of PreCision Dermatology, Inc. (“PreCision”) for an aggregate purchase price of $454.5 million. The Company may also pay contingent consideration of $25.0 million upon the achievement of a sales-based milestone for 2014. The fair value of this contingent consideration was determined to be nominal as of the acquisition date, based on the current sales forecast. The Company recognized a post-combination expense of $20.4 million within Other (income) expense in the third quarter of 2014 related to the acceleration of unvested stock options for PreCision employees. In connection with the acquisition of PreCision, the Company was required by the Federal Trade Commission (“FTC”) to divest the rights to PreCision’s Tretin-X® (tretinoin) cream product and PreCision’s generic tretinoin gel and cream products. For further details, see note 4 titled “DIVESTITURES”. PreCision develops and markets a range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis with products such as Locoid® and Clindagel®.
	•	On January 23, 2014, the Company acquired all of the outstanding common stock of Solta Medical, Inc. (“Solta Medical”) for $292.5 million, which includes $2.92 per share in cash and $44.2 million for the repayment of Solta Medical’s long-term debt, including accrued interest. In connection with the acquisition, the Company recognized a charge of $5.6 million in the first quarter of 2014 relating to a settlement of a pre-existing relationship with Solta Medical, which is included in Other (income) expense in the consolidated statements of income (loss). Solta Medical designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications. Solta Medical’s products include the Thermage CPT® system that provides non-invasive treatment options using radiofrequency energy for skin tightening, the Fraxel® repair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, the Clear + Brilliant® system to improve skin texture and help prevent the signs of aging skin, and the Liposonix® system that destroys unwanted fat cells resulting in waist circumference reduction.
	•	During the nine-month period ended September 30, 2014, the Company completed other smaller acquisitions which are not material individually or in the aggregate. These acquisitions are included in the aggregated amounts presented below.
	Assets Acquired and Liabilities Assumed
	These transactions have been accounted for as business combinations under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates. Due to the timing of the PreCision acquisition, all such amounts are provisional and subject to change. The following recognized amounts related to the Solta Medical acquisition, as well as certain smaller acquisitions, are provisional and subject to change:
	•	amounts for intangible assets, property and equipment, inventories, receivables and other working capital adjustments pending finalization of the valuation;
	•	amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and
	•	amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.
	The Company will finalize these amounts as it obtains the information necessary to complete the measurement processes. Any changes resulting from facts and circumstances that existed as of the acquisition dates may result in retrospective adjustments to the provisional amounts recognized at the acquisition dates. These changes could be significant. The Company will finalize these amounts no later than one year from the respective acquisition dates.
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Dates				Adjustments(a)				30-Sep-14
											(as adjusted)
	Cash and cash equivalents		$	18.3			$	—			$	18.3
	Accounts receivable(b)		57.1				0.2				57.3
	Assets held for sale(c)		125.7				—				125.7
	Inventories		87				(10.0		)		77
	Other current assets		17				(0.8		)		16.2
	Property, plant and equipment, net		37.3				(0.7		)		36.6
	Identifiable intangible assets, excluding acquired IPR&D(d)		590.3				15				605.3
	Acquired IPR&D(e)		65.8				0.8				66.6
	Other non-current assets		3.4				—				3.4
	Current liabilities		(129.3		)		(10.5		)		(139.8		)
	Long-term debt, including current portion		(8.5		)		—				(8.5		)
	Deferred income taxes, net		(112.0		)		(4.7		)		(116.7		)
	Other non-current liabilities		(12.8		)		(3.1		)		(15.9		)
	Total identifiable net assets		739.3				(13.8		)		725.5
	Goodwill(f)		315				6.1				321.1
	Total fair value of consideration transferred		$	1,054.30			$	(7.7	)		$	1,046.60
	________________________
	(a)	The measurement period adjustments primarily relate to the Solta Medical acquisition and reflect: (i) increases in the estimated fair value of intangible assets, (ii) reductions in the estimated fair value of inventory, and (iii) the tax impact of pre-tax measurement period adjustments. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
	(b)	The fair value of trade accounts receivable acquired was $57.3 million, with the gross contractual amount being $61.7 million, of which the Company expects that $4.4 million will be uncollectible.
	(c)	Assets held for sale relate to the divestitures of the Tretin-X® product rights and the product rights for the generic tretinoin gel and cream products acquired in the PreCision acquisition. See note 4 titled “DIVESTITURES” for further information.
	(d)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				30-Sep-14
			(Years)										(as adjusted)
	Product brands		10		$	468.4			$	14.2			$	482.6
	Product rights		8		95.2				(0.9		)		94.3
	Corporate brand		15		25.2				1.6				26.8
	In-licensed products		8		1.5				0.1				1.6
	Total identifiable intangible assets acquired		10		$	590.3			$	15			$	605.3
	(e)	The acquired in-process research and development (“IPR&D”) assets primarily relate to programs from smaller acquisitions. In addition, the Solta Medical acquisition includes a program for the development of a next generation Thermage® product.
	(f)	The goodwill relates primarily to the PreCision and Solta Medical acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is not expected to be deductible for tax purposes. The goodwill recorded from the PreCision and Solta Medical acquisitions represents the following:
	•	cost savings, operating synergies and other benefits expected to result from combining the operations of PreCision and Solta Medical with those of the Company;
	•	the Company’s expectation to develop and market new products and technology; and
	•	intangible assets that do not qualify for separate recognition (for instance, Precision’s and Solta Medical’s assembled workforce).
	The provisional amount of goodwill from the PreCision acquisition has been allocated to the Company’s Developed Markets segment ($181.3 million). The provisional amount of goodwill from the Solta Medical acquisition has been allocated to both the Company’s Developed Markets segment ($64.4 million) and Emerging Markets segment ($42.9 million).
	Acquisition-Related Costs
	The Company has incurred to date $4.2 million, in the aggregate, of transaction costs directly related to business combinations which closed in 2014, which includes expenditures for advisory, legal, valuation, accounting and other similar services. These costs have been expensed as acquisition-related costs.
	Revenue and Net Loss
	The revenues of these business combinations for the period from the respective acquisition dates to September 30, 2014 were $133.0 million, in the aggregate, and net loss was $44.4 million, in the aggregate. The net loss includes the effects of the acquisition accounting adjustments and acquisition-related costs.
	(b) Business combinations in 2013 included the following:
	B&L
	Description of the Transaction
	On August 5, 2013, the Company acquired B&L, pursuant to the Merger Agreement dated May 24, 2013 (as amended), among the Company, Valeant, Stratos Merger Corp., a Delaware corporation and wholly-owned subsidiary of Valeant (“Merger Sub”), and B&L. Pursuant to the terms and conditions set forth in the Merger Agreement, B&L became a wholly-owned subsidiary of Valeant. At the effective time of this merger, each share of B&L common stock, par value $0.01 per share, issued and outstanding immediately prior to such effective time, other than any dissenting shares and any shares held by B&L, Valeant, Merger Sub or any of their subsidiaries, was converted into the right to receive its pro rata share (the “Per Share Merger Consideration”), without interest, of an aggregate purchase price equal to $8.7 billion minus B&L’s existing indebtedness for borrowed money (which was paid off by Valeant in accordance with the terms of the Merger Agreement) and related fees and costs, minus certain of B&L’s transaction expenses, minus certain payments with respect to certain cancelled B&L performance-based options (which were not outstanding immediately prior to such effective time), plus the aggregate exercise price applicable to B&L’s outstanding options immediately prior to such effective time, and plus certain cash amounts, all as further described in the Merger Agreement. The B&L Acquisition was financed with debt and equity issuances. Each B&L restricted share and stock option, whether vested or unvested, that was outstanding immediately prior to such effective time, was cancelled and converted into the right to receive the Per Share Merger Consideration in the case of restricted shares or, in the case of stock options, the excess, if any, of the Per Share Merger Consideration over the exercise price of such stock option.
	B&L is a global eye health company that focuses primarily on the development, manufacture and marketing of eye health products, including contact lenses, contact lens care solutions, ophthalmic pharmaceuticals and ophthalmic surgical products.
	Fair Value of Consideration Transferred
The following table indicates the consideration transferred to effect the B&L Acquisition:
		Fair Value
Enterprise value		$	8,700.00
Adjusted for the following:
B&L’s outstanding debt, including accrued interest		(4,248.3		)
B&L’s company expenses		(6.4		)
Payment in B&L’s performance-based option(a)		(48.5		)
Payment for B&L’s cash balance(b)		149
Additional cash payment(b)		75
Other		(3.2		)
Equity purchase price		4,617.60
Less: Cash consideration paid for B&L’s unvested stock options(c)		(4.3		)
Total fair value of consideration transferred		$	4,613.30
___________________________________
(a)	The cash consideration paid for previously cancelled B&L’s performance-based options was recognized as a post-combination expense within Other (income) expense in the third quarter of 2013.
(b)	As defined in the Merger Agreement.
(c)	The cash consideration paid for B&L stock options and restricted stock attributable to pre-combination services has been included as a component of purchase price. The remaining $4.3 million balance related to the acceleration of unvested stock options for B&L employees was recognized as a post-combination expense within Other (income) expense in the third quarter of 2013.
Assets Acquired and Liabilities Assumed
The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of acquisition date.
		Amounts				Measurement				Amounts
		Recognized as of				Period				Recognized as of
		Acquisition Date				Adjustments(b)				30-Sep-14
		(as previously								(as adjusted)
		reported)(a)
Cash and cash equivalents		$	209.5			$	(31.4	)		$	178.1
Accounts receivable(c)		547.9				(7.2		)		540.7
Inventories(d)		675.8				(34.0		)		641.8
Other current assets(e)		146.6				0.3				146.9
Property, plant and equipment, net(f)		761.4				33.2				794.6
Identifiable intangible assets, excluding acquired IPR&D(g)		4,316.10				17.3				4,333.40
Acquired IPR&D(h)		398.1				17				415.1
Other non-current assets		58.8				(1.9		)		56.9
Current liabilities(i)		(885.6		)		2.1				(883.5		)
Long-term debt, including current portion(j)		(4,209.9		)		—				(4,209.9		)
Deferred income taxes, net(k)		(1,410.9		)		36				(1,374.9		)
Other non-current liabilities(l)		(280.2		)		(1.0		)		(281.2		)
Total identifiable net assets		327.6				30.4				358
Noncontrolling interest(m)		(102.3		)		(0.4		)		(102.7		)
Goodwill(n)		4,388.00				(30.0		)		4,358.00
Total fair value of consideration transferred		$	4,613.30			$	—			$	4,613.30
________________________
(a)	As previously reported in the 2013 Form 10-K.
(b)	The measurement period adjustments primarily reflect: (i) a decrease in the net deferred tax liability, (ii) a reduction in the estimated fair value of inventory, (iii) an increase in the estimated fair value of property, plant and equipment mainly related to certain machinery and equipment in Western Europe and the U.S., partially offset by a reduction in the estimated fair value related to certain manufacturing facilities and an office building, (iv) an adjustment between cash and accounts payable, and (v) increases in the estimated fair value of intangible assets, which included a net increase to IPR&D assets driven by a higher fair value for the next generation silicone hydrogel lens (Bausch + Lomb Ultra®). The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
(c)	The fair value of trade accounts receivable acquired was $540.7 million, with the gross contractual amount being $555.6 million, of which the Company expects that $14.9 million will be uncollectible.
(d)	Includes an estimated fair value adjustment to inventory of $269.1 million.
(e)	Includes primarily prepaid expenses.
(f)	The following table summarizes the amounts and useful lives assigned to property, plant and equipment:
		Weighted-		Amounts				Measurement				Amounts
		Average		Recognized as of				Period				Recognized as of
		Useful Lives		Acquisition Date				Adjustments				30-Sep-14
		(Years)		(as previously								(as adjusted)
				reported)
Land		NA		$	47.4			$	(12.6	)		$	34.8
Buildings		24		273.1				(23.8		)		249.3
Machinery and equipment		5		273.5				76.3				349.8
Leasehold improvements		5		22.5				(0.3		)		22.2
Equipment on operating lease		3		13.8				(0.2		)		13.6
Construction in progress		NA		131.1				(6.2		)		124.9
Total property, plant and equipment acquired				$	761.4			$	33.2			$	794.6
The Company sold an office building in Rochester, New York, with an adjusted carrying amount of $14.2 million, in the third quarter of 2014. There was no gain or loss associated with the sale.
(g)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
		Weighted-		Amounts				Measurement				Amounts
		Average		Recognized as of				Period				Recognized as of
		Useful Lives		Acquisition Date				Adjustments				September 30, 2014
		(Years)		(as previously								(as adjusted)
				reported)
Product brands		10		$	1,770.20			$	4.6			$	1,774.80
Product rights		8		855.4				5.7				861.1
Corporate brand		Indefinite		1,690.50				7				1,697.50
Total identifiable intangible assets acquired		9		$	4,316.10			$	17.3			$	4,333.40
The corporate brand represents the B&L corporate trademark and has an indefinite useful life as there are no legal, regulatory, contractual, competitive, economic, or other factors that limit the useful life of this intangible asset. The estimated fair value was determined using the relief from royalty method.
(h)	The significant components of the acquired IPR&D assets primarily relate to the development of (i) various vision care products ($223.4 million in the aggregate), such as the next generation silicone hydrogel lens (Bausch + Lomb Ultra®), (ii) various pharmaceutical products ($170.9 million, in the aggregate), such as latanoprostene bunod, a nitric oxide-donating prostaglandin for reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, and (iii) various surgical products ($20.8 million, in the aggregate). A multi-period excess earnings methodology (income approach) was used to determine the estimated fair values of the acquired IPR&D assets from market participant perspective. The projected cash flows from these assets were adjusted for the probabilities of successful development and commercialization of each project. A risk-adjusted discount rate of 10% was used to present value the projected cash flows. The next generation silicone hydrogel lens (Bausch + Lomb Ultra®) was launched in February 2014.
(i)	Includes accrued liabilities, including reserves for sales returns, rebates and managed care, accounts payable and accrued compensation-related liabilities.
(j)	The following table summarizes the fair value of long-term debt assumed as of the acquisition date:
		Amounts
		Recognized as of
		Acquisition Date
Holdco unsecured term loan(1)		$	707
U.S. dollar-denominated senior secured term loan(1)		1,915.80
Euro-denominated senior secured term loan(1)		604
U.S. dollar-denominated delayed draw term loan(1)		398
U.S. dollar-denominated revolver loan(1)		170
9.875% senior notes(1)		350
Multi-currency denominated revolver loan(1)		15
Japanese revolving credit facility(2)		33.8
Debentures		11.8
Other(1)		4.5
Total long-term debt assumed		$	4,209.90
___________________________________
-1	The Company subsequently repaid these amounts in full in the third quarter of 2013. In connection with the redemption of the 9.875% senior notes, the Company recognized a loss on extinguishment of debt of $8.2 million in the third quarter of 2013.
-2	In the fourth quarter of 2013, the Company repaid in full the amounts outstanding. In January 2014, the Company terminated this facility.
(k)	Comprises current net deferred tax assets ($61.6 million) and non-current net deferred tax liabilities ($1,436.5 million).
(l)	Includes $224.2 million related to the estimated fair value of pension and other benefits liabilities.
(m)	Represents the estimated fair value of B&L’s noncontrolling interest related primarily to Chinese joint ventures. A discounted cash flow methodology was used to determine the estimated fair values as of the acquisition date.
(n)	Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents the following:
•	the Company’s expectation to develop and market new product brands, product lines and technology;
•	cost savings and operating synergies expected to result from combining the operations of B&L with those of the Company;
•	the value of the continuing operations of B&L’s existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately); and
•	intangible assets that do not qualify for separate recognition (for instance, B&L’s assembled workforce).
The amount of goodwill has been allocated to the Company’s Developed Markets segment ($3.3 billion) and Emerging Markets segment ($1.1 billion).
Other Business Combinations
Description of the Transactions
In the year ended December 31, 2013, the Company completed other business combinations, which included the acquisition of the following businesses, for an aggregate purchase price of $898.1 million. The aggregate purchase price included contingent consideration payment obligations with an aggregate acquisition date fair value of $59.1 million.
•	On April 25, 2013, the Company acquired all of the outstanding shares of Obagi Medical Products, Inc. (“Obagi”) at a price of $24.00 per share in cash. The aggregate purchase price paid by the Company was approximately $437.1 million. Obagi is a specialty pharmaceutical company that develops, markets, and sells topical aesthetic and therapeutic skin-health systems with a product portfolio of dermatology brands including Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®.
•	On February 20, 2013, the Company acquired certain assets from Eisai Inc. (“Eisai”) relating to the U.S. rights to Targretin®, which is indicated for the treatment of Cutaneous T-Cell Lymphoma. The consideration includes up-front payments of $66.5 million and the Company may pay up to an additional $60.0 million of contingent consideration based on the occurrence of potential future events. The fair value of the contingent consideration was determined to be $50.8 million as of the acquisition date. As of September 30, 2014, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date. In April 2014, the Company made a contingent consideration payment of $30.0 million.
•	On February 1, 2013, the Company acquired Natur Produkt International, JSC (“Natur Produkt”), a specialty pharmaceutical company in Russia, for a purchase price of $149.9 million, including a $20.0 million contingent refund of purchase price relating to the outcome of certain litigation involving AntiGrippin® that commenced prior to the acquisition. Subsequent to the acquisition, during the three-month period ended March 31, 2013, the litigation was resolved, and the $20.0 million was refunded back to the Company. Natur Produkt’s key brand products include AntiGrippin®, Anti-Angin®, Sage™ and Eucalyptus MA™.
•	During the year ended December 31, 2013, the Company completed other smaller acquisitions which are not material individually or in the aggregate. These acquisitions are included in the aggregated amounts presented below.
Assets Acquired and Liabilities Assumed
These transactions have been accounted for as business combinations under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates.
		Amounts				Measurement				Amounts
		Recognized as of				Period				Recognized as of
		Acquisition Dates				Adjustments(a)				September 30, 2014
										(as adjusted)
Cash		$	43.1			$	—			$	43.1
Accounts receivable(b)		64				0.5				64.5
Inventories		33.6				1.9				35.5
Other current assets		14				—				14
Property, plant and equipment		13.9				(3.3		)		10.6
Identifiable intangible assets, excluding acquired IPR&D(c)		722.9				3.9				726.8
Acquired IPR&D(d)		18.7				0.2				18.9
Indemnification assets		3.2				(0.7		)		2.5
Other non-current assets		0.2				3.7				3.9
Current liabilities		(36.2		)		(0.4		)		(36.6		)
Short-term borrowings(e)		(33.3		)		0.5				(32.8		)
Long-term debt(e)		(24.0		)		—				(24.0		)
Deferred tax liability, net		(147.8		)		(1.1		)		(148.9		)
Other non-current liabilities		(1.5		)		—				(1.5		)
Total identifiable net assets		670.8				5.2				676
Noncontrolling interest(f)		(11.2		)		—				(11.2		)
Goodwill(g)		224.3				9				233.3
Total fair value of consideration transferred		$	883.9			$	14.2			$	898.1
________________________
(a)	The measurement period adjustments primarily reflect an increase in the total fair value of consideration transferred with respect to the Natur Produkt acquisition pursuant to a purchase price adjustment. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
(b)	The fair value of trade accounts receivable acquired was $64.5 million, with the gross contractual amount being $68.2 million, of which the Company expects that $3.7 million will be uncollectible.
(c)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
		Weighted-		Amounts				Measurement				Amounts
		Average		Recognized as of				Period				Recognized as of
		Useful Lives		Acquisition Dates				Adjustments				September 30, 2014
		(Years)										(as adjusted)
Product brands		7		$	517.2			$	3.1			$	520.3
Corporate brand		13		86.1				0.8				86.9
Patents		3		71.7				—				71.7
Royalty Agreement		5		26.5				—				26.5
Partner relationships		5		16				—				16
Technology		10		5.4				—				5.4
Total identifiable intangible assets acquired		8		$	722.9			$	3.9			$	726.8
(d)	The acquired IPR&D assets relate to the Obagi and Natur Produkt acquisitions. Obagi’s acquired IPR&D assets primarily relate to the development of dermatology products for anti-aging and suncare. Natur Produkt’s acquired IPR&D assets include a product indicated for the prevention of viral diseases, specifically cold and flu, and a product indicated for the treatment of inflammation and muscular disorders.
(e)	Short-term borrowings and long-term debt primarily relate to the Natur Produkt acquisition. In March 2013, the Company settled all of Natur Produkt’s outstanding third party short-term borrowings and long-term debt.
(f)	Represents the estimated fair value of noncontrolling interest related to a smaller acquisition completed in the third quarter of 2013.
(g)	The goodwill relates primarily to the Obagi and Natur Produkt acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of Obagi’s and Natur Produkt’s goodwill is expected to be deductible for tax purposes. The goodwill recorded from the Obagi and the Natur Produkt acquisitions represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations with those of the Company.
The amount of goodwill from the Eisai acquisition has been allocated to the Company’s Developed Markets segment. The amount of goodwill from the Natur Produkt acquisition has been allocated to the Company’s Emerging Markets segment. The amount of goodwill from the Obagi acquisition has been allocated primarily to the Company’s Developed Markets segment.
Pro Forma Impact of Business Combinations
The following table presents unaudited pro forma consolidated results of operations for the three-month and nine-month periods ended September 30, 2014 and 2013, as if the 2014 acquisitions had occurred as of January 1, 2013 and the 2013 acquisitions had occurred as of January 1, 2012.
	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2014				2013				2014				2013
Revenues	$	2,060.20			$	1,867.30			$	6,039.60			$	5,794.90
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	279.8				(907.8		)		376.1				(1,023.9		)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic	$	0.83			$	(2.72	)		$	1.12			$	(3.07	)
Diluted	$	0.82			$	(2.72	)		$	1.1			$	(3.07	)
The increase in pro forma revenues in the nine-month period ended September 30, 2014 as compared to the nine-month period ended September 30, 2013 was primarily due to higher B&L revenues and growth from the remaining business, including the launches of Jublia®, Luzu™, and Retin-A Micro® Microsphere 0.08% ("RAM 0.08%"). These increases were partially offset by lower sales of the Vanos®, Retin-A Micro® (excluding RAM 0.08%), and Zovirax® franchises and Wellbutrin® XL (Canada) due to generic competition and lower sales of facial injectables (filler and toxin assets).
The unaudited pro forma consolidated results of operations were prepared using the acquisition method of accounting and are based on the historical financial information of the Company and the acquired businesses described above. Except to the extent realized in the three-month and nine-month periods ended September 30, 2014, the unaudited pro forma information does not reflect any cost savings, operating synergies and other benefits that the Company may achieve as a result of these acquisitions, or the costs necessary to achieve these cost savings, operating synergies and other benefits. In addition, except to the extent recognized in the three-month and nine-month periods ended September 30, 2014, the unaudited pro forma information does not reflect the costs to integrate the operations of the Company with those of the acquired businesses.
The unaudited pro forma information is not necessarily indicative of what the Company’s consolidated results of operations actually would have been had the 2014 acquisitions and the 2013 acquisitions been completed on January 1, 2013 and January 1, 2012, respectively. In addition, the unaudited pro forma information does not purport to project the future results of operations of the Company. The unaudited pro forma information reflects primarily the following adjustments:
•	elimination of the historical intangible asset amortization expense of these acquisitions;
•	additional amortization expense related to the fair value of identifiable intangible assets acquired;
•	additional depreciation expense related to fair value adjustment to property, plant and equipment acquired;
•	additional interest expense associated with the financing obtained by the Company in connection with the various acquisitions; and
•	the exclusion from pro forma earnings in the three-month and nine-month periods ended September 30, 2014 of (i) the acquisition accounting adjustments on these acquisitions’ inventories that were sold subsequent to the acquisition date and (ii) the acquisition-related costs incurred for these acquisitions, and the inclusion of those amounts in pro forma earnings for the corresponding comparative periods.
In addition, all of the above adjustments were adjusted for the applicable tax impact.

DIVESTITURES

DIVESTITURES	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
DIVESTITURES	'
	DIVESTITURES
	Divestiture of Filler and Toxin Assets
	On July 10, 2014, the Company sold all rights to Restylane®, Perlane®, Emervel®, Sculptra®, and Dysport® owned or held by the Company to Galderma S.A. (“Galderma”) for approximately $1.4 billion in cash. These assets were included primarily in the Company's Developed Markets segment. As a result of this transaction, the Company recognized a net gain on sale of $323.9 million in the third quarter of 2014 within Other (income) expense in the consolidated statement of income (loss). The costs to sell for this divestiture of approximately $43 million were recognized in the third quarter of 2014 and included as part of the net gain on sale (netted against the proceeds in the consolidated statements of cash flows). As this divestiture does not represent a strategic shift that has, or will have, a major effect on operations and financial results, a discontinued operations presentation was not appropriate.
	Sale of Metronidazole 1.3%
	On July 1, 2014, the Company sold the worldwide rights in its Metronidazole 1.3% Vaginal Gel antibiotic development product, a topical antibiotic for the treatment of bacterial vaginosis, to Actavis Specialty Brands for upfront and certain milestone payments of $10.0 million, in the aggregate, and minimum royalties for the first three years of commercialization.  This asset was included in the Company's Developed Markets segment. In addition, royalties are payable to the Company beyond the initial three-year commercialization period. In the event of generic competition on Metronidazole 1.3%, should Actavis Specialty Brands choose to launch an authorized generic product, Actavis Specialty Brands would share the gross profits of the authorized generic with the Company.  The Food and Drug Administration (“FDA”) approved the New Drug Application (“NDA”) for Metronidazole 1.3% in March 2014. In connection with the sale of the Metronidazole 1.3%, the Company recognized a loss on sale of $58.5 million, as the Company’s accounting policy is to not recognize contingent payments until such amounts are realizable. The loss on sale was included within Other (income) expense in the consolidated statement of income (loss). As this divestiture does not represent a strategic shift that has, or will have, a major effect on operations and financial results, a discontinued operations presentation was not appropriate.
	Divestiture of Tretin-X® and Generic Tretinoin
	In connection with the acquisition of PreCision, the Company was required by the FTC to divest the rights to PreCision’s Tretin-X® (tretinoin) cream product and PreCision’s generic tretinoin gel and cream products. In July 2014, the Tretin-X product rights were sold to Watson Laboratories, Inc. for an up-front purchase price of $70 million, and the generic tretinoin products rights were sold to Matawan Pharmaceuticals, LLC ("Matawan") for an up-front purchase price of $45 million plus additional contingent payments. In connection with the sale of the generic tretinoin product rights to Matawan, the Company recognized a loss on sale of $8.8 million in the third quarter of 2014 within Other (income) expense in the consolidated statement of income (loss), as the Company’s accounting policy is to not recognize contingent payments until such amounts are realizable. There was no gain or loss associated with the sale of the Tretin-X product rights. As these divestitures do not represent strategic shifts that have or will have, a major effect on operations and financial results, a discontinued operations presentation was not appropriate.

COPROMOTION_AGREEMENTS

CO-PROMOTION AGREEMENTS	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
CO-PROMOTION AGREEMENTS	'
	CO-PROMOTION AGREEMENTS
	Zovirax Authorized Generic Agreement and Termination of Co-Promotion Agreements
	In April 2014, the Company and Actavis, Inc. (“Actavis”) signed an agreement terminating their previously-announced co-promotion agreement for Cordran® Tape, pursuant to which Actavis had granted the Company the exclusive right to co-promote Actavis Specialty Brands’ Cordran® Tape product in the U.S. Following the termination, the Company no longer has any rights to co-promote the Cordran® Tape product. In addition, in April 2014, the Company and Actavis signed an agreement terminating their co-promotion agreement for Zovirax® cream, pursuant to which the Company had granted Actavis the exclusive right to co-promote Zovirax® cream to obstetricians and gynecologists in the U.S. Following the termination, Actavis no longer has any rights to co-promote Zovirax® cream. Amounts received by the Company with respect to these terminations were not significant.
	However, notwithstanding the termination of the co-promotion arrangements, Actavis continues to be the exclusive marketer and distributor of the authorized generic of the Company’s Zovirax® ointment product (other than to certain dispensing physicians) (the “Zovirax® ointment agreement”). Under the terms of the exclusive Zovirax® ointment agreement, the Company is continuing to supply Actavis with a generic version of the Company’s Zovirax® ointment product, Actavis is continuing to market and distribute the product in the U.S. (other than to certain dispensing physicians) and the Company continues to receive a share of the economics.

RESTRUCTURING_INTEGRATION_AND_

RESTRUCTURING, INTEGRATION AND OTHER COSTS	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING, INTEGRATION AND OTHER COSTS	'
	RESTRUCTURING, INTEGRATION AND OTHER COSTS
	In connection with the B&L and Medicis Pharmaceutical Corporation (“Medicis”) acquisitions, as well as other smaller acquisitions, the Company has implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included:
	•	workforce reductions across the Company and other organizational changes;
	•	closing of duplicative facilities and other site rationalization actions company-wide, including research and development facilities, sales offices and corporate facilities;
	•	leveraging research and development spend; and
	•	procurement savings.
	B&L Acquisition-Related Cost-Rationalization and Integration Initiatives
	The Company estimates that it will incur total costs of approximately $600 million (excluding charges of $52.8 million described below) in connection with these cost-rationalization and integration initiatives, which are expected to be substantially completed by the end of 2014. Since the acquisition date, total costs of $554.6 million (including $56.7 million related to cost-rationalization measures at a contact lens manufacturing plant in Waterford, Ireland as described below) have been incurred through September 30, 2014, including (i) $302.2 million of restructuring expenses, (ii) $239.0 million of integration expenses, and (iii) $13.4 million of acquisition-related costs. The estimate of total costs to be incurred primarily includes: employee termination costs payable to approximately 3,000 employees of the Company and B&L who have been or will be terminated as a result of the B&L Acquisition; IPR&D termination costs related to the transfer to other parties of product-development programs that did not align with our research and development model; costs to consolidate or close facilities and relocate employees; and contract termination and lease cancellation costs. The costs described above do not include charges of $52.8 million, in the aggregate, recognized and paid in the third quarter of 2013 related to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition. As described in note 2 titled “SIGNIFICANT ACCOUNTING POLICIES”, the charges of $52.8 million were reclassified to Other (income) expense to conform to the current year presentation.
	B&L Restructuring Costs
	The following table summarizes the major components of the restructuring costs incurred in connection with the B&L Acquisition since the acquisition date through September 30, 2014:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2013		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		155.7			52.8			—		25.6			234.1
	Cash payments		(77.8		)	(52.8		)	—		(7.8		)	(138.4		)
	Non-cash adjustments		11.4			—			—		(6.8		)	4.6
	Balance, December 31, 2013		89.3			—			—		11			100.3
	Costs incurred and/or charged to expense		22.5			—			—		6.6			29.1
	Cash payments		(50.9		)	—			—		(3.2		)	(54.1		)
	Non-cash adjustments		(2.3		)	—			—		(3.1		)	(5.4		)
	Balance, March 31, 2014		58.6			—			—		11.3			69.9
	Costs incurred and charged to expense		12.3			—			—		10.1			22.4
	Cash payments		(25.7		)	—			—		(1.8		)	(27.5		)
	Non-cash adjustments		(0.5		)	—			—		(0.4		)	(0.9		)
	Balance, June 30, 2014		44.7			—			—		19.2			63.9
	Costs incurred and charged to expense		8.2			—			—		4.5			12.7
	Cash payments		(22.2		)	—			—		(18.7		)	(40.9		)
	Non-cash adjustments		(1.7		)	—			—		(0.2		)	(1.9		)
	Balance, September 30, 2014		$	29		$	—		$	—	$	4.8		$	33.8
	___________________________________
	-1	Relates to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition. These charges were reclassified to Other (income) expense to conform to the current year presentation.
	B&L Integration Costs
	As mentioned above, the Company has incurred $239.0 million of integration costs related to the B&L Acquisition since the acquisition date. In the nine-month periods ended September 30, 2014 and 2013, the Company incurred $123.0 million and $45.8 million, respectively, of integration costs related to the B&L Acquisition, which related primarily to integration consulting and manufacturing, duplicate labor, transition service, and other costs. The Company made payments of $128.5 million and $40.4 million related to B&L integration costs during the nine-month periods ended September 30, 2014 and 2013, respectively.
	In addition to the restructuring and integration costs described above, the Company incurred $56.7 million of restructuring costs in the nine-month period ended September 30, 2014 related to employee termination costs with respect to cost-rationalization measures at a contact lens manufacturing plant in Waterford, Ireland (the plant was acquired as part of the B&L Acquisition). The Company made payments of $17.5 million in the nine-month period ended September 30, 2014 with respect to this initiative.
	Medicis Acquisition-Related Cost-Rationalization and Integration Initiatives
	The Company estimates that it will incur total costs of approximately $200 million in connection with these cost-rationalization and integration initiatives, which were substantially completed by the end of 2013. However, additional costs have been incurred in 2014, and the Company expects to incur certain costs during the next six months. Since the acquisition date, total costs of $193.1 million (excluding the charge of $77.3 million described below), including (i) $109.2 million of restructuring expenses, (ii) $51.7 million of integration expenses, and (iii) $32.2 million of acquisition-related costs, which excludes $24.2 million of acquisition-related costs recognized in the fourth quarter of 2012 related to royalties to be paid to Galderma on sales of Sculptra®, have been incurred through September 30, 2014. In connection with the divestiture of Sculptra® and certain other products to Galderma in July 2014, the royalty obligation owed to Galderma on sales of Sculptra® was relieved in the third quarter of 2014 and included as part of the gain on sale. See note 4 “DIVESTITURES” for additional information regarding this divestiture. The estimated costs primarily include: employee termination costs payable to approximately 750 employees of the Company and Medicis who have been terminated as a result of the Medicis acquisition; IPR&D termination costs related to the transfer to other parties of product-development programs that did not align with our research and development model; costs to consolidate or close facilities and relocate employees; and contract termination and lease cancellation costs. The estimate of total costs to be incurred of approximately $200 million does not include a charge of $77.3 million recognized within Other (income) expense and paid in the fourth quarter of 2012 related to the acceleration of unvested stock options, restricted stock awards, and share appreciation rights for Medicis employees that was triggered by the change in control.
	Medicis Restructuring Costs
	The following table summarizes the major components of the $109.2 million of restructuring costs incurred in connection with the Medicis acquisition since the acquisition date through September 30, 2014:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2012		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		85.3			77.3			—		0.4			163
	Cash payments		(78.0		)	(77.3		)	—		—			(155.3		)
	Non-cash adjustments		4.1			—			—		(0.2		)	3.9
	Balance, December 31, 2012		11.4			—			—		0.2			11.6
	Costs incurred and/or charged to expense		20			—			—		3.5			23.5
	Cash payments		(31.4		)	—			—		(3.6		)	(35.0		)
	Non-cash adjustments		0.3			—			—		(0.1		)	0.2
	Balance, December 31, 2013(2)		$	0.3		$	—		$	—	$	—		$	0.3
	____________________________________
	-1	Relates to the acceleration of unvested stock options, restricted stock awards, and share appreciation rights for Medicis employees that was triggered by the change in control. These charges were reclassified to Other (income) expense to conform to the current year presentation.
	-2	The Company has not recognized any restructuring charges, and made a payment of $0.1 million, in the nine-month period ended September 30, 2014 with respect to the Medicis acquisition-related initiatives. In the nine-month period ended September 30, 2013, the Company recognized $23.1 million of restructuring charges and made payments of $34.4 million.
	Medicis Integration Costs
	As mentioned above, the Company has incurred $51.7 million of integration costs related to the Medicis acquisition since the acquisition date. In the nine-month periods ended September 30, 2014 and 2013, the Company incurred $11.8 million and $31.2 million, respectively, of integration costs related to the Medicis acquisition. The costs incurred in 2014 related primarily to an R&D collaboration inherited from Medicis which does not align with the Company’s research and development model. The costs incurred in 2013 related primarily to integration consulting, duplicate labor, transition service, and other costs. The Company made payments of $8.4 million and $28.3 million related to Medicis integration costs during the nine-month periods ended September 30, 2014 and 2013, respectively.
	Other Restructuring and Integration-Related Costs (Excluding B&L and Medicis)
	In the nine-month period ended September 30, 2014, in addition to the restructuring and integration costs associated with the B&L and Medicis acquisitions described above, the Company incurred an additional $81.7 million of other restructuring, integration-related and other costs. These costs included (i) $49.3 million of integration consulting, duplicate labor, transition service, and other costs, (ii) $18.5 million of severance costs, (iii) $7.3 million of facility closure costs, and (iv) $6.6 million of other costs. These costs primarily related to (i) integration and restructuring costs for PreCision, Solta Medical and other smaller acquisitions, and (ii) intellectual property migration and the global consolidation of the Company’s manufacturing facilities. The Company made payments of $78.6 million during the nine-month period ended September 30, 2014 (in addition to the payments related to the B&L and Medicis acquisitions described above).
	In the nine-month period ended September 30, 2013, in addition to the restructuring and integration costs associated with the B&L and Medicis acquisitions described above, the Company incurred an additional $81.1 million of other restructuring, integration-related and other costs. These costs included (i) $46.8 million of integration consulting, duplicate labor, transition service, and other costs, (ii) $14.9 million of facility closure costs, (iii) $12.4 million of severance costs, and (iv) $7.0 million of other costs, including non-personnel manufacturing integration costs. These costs primarily related to (i) integration and restructuring costs for other smaller acquisitions, (ii) intellectual property migration and the global consolidation of the Company’s manufacturing facilities, and (iii) systems integration initiatives. The Company made payments of $75.9 million, in the aggregate, during the nine-month period ended September 30, 2013 (in addition to the payments related to the B&L and Medicis acquisitions described above).

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

'

FAIR VALUE MEASUREMENTS

'

FAIR VALUE MEASUREMENTS

Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities;

•

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value as of September 30, 2014 and December 31, 2013:

As of September 30, 2014

As of December 31, 2013

Carrying

Quoted

Significant

Significant

Carrying

Quoted

Significant

Significant

Value

Prices

Other

Unobservable

Value

Prices

Other

Unobservable

in Active

Observable

Inputs

in Active

Observable

Inputs

Markets for

Inputs

(Level 3)

Markets for

Inputs

(Level 3)

Identical

(Level 2)

Identical

(Level 2)

Assets

Assets

(Level 1)

(Level 1)

Assets:

Cash equivalents(1)

$

395.9

$

389.5

$

6.4

$

—

$

171.3

$

171.3

$

—

$

—

Liabilities:

Acquisition-related contingent consideration

$

(327.8

)

$

—

$

—

$

(327.8

)

$

(355.8

)

$

—

$

—

$

(355.8

)

___________________________________

-1

Cash equivalents include highly liquid investments with an original maturity of three months or less at acquisition, primarily including money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

In addition to the cash equivalents (described under the table above), the Company has time deposits valued at cost, which approximates fair value due to their short-term maturities. The carrying value of $33.1 million and $25.2 million as of September 30, 2014 and December 31, 2013, respectively, related to these investments is classified within Prepaid expenses and other current assets in the consolidated balance sheets. These investments are Level 2.

During the three-month period ended September 30, 2014, the Company sold its investment in available-for-sale equity securities and realized a gain of $3.4 million.

There were no transfers between Level 1 and Level 2 during the nine-month period ended September 30, 2014.

Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)

The fair value measurement of contingent consideration obligations arising from business combinations is determined using unobservable (Level 3) inputs. These inputs include (i) the estimated amount and timing of projected cash flows; (ii) the probability of the achievement of the factor(s) on which the contingency is based; and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower (higher) fair value measurement.

The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the nine-month period ended September 30, 2014:

Balance,

Issuances(a)

Payments(b)

Net

Foreign

Transfers

Transfers

Balance,

January 1,

Unrealized

Exchange(d)

Into

Out of

September 30,

2014

Loss(c)

Level 3

Level 3

2014

Acquisition-related contingent consideration

$

(355.8

)

$

(65.1

)

$

106.1

$

(14.8

)

$

1.8

$

—

$

—

$

(327.8

)

____________________________________

(a)

Primarily relates to a contingent consideration liability assumed in the Solta Medical acquisition, as well as contingent consideration with respect to other smaller acquisitions, as described in note 3.

(b)

Relates primarily to payments of acquisition-related contingent consideration related to the OraPharma Topco Holdings, Inc. and Eisai (Targretin®) acquisitions and the Elidel®/Xerese®/Zovirax® agreement entered into with Meda Pharma SARL (“Meda”) in June 2011 (the “Elidel®/Xerese®/Zovirax® agreement”).

(c)

For the nine months ended September 30, 2014, a net loss of $14.8 million was recognized as Acquisition-related contingent consideration in the consolidated statements of income (loss). The acquisition-related contingent consideration net loss was primarily driven by fair value adjustments to reflect accretion for the time value of money related to the Elidel®/Xerese®/Zovirax® agreement.

(d)

Included in other comprehensive (loss) income.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

There were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis subsequent to initial recognition in the nine-month period ended September 30, 2014.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	INVENTORIES
	The components of inventories as of September 30, 2014 and December 31, 2013 were as follows:
		As of			As of
		September 30,			December 31,
		2014			2013
	Raw materials	$	241.1		$	221.8
	Work in process	108.1			104.7
	Finished goods	697.3			656.3
		1,046.50			982.8
	Less allowance for obsolescence	(113.8		)	(99.8		)
		$	932.7		$	883
	In the nine-month period ended September 30, 2014, the increase in inventories was primarily driven by (i) the 2014 acquisitions of businesses, primarily from the $30.3 million and $18.8 million of inventory acquired in the Solta Medical and PreCision acquisitions, respectively, and (ii) investments in inventory (inclusive of cost increases) to support growth of the business.
	For further information regarding the 2014 acquisitions of businesses, see note 3 titled “BUSINESS COMBINATIONS”.

INTANGIBLE_ASSETS_AND_GOODWILL

INTANGIBLE ASSETS AND GOODWILL	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS AND GOODWILL	'
	INTANGIBLE ASSETS AND GOODWILL
	Intangible Assets
	The major components of intangible assets as of September 30, 2014 and December 31, 2013 were as follows:
			As of September 30, 2014									As of December 31, 2013
			Gross			Accumulated			Net			Gross		Accumulated			Net
			Carrying			Amortization,			Carrying			Carrying		Amortization,			Carrying
			Amount			Including			Amount			Amount		Including			Amount
						Impairments								Impairments
	Finite-lived intangible assets:
	Product brands		$	10,378.00		$	(3,384.1	)	$	6,993.90		$	10,554.20	$	(2,729.1	)	$	7,825.10
	Corporate brands		379			(67.3		)	311.7			365.6		(44.4		)	321.2
	Product rights		3,193.10			(1,101.3		)	2,091.80			3,021.00		(876.9		)	2,144.10
	Partner relationships		195.9			(104.2		)	91.7			194		(83.2		)	110.8
	Out-licensed technology and other		250.8			(111.9		)	138.9			264		(93.8		)	170.2
	Total finite-lived intangible assets		14,396.80			(4,768.8		)	9,628.00			14,398.80		(3,827.4		)	10,571.40
	Indefinite-lived intangible assets:
	Acquired IPR&D(1)		294.9			—			294.9			579.3		—			579.3
	Corporate brand(2)		1,697.50			—			1,697.50			1,697.50		—			1,697.50
			$	16,389.20		$	(4,768.8	)	$	11,620.40		$	16,675.60	$	(3,827.4	)	$	12,848.20
	____________________________________
	-1	In the third quarter of 2014, the Company wrote-off IPR&D assets of $19.9 million primarily related to analysis of Phase 2 study data for a dermatological product candidate acquired in the December 2012 Medicis acquisition.
	In the third quarter of 2013, the Company wrote-off an IPR&D asset of $93.8 million related to a modified-release formulation of ezogabine/retigabine.
	The write-offs of the IPR&D assets were recorded in In-process research and development impairments and other charges in the consolidated statements of income (loss).
	-2	Represents the B&L corporate trademark, which has an indefinite useful life and is not amortizable. See note 3 “BUSINESS COMBINATIONS” for further information.
	The decrease in intangible assets, net primarily reflects (i) the divestitures of filler and toxin assets and Metronidazole 1.3% in July 2014, (ii) amortization expense, and (iii) the negative impact of foreign currency exchange. These factors were partially offset by the acquisition of the PreCision and Solta Medical identifiable intangible assets (as described in note 3). See note 4 “DIVESTITURES” for further information related to the divestitures of filler and toxin assets and Metronidazole 1.3%. The reduction in Acquired IPR&D is largely driven by the reclassification to finite-lived intangible assets with respect to Jublia®, which received regulatory approval in the first half of 2014.
	Amortization and impairments of finite-lived intangible assets amounted to $393.1 million and $1,113.9 million in the three-month and nine-month periods ended September 30, 2014, respectively, and $910.2 million and $1,540.0 million in the three-month and nine-month periods ended September 30, 2013, respectively.
	Amortization and impairments of finite-lived intangible assets in the nine-month period ended September 30, 2014 included a $32.4 million write-off in the third quarter of 2014 related to Grifulvin®, an anti-fungal product within the Developed Markets segment. The write-off was driven by withdrawal of the supplemental Abbreviated New Drug Application, which resulted from assessment of extended timelines and increased costs associated with a change in the supplier and the manufacturing process, based on feedback received from the FDA.
	Amortization and impairments of finite-lived intangible assets in the nine-month period ended September 30, 2013 included a $551.6 million impairment charge in the third quarter of 2013 related to ezogabine/retigabine (immediate-release formulation), which is included within the Developed Markets segment. This product is co-developed and marketed under a collaboration agreement with GlaxoSmithKline (“GSK”). This impairment charge was driven by analysis of expected future cash flows based on the communication received from the FDA in September 2013 regarding labeling changes and a required modification of the approved risk evaluation and mitigation strategy (REMS), which includes restrictions on distribution and additional patient monitoring. Further, as a result of this feedback received from the FDA, GSK decided that all sales force promotion for the product would be eliminated in the U.S., and they will not launch the product in certain other planned territories. Under the terms of the collaboration agreement with GSK, GSK controls all sales force promotion for the product. Such changes are expected to have a significant impact on future cash flows of ezogabine/retigabine.
	Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows:
			2014			2015			2016			2017		2018
	Amortization expense(1)		$	1,421.70		$	1,379.90		$	1,289.20		$	1,231.10	$	1,108.60
	____________________________________
	-1	Estimated amortization expense shown in the table above does not include potential future impairments of finite-lived intangible assets, if any.
	Goodwill
	The changes in the carrying amount of goodwill in the nine-month period ended September 30, 2014 were as follows:
			Developed			Emerging			Total
			Markets			Markets
	Balance, January 1, 2014		$	7,428.70		$	2,323.40		$	9,752.10
	Additions(a)		259.5			61.6			321.1
	Adjustments(b)		10.3			(4.3		)	6
	Divestitures(c)		(428.9		)	—			(428.9		)
	Foreign exchange and other		(111.8		)	(70.7		)	(182.5		)
	Balance, September 30, 2014		$	7,157.80		$	2,310.00		$	9,467.80
	____________________________________
	(a)	Primarily relates to the PreCision and Solta Medical acquisitions (as described in note 3).
	(b)	Primarily reflects the impact of measurement period adjustments related to the B&L Acquisition (as described in note 3).
	(c)	See note 4, titled “DIVESTITURES” for additional information.
	As described in note 3, the allocation of the goodwill balance associated with the PreCision and Solta Medical acquisitions is provisional and subject to the completion of the valuation of the assets acquired and liabilities assumed.

LONGTERM_DEBT

LONG-TERM DEBT	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
LONG-TERM DEBT	'
	LONG-TERM DEBT
	A summary of the Company’s consolidated long-term debt as of September 30, 2014 and December 31, 2013, respectively, is outlined in the table below:
			Maturity	As of			As of
			Date	September 30,			December 31,
				2014			2013
	Revolving Credit Facility(1)		April 2018	$	—		$	—
	Series A-1 Tranche A Term Loan Facility(1)		April 2016	182.3			259
	Series A-2 Tranche A Term Loan Facility(1)		Apr-16	166.3			228.1
	Series A-3 Tranche A Term Loan Facility(1)		Oct-18	1,813.90			1,935.70
	Series D-2 Tranche B Term Loan Facility(1)		Feb-19	1,088.60			1,256.70
	Series C-2 Tranche B Term Loan Facility(1)		Dec-19	837.5			966.8
	Series E-1 Tranche B Term Loan Facility(1)		Aug-20	2,544.80			3,090.50
	Senior Notes:
	6.75%(2)		October 2017	498.9			498.7
	6.88%		December 2018	940.9			940.2
	7.00%		October 2020	687.4			687.1
	6.75%		August 2021	650			650
	7.25%		July 2022	542.9			542.2
	6.38%		Oct-20	2,224.50			2,221.40
	6.75%		Aug-18	1,584.80			1,581.90
	7.50%		Jul-21	1,607.80			1,605.90
	5.63%		Dec-21	892.3			891.5
	Other(3)		Various	12			12
				16,274.90			17,367.70
	Less current portion			(690.6		)	(204.8		)
	Total long-term debt			$	15,584.30		$	17,162.90
	____________________________________
	-1	Together, the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Credit Agreement”).
	-2	On October 15, 2014, Valeant redeemed all of the outstanding $500.0 million aggregate principal amount of its 6.75% senior notes due 2017 (the “2017 Notes”) for $518.2 million, including a call premium of $16.9 million, plus accrued and unpaid interest, and satisfied and discharged the 2017 Notes indenture, solely with respect to the 2017 Notes (the 7.00% senior notes due 2020, issued under the same indenture, remain outstanding at this time). The balance of the 2017 Notes was reclassified to Current portion of long-term debt as of September 30, 2014.
	-3	Relates primarily to the debentures from B&L.
	The Company’s Senior Secured Credit Facilities and indentures related to its senior notes contain customary covenants, including, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates.
	The Company’s Senior Secured Credit Facilities also contain specified financial covenants (consisting of a secured leverage ratio and an interest coverage ratio), various customary affirmative covenants and specified events of default. The Company’s indentures also contain certain customary affirmative covenants and specified events of default.
	The total fair value of the Company’s long-term debt, including current portion, with carrying values of $16.3 billion and $17.4 billion at September 30, 2014 and December 31, 2013, was $16.8 billion and $18.4 billion, respectively. The fair value of the Company’s long-term debt is estimated using the quoted market prices for the same or similar debt issuances (Level 2).
	Senior Secured Credit Facilities
	On February 6, 2014, the Company and certain of its subsidiaries as guarantors entered into a joinder agreement to reprice and refinance the Company’s previous Series E tranche B term loans (the “Series E Tranche B Term Loan Facility”) by the issuance of $2.95 billion in new term loans (the “Series E-1 Tranche B Term Loan Facility”). Term loans under the Series E Tranche B Term Loan Facility were either exchanged for, or repaid with the proceeds of, the Series E-1 Tranche B Term Loan Facility and proceeds of the additional Series A-3 tranche A term loans issuance (the “Series A-3 Tranche A Term Loan Facility”) described below. The applicable margins for borrowings under the Series E-1 Tranche B Term Loan Facility are 2.0% with respect to base rate borrowings and 3.0% with respect to LIBO rate borrowings, subject to a 1.75% base rate floor and a 0.75% LIBO rate floor. The Series E-1 Tranche B Term Loan Facility has terms consistent with the Series E Tranche B Term Loan Facility. In connection with this transaction, the Company recognized a loss on extinguishment of debt of $93.7 million in the three-month period ended March 31, 2014.
	Concurrently, on February 6, 2014, the Company and certain of its subsidiaries as guarantors entered into a joinder agreement for the issuance of $225.6 million in incremental term loans under the Series A-3 Tranche A Term Loan Facility. Proceeds from this transaction were used to repay part of the term loans outstanding under the Series E Tranche B Term Loan Facility.
	For the nine-month period ended September 30, 2014, the effective rate of interest on the Company’s borrowings was as follows: (i) 2.42% per annum under the Revolving Credit Facility, (ii) 2.41% per annum under the Series A-1 Tranche A Term Loan Facility, the Series A-2 Tranche A Term Loan Facility, and the Series A-3 Tranche A Term Loan Facility, (iii) 3.75% per annum under both the Series D-2 Tranche B Term Loan Facility and the Series C-2 Tranche B Term Loan Facility, and (iv) 3.86% under the Series E-1 Tranche B Term Loan Facility.
	During the third quarter of 2014, the Company made principal payments of $1.1 billion, in the aggregate, which included (1) principal payments of $1.0 billion, in the aggregate, related to the Senior Secured Credit Facilities, resulting in a principal reduction as follows: (i) $380.0 million under the Series E-1 Tranche B Term Loan Facility, (ii) $274.5 million under the Series A-3 Tranche A Term Loan Facility, (iii) $165.4 million under the Series D-2 Tranche B Term Loan Facility, (iv) $127.2 million under the Series C-2 Tranche B Term Loan Facility, and (v) $27.5 million and $25.4 million under the Series A-1 Tranche A Term Loan Facility and the Series A-2 Tranche A Term Loan Facility, respectively, and (2) a voluntary prepayment of the scheduled December 2014 amortization payments applicable to the Senior Secured Credit Facilities, resulting in an aggregate principal reduction of $70.3 million.
	As of September 30, 2014, the Company was in compliance with all covenants related to the Company’s outstanding debt.

SECURITIES_REPURCHASE_PROGRAM

SECURITIES REPURCHASE PROGRAM	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
SECURITIES REPURCHASE PROGRAM	'
	SECURITIES REPURCHASE PROGRAM
	On November 21, 2013, the Company’s Board of Directors approved a new securities repurchase program (the “2013 Securities Repurchase Program”). Under the 2013 Securities Repurchase Program, which commenced on November 22, 2013, the Company may make purchases of up to $1.5 billion of its convertible notes, senior notes, common shares and/or other future debt or shares, subject to any restrictions in the Company’s financing agreements and applicable law. The 2013 Securities Repurchase Program will terminate on November 21, 2014 or at such time as the Company completes its purchases. The amount of securities to be purchased and the timing of purchases under the 2013 Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under our financing agreements and applicable law. The securities to be repurchased will be funded using our cash resources.
	On November 19, 2012, the Company announced that its Board of Directors had approved a new securities repurchase program (the “2012 Securities Repurchase Program”). Under the 2012 Securities Repurchase Program, which commenced on November 15, 2012, the Company could make purchases of up to $1.5 billion of senior notes, common shares and/or other future debt or shares, subject to any restrictions in the Company’s financing agreements and applicable law. The 2012 Securities Repurchase Program terminated on November 14, 2013.
	Share Repurchases
	No common shares were repurchased during the nine-month period ended September 30, 2014 under the 2013 Securities Repurchase Program.
	In the nine-month period ended September 30, 2013, under the 2012 Securities Repurchase Program, the Company repurchased 507,957 of its common shares for an aggregate purchase price of $35.7 million. The excess of the purchase price over the carrying value of the common shares repurchased of $25.8 million was charged to the accumulated deficit. These common shares were subsequently cancelled.
	Total Repurchases under the 2013 Securities Repurchase Program
	As of September 30, 2014, the Company has not made any purchases of our senior notes or common shares under the 2013 Securities Repurchase Program.
	Additional Repurchases outside the 2012 Securities Repurchase Program
	In addition to the repurchases made under the 2012 Securities Repurchase Program, during the second quarter of 2013, the Company repurchased an additional 217,294 of its common shares on behalf of certain members of the Company’s Board of Directors, in connection with the share settlement of certain deferred stock units and restricted stock units held by such directors following the termination of the applicable equity program. These common shares were subsequently transferred to such directors. These common shares were repurchased for an aggregate purchase price of $19.9 million. The excess of the purchase price over the carrying value of the common shares repurchased of $15.6 million was charged to the accumulated deficit. As the common shares were repurchased on behalf of certain of the Company’s directors, these repurchases were not made under the 2012 Securities Repurchase Program.

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
SHARE-BASED COMPENSATION	'
	SHARE-BASED COMPENSATION
	In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan is equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered, in the aggregate, 20,000,000 common shares of common stock for issuance under the 2014 Plan. Approximately 17,611,183 shares were available for future grants as of September 30, 2014. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.
	The following table summarizes the components and classification of share-based compensation expense related to stock options and restricted share units (“RSUs”) for the three-month and nine-month periods ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options	$	5.4	$	4.6	$	14.7	$	12.8
	RSUs	14.8		11.4		45.9		19.7
	Share-based compensation expense	$	20.2	$	16	$	60.6	$	32.5
	Research and development expenses	$	1.4	$	—	$	4.2	$	—
	Selling, general and administrative expenses	18.8		16		56.4		32.5
	Share-based compensation expense	$	20.2	$	16	$	60.6	$	32.5
	The increase in share-based compensation expense for the three-month and nine-month periods ended September 30, 2014 was driven primarily by (i) the incremental compensation expense related to the higher fair value for share-based awards granted subsequent to the third quarter of 2013 and (ii) the impact of the accelerated vesting in the first half of 2014 related to certain performance-based RSU awards.
	In the nine-month periods ended September 30, 2014 and 2013, the Company granted approximately 261,000 stock options with a weighted-average exercise price of $117.82 per option and approximately 912,000 stock options with a weighted-average exercise price of $84.51 per option, respectively. The weighted-average fair values of all stock options granted to employees in the nine-month periods ended September 30, 2014 and 2013 were $62.15 and $26.10, respectively.
	In the nine-month periods ended September 30, 2014 and 2013, the Company granted approximately 94,000 time-based RSUs with a weighted-average grant date fair value of $135.06 per RSU and approximately 95,000 time-based RSUs with a weighted-average grant date fair value of $73.90 per RSU, respectively.
	In the nine-month periods ended September 30, 2014 and 2013, the Company granted approximately 410,000 performance-based RSUs with a weighted-average grant date fair value of $209.72 per RSU and approximately 338,000 performance-based RSUs with a weighted-average grant date fair value of $125.04 per RSU, respectively.
	As of September 30, 2014, the total remaining unrecognized compensation expense related to non-vested stock options, time-based RSUs and performance-based RSUs amounted to $169.6 million, in the aggregate, which will be amortized over a weighted-average period of 3.41 years.

PENSION_AND_POSTRETIREMENT_EMP

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	9 Months Ended
	Sep. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	'
	PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
	In connection with the B&L Acquisition completed on August 5, 2013, the Company assumed all of B&L’s defined benefit obligations and related plan assets. This includes defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which cover a closed grandfathered group of legacy B&L U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance. The most significant non-U.S. plans are two defined benefit plans in Ireland. Both Ireland plans were closed to future service benefit accruals in 2011. All of the pension benefits that were earned prior to the closure of the plans were preserved; however, the only additional benefits that accrue are annual salary and inflation increases. The postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.
	Net Periodic (Benefit) Cost
	The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the three-month and nine-month periods ended September 30, 2014 and 2013:
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Three Months Ended September 30,
		2014			2013			2014			2013			2014			2013
	Service cost	$	0.1		$	0.1		$	1		$	0.7		$	0.4		$	0.4
	Interest cost	2.7			1.8			2.1			1.4			0.6			0.6
	Expected return on plan assets	(3.7		)	(2.4		)	(2.0		)	(1.2		)	(0.1		)	(0.1		)
	Amortization of prior service credit	—			—			—			—			(0.6		)	—
	Net periodic (benefit) cost	$	(0.9	)	$	(0.5	)	$	1.1		$	0.9		$	0.3		$	0.9
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Nine Months Ended September 30,
		2014			2013			2014			2013			2014			2013
	Service cost	$	0.3		$	0.1		$	3		$	1.2		$	1.2		$	0.4
	Interest cost	8.1			1.8			6.4			1.6			1.8			0.6
	Expected return on plan assets	(11.1		)	(2.4		)	(6.0		)	(1.2		)	(0.3		)	(0.1		)
	Amortization of prior service credit	—			—			—			—			(1.8		)	—
	Net periodic (benefit) cost	$	(2.7	)	$	(0.5	)	$	3.4		$	1.6		$	0.9		$	0.9
	During the nine-month period ended September 30, 2014, the Company contributed $8.5 million and $6.9 million to the U.S. and Non-U.S. pension benefit plans, respectively. In 2014, the Company expects to contribute $10.8 million and $8.5 million to the U.S. and Non-U.S. pension benefit plans, respectively, inclusive of amounts contributed to the U.S. and Non-U.S. pension plans during the nine-month period ended September 30, 2014.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
SHAREHOLDERS' EQUITY	'
	SHAREHOLDERS’ EQUITY
		Valeant Pharmaceuticals International, Inc. Shareholders
		Common Shares					Additional			Accumulated			Accumulated			Valeant			Noncontrolling			Total
							Paid-In			Deficit			Other			Pharmaceuticals			Interest			Equity
							Capital						Comprehensive			International, Inc.
													Loss			Shareholders’
		Shares		Amount												Equity
	Balance, January 1, 2013	303.9		$	5,940.70		$	267.1		$	(2,371.0	)	$	(119.4	)	$	3,717.40		$	—		$	3,717.40
	Issuance of common stock(1)	27.1		2,269.30			—			—			—			2,269.30			—			2,269.30
	Common shares issued under share-based compensation plans(2)	2.5		64.2			(60.6		)	—			—			3.6			—			3.6
	Repurchase of common shares(2)	(0.7	)	(14.2		)	—			(41.4		)	—			(55.6		)	—			(55.6		)
	Share-based compensation	—		—			32.5			—			—			32.5			—			32.5
	Employee withholding taxes related to share-based awards	—		—			(35.9		)	—			—			(35.9		)	—			(35.9		)
	Tax benefits from stock options exercised	—		—			48.6			—			—			48.6			—			48.6
	Noncontrolling interest from business combinations	—		—			—			—			—			—			113.5			113.5
	Noncontrolling interest distributions	—		—			—			—			—			—			(2.1		)	(2.1		)
		332.8		8,260.00			251.7			(2,412.4		)	(119.4		)	5,979.90			111.4			6,091.30
	Comprehensive loss:
	Net loss (income)	—		—			—			(989.9		)	—			(989.9		)	1.3			(988.6		)
	Other comprehensive loss	—		—			—			—			(40.9		)	(40.9		)	(0.6		)	(41.5		)
	Total comprehensive loss															(1,030.8		)	0.7			(1,030.1		)
	Balance, September 30, 2013	332.8		$	8,260.00		$	251.7		$	(3,402.3	)	$	(160.3	)	$	4,949.10		$	112.1		$	5,061.20
	Balance, January 1, 2014	333		$	8,301.20		$	228.8		$	(3,278.5	)	$	(132.8	)	$	5,118.70		$	114.6		$	5,233.30
	Common shares issued under share-based compensation plans	1		33.2			(23.6		)	—			—			9.6			—			9.6
	Settlement of stock options	—		—			(3.1		)	—			—			(3.1		)	—			(3.1		)
	Share-based compensation	—		—			60.6			—			—			60.6			—			60.6
	Employee withholding taxes related to share-based awards	—		—			(38.5		)	—			—			(38.5		)	—			(38.5		)
	Tax benefits from stock options exercised	—		—			17.1			—			—			17.1			—			17.1
	Acquisition of noncontrolling interest	—		—			(1.1		)	—			—			(1.1		)	(2.2		)	(3.3		)
	Noncontrolling interest distributions	—		—			—			—			—			—			(0.5		)	(0.5		)
		334		8,334.40			240.2			(3,278.5		)	(132.8		)	5,163.30			111.9			5,275.20
	Comprehensive loss:
	Net income (loss)	—		—			—			378.6			—			378.6			(0.5		)	378.1
	Other comprehensive loss	—		—			—			—			(419.2		)	(419.2		)	(0.5		)	(419.7		)
	Total comprehensive loss															(40.6		)	(1.0		)	(41.6		)
	Balance, September 30, 2014	334		$	8,334.40		$	240.2		$	(2,899.9	)	$	(552.0	)	$	5,122.70		$	110.9		$	5,233.60
	____________________________________
	-1	On June 24, 2013, the Company completed, pursuant to an Underwriting Agreement with Goldman Sachs & Co. and Goldman Sachs Canada, Inc., a public offering of 27,058,824 of its common shares, no par value, at a price of $85.00 per share, or aggregate gross proceeds of approximately $2.3 billion. In connection with the issuance of these new common shares, the Company incurred approximately $30.7 million of issuance costs, which has been reflected as reduction to the gross proceeds from the equity issuance.
	-2	During the second quarter of 2013, 225,000 common shares were repurchased by the Company pursuant to a purchase agreement with Goldman, Sachs & Co. Under this purchase program, the repurchases were made by Goldman, Sachs & Co. in compliance with Rule 10b5-1(c)(1)(i) of the Securities Exchange Act of 1934. 217,294 of these common shares were repurchased on behalf of certain members of the Company’s Board of Directors, and were subsequently transferred to such directors, in connection with the share settlement of certain deferred stock units and restricted stock units held by such directors following the termination of the applicable equity program. The remaining 7,706 common shares were repurchased on behalf of the Company pursuant to the 2012 Securities Repurchase Program (and therefore these shares are included in the 507,957 of total common shares repurchased under the 2012 Securities Repurchase Program as of September 30, 2013) and were subsequently cancelled (see note 11 titled “SECURITIES REPURCHASE PROGRAM” for further information).

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	9 Months Ended
	Sep. 30, 2014
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
	ACCUMULATED OTHER COMPREHENSIVE LOSS
	The components of accumulated other comprehensive loss as of September 30, 2014 and 2013, were as follows:
			Foreign			Unrealized		Net			Pension			Total
			Currency			Gain on		Unrealized			Adjustment
			Translation			Equity Investment		Holding
			Adjustment					Gain
								on Available-
								For-Sale
								Equity
								Securities
	Balance, January 1, 2013		$	(119.5	)	$	—	$	0.4		$	(0.3	)	$	(119.4	)
	Foreign currency translation adjustment		(40.5		)	—		—			—			(40.5		)
	Reclassification to net income (loss)(1)		—			—		(4.0		)	—			(4.0		)
	Net unrealized holding gain on available-for-sale equity securities		—			—		3.6			—			3.6
	Balance, September 30, 2013		$	(160.0	)	$	—	$	—		$	(0.3	)	$	(160.3	)
	Balance, January 1, 2014		$	(170.3	)	$	—	$	—		$	37.5		$	(132.8	)
	Foreign currency translation adjustment		(439.9		)	—		—			—			(439.9		)
	Unrealized gain on equity method investment, net of tax		—			22.5		—			—			22.5
	Net unrealized holding gain on available-for-sale equity securities, net of tax		—			—		1.8			—			1.8
	Reclassification to net income (loss)(1)		—			—		(1.8		)	—			(1.8		)
	Pension adjustment(2)		—			—		—			(1.8		)	(1.8		)
	Balance, September 30, 2014		$	(610.2	)	$	22.5	$	—		$	35.7		$	(552.0	)
	____________________________________
	-1	Included in gain on investments, net.
	-2	Reflects changes in defined benefit obligations and related plan assets of the Company’s defined benefit pension plans and the U.S. postretirement benefit plan (as described in note 13).
	Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar. Income taxes allocated to pension adjustments and reclassification adjustments were not material.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	In the three-month period ended September 30, 2014, the Company recognized an income tax expense of $100.3 million, comprised of $101.4 million related to the expected tax expense in tax jurisdictions outside of Canada and an income tax benefit of $1.1 million related to Canadian income taxes. In the nine-month period ended September 30, 2014, the Company recognized an income tax expense of $124.4 million, comprised of $130.7 million related to the expected tax expense in tax jurisdictions outside of Canada and an income tax benefit of $6.3 million related to Canadian income taxes. In the three-month period ended September 30, 2014, the Company’s effective tax rate was different from the Company’s statutory Canadian tax rate due to (i) tax expense generated from the Company’s annualized mix of earnings by jurisdiction, (ii) a tax benefit on losses in Canada associated with unrealized gains in other comprehensive (loss) income, (iii) tax expense of $97.2 million associated with the divestiture of filler and toxin assets to Galderma, and (iv) tax benefit of $22.2 million related to the U.S. Federal tax return filing update to the prior year estimate of taxes. In addition to the points noted immediately above, the nine-month period ended September 30, 2014 was also impacted by (i) tax expense incurred in the first quarter of 2014 of approximately $13.3 million, associated with an out of period adjustment for the tax impacts of intercompany profit in ending inventory and (ii) a tax benefit of approximately $20.4 million, inclusive of an out of period adjustment of $15.9 million, associated with the adjustment of various uncertain tax positions previously accrued by the Company in the second quarter of 2014. Management does not believe that these adjustments are material to the current or prior periods.
	The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $487.2 million as of September 30, 2014 and $477.6 million as of December 31, 2013. The majority of the increase is due to the establishment of a valuation allowance on certain previously recorded U.S. State deferred tax assets due to the internal restructuring of the Company, the effect of which is deferred under U.S. GAAP. The Company will continue to assess this amount for appropriateness on a go-forward basis associated with the deferred tax assets previously established.
	The Company completed certain additional steps in early 2014 related to the internal reorganization that it undertook in December 2013 whereby it contributed assets to its Irish and Luxembourg subsidiaries. The internal reorganization had no tax impact on the Company's financial position.
	As of September 30, 2014, the Company had $222.8 million of unrecognized tax benefits, which included $39.8 million relating to interest and penalties. Of the total unrecognized tax benefits, $115.7 million would reduce the Company’s effective tax rate, if recognized. The Company anticipates that a minimal amount of unrecognized tax benefits may be resolved within the next 12 months.
	The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of September 30, 2014, the Company had accrued $4.0 million for interest and $0.8 million for penalties.
	The Company is under examination by the Canada Revenue Agency ("CRA") for its 2005 to 2008 and 2010-2011 tax years. In 2013, the Company received updated reassessments for the 2005, 2006, 2007, and 2008 tax years which mainly relate to CRA’s denial of deductions for legal and consulting fees. In 2014, the Company received a notice of the CRA’s intent to audit the 2009 tax year. The 2009 and 2010-2011 examinations are in their preliminary phase and no reassessments have been issued.
	During the second quarter of 2014, the Internal Revenue Service (“IRS”) commenced an audit of the Valeant U.S. consolidated group for its 2011 and 2012 tax years. Valeant is also currently under examination for various state tax audits for years 2002 to 2010. B&L (U.S.) has effectively closed IRS audits through the 2010 tax year. B&L (U.S.) is currently open to audit for various state tax audits for years 1999 to 2012. In addition, certain affiliates of the Company in other regions outside of Canada and the U.S. are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect proposed adjustments, if any, would be material to the Company's financial statements.

EARNINGS_LOSS_PER_SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
EARNINGS (LOSS) PER SHARE	'
	EARNINGS (LOSS) PER SHARE
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and nine-month periods ended September 30, 2014 and 2013 were calculated as follows:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014		2013
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$	275.4	$	(973.2	)	$	378.6	$	(989.9	)
	Basic weighted-average number of common shares outstanding	335.4		333.6			335.2		316.5
	Diluted effect of stock options and RSUs(a)	5.9		—			6.2		—
	Diluted weighted-average number of common shares outstanding	341.3		333.6			341.4		316.5
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.82	$	(2.92	)	$	1.13	$	(3.13	)
	Diluted	$	0.81	$	(2.92	)	$	1.11	$	(3.13	)
	____________________________________
	(a)	In the three-month and nine-month periods ended September 30, 2013, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months	Nine Months
			Ended	Ended
			September 30,	September 30,
			2013	2013
	Basic weighted-average number of common shares outstanding		333.6	316.5
	Dilutive effect of stock options and RSUs		6.6	6.4
	Diluted weighted-average number of common shares outstanding		340.2	322.9
	In the three-month and nine-month periods ended September 30, 2014, stock options to purchase approximately 1,130,000 and 896,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method, compared with approximately 401,000 and 415,000 common shares in the corresponding periods of 2013.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	9 Months Ended
	Sep. 30, 2014
Loss Contingency, Information about Litigation Matters [Abstract]	'
LEGAL PROCEEDINGS	'
	LEGAL PROCEEDINGS
	From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, antitrust, governmental and regulatory investigations, and related private litigation. There are also ordinary course employment-related issues and other types of claims in which the Company routinely becomes involved, but which individually and collectively are not material.
	Unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares to decline.
	From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company cannot reasonably predict the outcome of these proceedings, some of which may involve significant legal fees. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets.
	Governmental and Regulatory Inquiries
	On May 16, 2008, Biovail Pharmaceuticals, Inc. (“BPI”), the Company’s former subsidiary, entered into a written plea agreement with the U.S. Attorney’s Office (“USAO”) for the District of Massachusetts whereby it agreed to plead guilty to violating the U.S. Anti-Kickback Statute and pay a fine of $22.2 million.
	In addition, on May 16, 2008, the Company entered into a non-prosecution agreement with the USAO whereby the USAO agreed to decline prosecution of Biovail in exchange for continuing cooperation and a civil settlement agreement and pay a civil penalty of $2.4 million. A hearing before the U.S. District Court in Boston took place on September 14, 2009 and the plea was approved.
	In addition, as part of the overall settlement, Biovail entered into a Corporate Integrity Agreement (“CIA”) with the Office of the Inspector General and the Department of Health and Human Services on September 11, 2009. The CIA requires the Company to have a compliance program in place and to undertake a set of defined corporate integrity obligations for a five-year term. The CIA also includes requirements for an annual independent review of these obligations. Pursuant to the terms of the CIA, the Company expects the requirements contained in the CIA to terminate by the end of the second quarter of 2015. Failure to comply with the obligations under the CIA could result in financial penalties.
	Securities
	Medicis Shareholder Class Actions
	Prior to the Company’s acquisition of Medicis, several purported holders of then public shares of Medicis filed putative class action lawsuits in the Delaware Court of Chancery and the Arizona Superior Court against Medicis and the members of its Board of Directors, as well as one or both of Valeant and Merlin Merger Sub (the wholly-owned subsidiary of Valeant formed in connection with the Medicis Acquisition). The Delaware actions (which were instituted on September 11, 2012 and October 1, 2012, respectively) were consolidated for all purposes under the caption In re Medicis Pharmaceutical Corporation Stockholders Litigation, C.A. No. 7857-CS (Del. Ch.). The Arizona action (which was instituted on September 11, 2012) bears the caption Swint v. Medicis Pharmaceutical Corporation, et. al., Case No. CV2012-055635 (Ariz. Sup. Ct.). The actions all alleged, among other things, that the Medicis directors breached their fiduciary duties because they supposedly failed to properly value Medicis and caused materially misleading and incomplete information to be disseminated to Medicis’ public shareholders, and that Valeant and/or Merlin Merger Sub aided and abetted those alleged breaches of fiduciary duty. The actions also sought, among other things, injunctive and other equitable relief, and money damages.
	On November 20, 2012, Medicis and the other named defendants in the Delaware action signed a memorandum of understanding (“MOU”) to settle the Delaware action and resolve all claims asserted by the purported class.  The parties executed a Stipulation and Agreement of Compromise and Settlement on November 25, 2013, which provided, among other things, that Medicis and the other defendants would not oppose plaintiffs’ request for a fee award (subject to a capped amount). The settlement and fee award were subject to court approval. At the settlement hearing on February 26, 2014, the Delaware Court of Chancery declined to approve the settlement or award plaintiffs any attorneys’ fees. The matter was dismissed with prejudice to allow the plaintiff to revise their fee request, which they have subsequently decided not to bring. The Delaware action is now concluded.
	The plaintiff in the Arizona action agreed to dismiss her complaint. On January 15, 2013, the Arizona Superior Court issued an order granting the parties' joint stipulation to dismiss the Arizona action.
	Obagi Shareholder Class Actions
	Prior to the acquisition of all of the outstanding common stock of Obagi, the following complaints were filed: (i) a complaint in the Court of Chancery of the State of Delaware, dated March 22, 2013, and amended on April 1, 2013 and on April 8, 2013, captioned Michael Rubin v. Obagi Medical Products, Inc., et al.; (ii) a complaint in the Superior Court of the State of California, County of Los Angeles, dated March 22, 2013, and amended on March 27, 2013, captioned Gary Haas v. Obagi Medical Products, Inc., et al.; and (iii) a complaint in the Superior Court of the State of California, County of Los Angeles, dated March 27, 2013, captioned Drew Leonard v. Obagi Medical Products, Inc., et al. Each complaint is a purported shareholder class action and names as defendants Obagi and the members of the Obagi Board of Directors. The two complaints filed in California also name Valeant and Odysseus Acquisition Corp. (the wholly-owned subsidiary of Valeant formed in connection with the Obagi acquisition) as defendants. The plaintiffs’ allegations in each action are substantially similar. The plaintiffs allege that the members of the Obagi Board of Directors breached their fiduciary duties to Obagi’s stockholders in connection with the sale of the company, and the California complaints further allege that Obagi, Valeant and Odysseus Acquisition Corp. aided and abetted the purported breaches of fiduciary duties. In support of their purported claims, the plaintiffs allege that the proposed transaction undervalued Obagi, involved an inadequate sales process and included preclusive deal protection devices. The plaintiffs in the Rubin case in Delaware and in the Haas case in California also filed amended complaints, which added allegations challenging the adequacy of the disclosures concerning the transaction. The plaintiffs sought damages and to enjoin the transaction, and also sought attorneys’ and expert fees and costs. On April 12, 2013, the defendants entered into an MOU with the plaintiffs in the actions pending in the Court of Chancery of the State of Delaware and the Superior Court of the State of California, pursuant to which Obagi and such parties agreed in principle, and subject to certain conditions, to settle those stockholder lawsuits. The parties executed a Stipulation and Agreement of Compromise, Settlement and Release on January 31, 2014, which set forth the terms for the settlement and dismissal of the lawsuits and provided, among other things, that Obagi and the other defendants would not oppose plaintiffs’ request for a fee award (subject to a capped amount). That settlement and fee award were subject to court approval. On February 6, 2014, the Court of Chancery of the State of Delaware issued an Order for Notice and Scheduling of Hearing on Settlement, preliminarily certifying the Rubin case as a non-opt out class action for settlement purposes, directing notice of the proposed settlement to members of the class, and setting a hearing to consider final approval of the settlement for April 30, 2014. At the settlement hearing on April 30, 2014, the Delaware Court of Chancery declined to approve the settlement or award plaintiff any attorneys’ fees. On May 1, 2014, Obagi filed its Answer to Plaintiff’s Verified Second Amended Class Action Complaint in the Court of Chancery of the State of Delaware. After receiving notice that the parties had reached an agreement to settle the litigation, the Superior Court of the State of California scheduled a “Hearing on Order to Show Cause Re Dismissal” and continued the hearing several times pending completion of definitive documentation and approval proceedings in the Court of Chancery of the State of Delaware. Following the decision of the Court of Chancery of the State of Delaware declining to approve the settlement, that “OSC re: Dismissal” hearing in the Superior Court of the State of California has been continued to December 24, 2014 pending the parties’ discussions regarding further proceedings. On October 3, 2014, plaintiffs in the action pending in Delaware filed a notice of dismissal with prejudice.  The Delaware Court of Chancery entered the dismissal of the action with prejudice as to the named plaintiffs on October 8, 2014.  On October 15, 2014, plaintiffs in the California actions sought voluntary dismissal without prejudice of each of those actions without notice to the proposed class.  The court in the California actions has not yet ruled on plaintiffs' motion.
	Solta Medical Shareholder Class Actions
	Prior to the Company’s completion of the acquisition of Solta Medical, several purported holders of then public shares of Solta Medical filed putative class action lawsuits in the Delaware Court of Chancery and the Superior Court of the State of California, County of Alameda, against Solta Medical and the members of its board of directors, as well as the Company, Valeant, and Sapphire Subsidiary Corp. (the wholly-owned subsidiary of Valeant formed in connection with the Solta Medical acquisition). The Delaware actions were consolidated for all purposes under the caption In re Solta Medical, Inc. Stockholders Litigation, C.A. No. 9170-CS (Del. Ch.). The California actions were filed under the captions Lathrop v. Covert, et al., Case No. HG13-707363 (Cal. Super.); Walter, et al. v. Solta Medical, Inc., et al., Case No. RG13-707659 (Cal. Super.); and Bushansky v. Solta Medical, Inc., et al., Case No. RG13-707997 (Cal. Super.). The plaintiffs’ allegations in each action were substantially similar. The actions all alleged, among other things, that the directors of Solta Medical breached their fiduciary duties to the stockholders of Solta Medical in connection with the Company's proposed acquisition of Solta Medical. In support of their purported claims, the plaintiffs alleged that the proposed transaction did not appropriately value Solta Medical, was the result of an inadequate process and included preclusive deal protection devices. The plaintiffs also alleged that the Schedule 14D-9 filed by Solta Medical on December 23, 2013, in connection with the proposed transaction contained material omissions and misstatements. The complaints claimed that Solta Medical, the Company, Valeant, and Sapphire Subsidiary Corp. aided and abetted the purported breaches of fiduciary duty. The actions sought, among other things, injunctive and other equitable relief, and money damages. The plaintiffs also sought attorneys’ and expert fees and costs. While the defendants believed that each of the aforementioned lawsuits were without merit and that they had valid defenses to all claims, in an effort to minimize the cost and expense of any litigation relating to the lawsuits, on January 11, 2014, following arms-length negotiations, Solta Medical and the other named defendants signed an MOU to settle the actions and resolve all claims asserted by the purported stockholder classes. The settlement, which is subject to court approval and further definitive documentation, provides for a release and settlement by Solta Medical’s stockholders of all claims against Solta Medical and the other defendants and their respective affiliates and agents in connection with the Company's acquisition of Solta Medical. In connection with the proposed settlement, the plaintiffs intend to seek an award of attorneys’ fees and expenses, which amount is subject to approval by the Delaware Court of Chancery. On July 10, 2014, the parties entered into a Stipulation and Agreement of Compromise, Settlement and Release and the Court entered a scheduling order on July 14, 2014. Pursuant to the scheduling order, a settlement hearing was held on September 29, 2014 and the settlement was approved by the Court.
	Antitrust
	Solodyn® Antitrust Class Actions
	On July 22, 2013, United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, filed a civil antitrust class action complaint in the United States District Court for the Eastern District of Pennsylvania, Case No. 2:13-CV-04235-JCJ, against Medicis, the Company and various manufacturers of generic forms of Solodyn®, alleging that the defendants engaged in an anticompetitive scheme to exclude competition from the market for minocycline hydrochloride extended release tablets, a prescription drug for the treatment of acne marketed by Medicis under the brand name, Solodyn®.  The plaintiff further alleges that the defendants orchestrated a scheme to improperly restrain trade, and maintain, extend and abuse Medicis' alleged monopoly power in the market for minocycline hydrochloride extended release tablets to the detriment of plaintiff and the putative class of end-payor purchasers it seeks to represent, causing them to pay overcharges.  Plaintiff alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1, 2, and of various state antitrust and consumer protection laws, and further alleges that defendants have been unjustly enriched through their alleged conduct. Plaintiff seeks declaratory and injunctive relief and, where applicable, treble, multiple, punitive and/or other damages, including attorneys' fees.  Additional class action complaints making similar allegations against all defendants, including Medicis and the Company have been filed in various courts by other private plaintiffs purporting to represent certain classes of similarly-situated direct or end-payor purchasers of Solodyn® (Rochester Drug Co-Operative, Inc., Case No. 2:13-CV-04270-JCJ (E.D. Pa. filed July 23, 2013); Local 274 Health & Welfare Fund, Case No. 2:13-CV-4642-JCJ (E.D.Pa. filed Aug. 9, 2013); Sheet Metal Workers Local No. 25 Health & Welfare Fund, Case No. 2:13-CV-4659-JCJ (E.D. Pa. filed Aug. 8, 2013); Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund, Case No. 2:13-CV-5021-JCJ (E.D. Pa. filed Aug. 27, 2013); Heather Morgan, Case No. 2:13-CV-05097 (E.D. Pa. filed Aug. 29, 2013); Plumbers & Pipefitters Local 176 Health & Welfare Trust Fund, Case No. 2:13-CV-05105 (E.D. Pa. filed Aug. 30, 2013); Ahold USA, Inc., Case No. 1:13-cv-12225 (D. Mass. filed Sept. 9, 2013); City of Providence, Rhode Island, Case No. 2:13-cv-01952 (D. Ariz. filed Sept. 24, 2013); International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Trust Fund, Case No. 1:13-cv-12435 (D. Mass. filed Oct. 2, 2013); Painters District Council No. 30 Health and Welfare Fund et al., Case No. 1:13-cv-12517 (D. Mass. filed Oct. 7, 2013); Man-U Service Contract Trust Fund, Case No. 13-cv-06266-JCJ (E.D. Pa. filed Oct. 25, 2013)).  On August 29, 2013, International Union of Operating Engineers Local 132 Health and Welfare Fund voluntarily dismissed the class action complaint it had originally filed on August 1, 2013, in the United States District Court for the Northern District of California, and on August 30, 2013, re-filed its class action complaint in the United States District Court for the Eastern District of Pennsylvania (Case No. 2:13-cv-05108). The International Union of Operating Engineers Local 132 Health and Welfare Fund complaint makes similar allegations against all defendants, including Medicis and the Company, and seeks similar relief, to the other end-payor plaintiff complaints.  On October 11, 2013, Medicis and the Company filed a motion with the Judicial Panel for Multidistrict Litigation ("JPML") seeking an order transferring and consolidating the thirteen putative class action cases for coordinated pretrial proceedings.  On February 25, 2014, the JPML ordered that the cases pending outside the District of Massachusetts be transferred to the District of Massachusetts, with the consent of that court, for coordinated or consolidated pretrial proceedings with the actions already pending in that district.  The Multi-District Litigation (“MDL”), captioned In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation, Case No. 1:14-md-02503-DJC, is now pending before U.S. District Judge Denise Casper.  Two additional end-payor actions have been filed in the District of Massachusetts since the February 25th centralization order:  Allied Services Division Welfare Fund, Case No. 1:14-cv-10786 (D. Mass. filed Mar. 14, 2014); and NECA-IBEW Welfare Trust Fund, Case No. 1:14-cv-11015 (D. Mass. filed Mar. 19, 2014).  These cases have been included in the pending MDL.  On September 12, 2014, the Direct Purchaser Plaintiffs and the End-Payor Plaintiffs each filed a consolidated amended class action complaint; however, on September 19, 2014, both the Direct Purchasers Plaintiffs and End-Payor Plaintiffs notified Medicis and the Company of errors in their respective complaints. With Defendants’ consent, the Direct Purchaser Plaintiffs filed a corrected amended complaint on September 22, 2014. The Defendants did not consent to the End-Payor Plaintiffs’ filing of a corrected complaint, and the End-Payor Plaintiffs have yet to move for leave to file a further amended complaint. An initial status conference was held on September 29, 2014. Under the current schedule, any responsive pleadings are due on November 24, 2014.  The Company is in the process of evaluating the claims and plan to vigorously defend these actions.
	Intellectual Property
	AntiGrippin® Litigation
	Two suits have been brought against the Company's subsidiary, Natur Produkt, seeking lost profits in connection with the registration by Natur Produkt of its AntiGrippin trademark. The plaintiffs in these matters allege that Natur Produkt violated Russian competition law by preventing plaintiffs from producing and marketing their products under certain brand names. The first matter (Case No. A-56-23056/2013, Arbitration Court of St. Petersburg) was accepted for proceedings on June 24, 2013 and a hearing was held on November 28, 2013. In a decision dated December 4, 2013, the court found in favor of the plaintiff (AnviLab) and awarded the plaintiff lost profits in the amount of approximately $50 million. The $50 million charge was recognized in the fourth quarter of 2013 in Other (income) expense in the consolidated statements of income (loss). Natur Produkt appealed this decision, and a hearing in the appeal proceeding was held on March 16, 2014. The appeal court found in favor of Natur Produkt and dismissed the plaintiff’s claim in full. Following this decision, the Company concluded that the potential loss was no longer probable, and therefore the $50 million reserve was reversed in the first quarter of 2014 in Other (income) expense in the consolidated statements of income (loss). Anvilab appealed the appeal court's decision to the cassation court. On June 19, 2014, the cassation court resolved that the matter is within the jurisdiction of the Intellectual Property (IP) court in this instance. The hearing before the IP court was held on July 30, 2014 and August 1, 2014. The IP court found in favor of the plaintiff and ruled to send the case for the second review to the court of the first instance, indicating that the court of the first instance should decide on the amount of damages suffered by Anvilab. Natur Produkt appealed the decision of the IP Court to the Supreme Court on September 15, 2014, but, on October 22, 2014, the Supreme Court denied that appeal and the matter will now be sent back to the court of first instance for the second review. The Company believes that the potential damages in this matter, if any, are not estimable at this time. Natur Produkt intends to continue to vigorously defend this matter.
	Natur Produkt was served with a claim in the second matter (Case No. A-56-38592/2013, Arbitration Court of St. Petersburg) on July 16, 2013 by the plaintiff in that matter (ZAO Tsentr Vnedreniya PROTEK (“Protek”)). A hearing was held in this matter on September 29, 2013 and, on October 18, 2013, the court found in favor of Natur Produkt. Protek filed an appeal of the decision on November 26, 2013. A hearing in the appeal proceeding was held on January 30, 2014 and the appeal court also found in favor of Natur Produkt. Protek appealed that decision to the cassation court (Case No. A-56-38592/2013) and, on July 7, 2014, the cassation court also found in favor of Natur Produkt. Protek did not exercise its right to appeal the cassation court decision to the Supreme Court.
	Perrigo ACANYA® Litigation
	On October 3, 2013, the Company’s subsidiary, Dow Pharmaceutical Sciences, Inc. (“Dow”) received a Notice of Paragraph IV Certification dated October 2, 2013 from Perrigo Israel Pharmaceuticals Ltd. (“Perrigo”), related to Perrigo’s ANDA filing with the FDA for Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, which corresponds to the Company’s Acanya® Gel product. In the notice, Perrigo asserted that U.S. Patent No. 8,288,434 (the “'434 Patent”), which is listed in the FDA’s Orange Book for Acanya® Gel, is either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale or importation of Perrigo’s generic product for which the ANDA was submitted. Dow holds the NDA for Acanya® Gel and is the owner of the ‘434 Patent. Dow and its affiliate, Valeant Pharmaceuticals North America LLC (“VPNA”), filed suit pursuant to the Hatch-Waxman Act against Perrigo on November 15, 2013, in the U.S. District Court for the District of New Jersey (Case No. 13-CV-06922-SRC), thereby triggering a 30-month stay of the approval of Perrigo’s ANDA. In the suit, Dow and VPNA alleged infringement by Perrigo of one or more claims of the '434 Patent.
	On July 30, 2014, Perrigo, Perrigo Company, Dow and VPNA entered into a settlement agreement to settle all outstanding patent litigation related to Perrigo’s generic version of Acanya® Gel. Under the terms of the settlement agreement, Dow and VPNA will grant Perrigo a royalty-free license to market its generic version of Acanya® Gel beginning on December 29, 2018 or earlier under certain circumstances.
	Taro ACANYA® Litigation
	On July 1, 2014, Dow received a Notice of Paragraph IV Certification dated June 29, 2014 from Taro Pharmaceutical Sciences Inc. (“Taro”), related to Taro’s ANDA filing with the FDA for Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, which corresponds to the Company’s Acanya® Gel product. In the notice, Taro asserted that the '434 Patent and U.S. Patent No. 8,663,699 (the “’699 Patent”), which are listed in the FDA’s Orange Book for Acanya® Gel, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale or importation of Taro’s generic product for which the ANDA was submitted. Dow holds the NDA for Acanya® Gel and is the owner of the ‘434 Patent and the ‘699 Patent. Dow and VPNA filed suit pursuant to the Hatch-Waxman Act against Taro on August 13, 2014, in the U.S. District Court for the District of New Jersey (Case No. 2:14-cv-05079-SRS-CLW), thereby triggering a 30-month stay of the approval of Taro’s ANDA. In the suit, Dow and VPNA alleged infringement by Taro of one or more claims of the '434 Patent and the ‘699 Patent.
	On September 11, 2014, Taro, Dow and VPNA entered into a settlement agreement to settle all outstanding patent litigation related to Taro’s generic version of Acanya® Gel. Under the terms of the settlement agreement, Dow and VPNA will grant Taro a royalty-free license to market its generic version of Acanya® Gel beginning on December 29, 2018 or earlier under certain circumstances.
	Allergan Patent Infringement Proceeding - Restylane-L® and Perlane-L®
	On September 13, 2013, Allergan USA, Inc. and Allergan Industrie, SAS (collectively, “Allergan”) filed a Complaint for Patent Infringement in the United States District Court for the Central District of California (Case No. SACV13-1436 AG (JPRX)) against the Company and certain of its affiliates, including Medicis. The complaint alleges that the Company and its affiliates named in the complaint have infringed Allergan’s US Patent No. 8,450,475 (the “‘475 Patent”) by selling, offering to sell and importing in and into the United States the Company’s Restylane-L® and Perlane-L® dermal filler products. Allergan is seeking a permanent injunction and unspecified damages. The Company filed an Answer in this matter on November 18, 2013. On December 31, 2013, the parties to this matter filed a Joint Report with the Court, proposing certain case management dates, including a proposed trial date of July 27, 2015. The matter is proceeding in the ordinary course. The products that are the subject of this proceeding were sold by the Company as part of the transaction with Galderma that was completed on July 10, 2014 (see note 4 "DIVESTITURES"); however, the Company and its applicable affiliates remain party to this proceeding.
	Lupin PROLENSA® Litigation
	On or about December 20, 2013, the Company and B&L received a Notice of Paragraph IV Certification dated December 19, 2013 from Lupin, Ltd. (“Lupin”), related to Lupin’s ANDA filing with the FDA for bromfenac ophthalmic solution 0.07%, which corresponds to the Company’s Prolensa® product. In the notice, Lupin asserted that U.S. Patent No. 8,129,431 (the “'431 Patent”), which is listed in the FDA’s Orange Book for Prolensa®, is either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin’s generic product for which the ANDA was submitted. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju Pharmaceutical Co., Ltd. (“Senju”) of the ‘431 Patent. B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed suit pursuant to the Hatch-Waxman Act against Lupin on January 31, 2014, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-00667-JBS-KMW), thereby triggering a 30-month stay of the approval of Lupin’s ANDA. In the suit, the Plaintiffs allege infringement by Lupin of one or more claims of the ‘431 Patent. During a scheduling conference on May 16, 2014, a schedule in this matter was set through to opening submission in the Markman hearing in January 2015. Fact discovery commenced on May 20, 2014 in accordance with this schedule. There will be a scheduling conference on October 28, 2014 to consolidate, for pre-trial purposes, the ‘431 Patent’, the ‘290 Patent’ and the ‘131 Patent” (identified below). A scheduling conference has been set for February 4, 2015 to set the remainder of the schedule. This matter is proceeding in the ordinary course.
	On or about May 14, 2014, the Company and B&L received a Notice of Paragraph IV Certification dated May 13, 2014 from Lupin, related to Lupin’s ANDA filing with the FDA for bromfenac ophthalmic solution 0.07%, which corresponds to the Company’s Prolensa® product. In the notice, Lupin asserted that U.S. Patent No. 8,669,290 (the “'290 Patent”), which issued on March 11, 2014 and which is listed in the FDA’s Orange Book for Prolensa®, is either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin’s generic product for which the ANDA was submitted. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju of the ‘290 Patent. B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed suit pursuant to the Hatch-Waxman Act against Lupin on June 26, 2014, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-04149-JBS-KMW). In the suit, the Plaintiffs allege infringement by Lupin of one or more claims of the ‘290 Patent. This matter is proceeding in the ordinary course.
	On or about July 5, 2014, the Company and B&L received a Notice of Paragraph IV Certification dated July 3, 2014 from Lupin, related to Lupin’s ANDA filing with the FDA for bromfenac ophthalmic solution 0.07%, which corresponds to the Company’s Prolensa® product. In the notice, Lupin asserted that U.S. Patent No. 8,754,131 (the “'131 Patent”), which issued on June 17, 2014 and which is listed in the FDA’s Orange Book for Prolensa®, is either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin’s generic product for which the ANDA was submitted. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju of the ‘131 Patent. B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed suit pursuant to the Hatch-Waxman Act against Lupin on August 15, 2014, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-00667-JBS-KMW). In the suit, the Plaintiffs allege infringement by Lupin of one or more claims of the ‘131 Patent. This matter is proceeding in the ordinary course.
	Metrics PROLENSA® Litigation
	Metrics, Inc. (“Metrics”) filed an ANDA with the FDA seeking approval to market generic bromfenac ophthalmic solution 0.07%, which corresponds to the Company’s Prolensa® product. B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed suit pursuant to the Hatch-Waxman Act against Metrics and certain of its affiliated entities, namely Coastal Pharmaceuticals, Inc. (“Coastal”), Mayne Pharma Group Limited and Mayne Pharma (USA), Inc. (collectively, with Metrics, the “Defendants”) on June 20, 2014, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-03962-JBS-KMW), thereby triggering a 30-month stay of the approval of Metrics’ ANDA. In the suit, the Plaintiffs allege infringement by the Defendants of one or more claims of each of the ‘431 Patent, the ‘290 Patent and the ‘131 Patent. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju of the ‘431 Patent, ‘290 Patent and ‘131 Patent. Subsequent to the filing of the suit, B&L received, on or about June 27, 2014, a Notice of Paragraph IV Certification dated June 26, 2014 from Coastal, related to the ANDA filing described above for generic bromfenac ophthalmic solution 0.07%. In the notice, Coastal asserted that the ‘431 Patent and the ‘290 Patent, which are listed in the FDA’s Orange Book for Prolensa®, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, importation, offer for sale or sale of the generic product for which the ANDA was submitted. On August 14, 2014, Metrics moved to dismiss the Plaintiffs' action based on lack of personal jurisdiction and oral argument on this motion was held on October 3, 2014. A decision on this motion is pending.
	B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed a protective suit pursuant to the Hatch-Waxman Act against Metrics and certain of its affiliated entities, namely Coastal Pharmaceuticals, Inc. (“Coastal”), Mayne Pharma Group Limited and Mayne Pharma (USA), Inc. (collectively, with Metrics, the “Defendants”) on August 7, 2014, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-04964-JBS-KMW), thereby triggering a 30-month stay of the approval of Metrics’ ANDA. In the suit, the Plaintiffs allege infringement by the Defendants of one or more claims of each of the ‘431 Patent, the ‘290 Patent and the ‘131 Patent. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju of the ‘431 Patent, ‘290 Patent and ‘131 Patent. This matter is proceeding in the ordinary course.
	B&L, Bausch & Lomb Pharma Holdings and Senju (collectively, the “Plaintiffs”) filed a protective suit pursuant to the Hatch-Waxman Act against Metrics and certain of its affiliated entities, namely Coastal Pharmaceuticals, Inc. (“Coastal”), Mayne Pharma Group Limited and Mayne Pharma (USA), Inc. (collectively, with Metrics, the “Defendants”) on August 8, 2014, in the U.S. District Court for the District of North Carolina (Case No. 4:14-cv-141), thereby triggering a 30-month stay of the approval of Metrics’ ANDA. In the suit, the Plaintiffs allege infringement by the Defendants of one or more claims of each of the ‘431 Patent, the ‘290 Patent and the ‘131 Patent. B&L holds the NDA for Prolensa® and Bausch & Lomb Pharma Holdings is the exclusive licensee of Senju of the ‘431 Patent, ‘290 Patent and ‘131 Patent. This matter is proceeding in the ordinary course.
	On July 22, 2014, two Notices of Filing Date Accorded papers were issued by the US Patent & Trademark Office (“USPTO”) for petitions filed by Metrics for Inter Partes Reviews (“IPRs”) 2014-01041 and 2014-01043, which correspond to the ‘431 Patent and the ‘290 Patent, respectively.  A petitioner for IPR may request the USPTO to cancel as unpatentable one or more claims of a patent on a ground that could be raised under 35 USC 102 or 35 USC 103 of the U.S. Patent Act and only on the basis of prior art consisting of patents or printed publications. A patent owner may file a preliminary response to an IPR petition to provide reasons why no such review should be instituted. A patent owner has three months to submit a preliminary response to an IPR and a response in these proceedings is due November 20, 2014. On July 10, 2014, Plaintiffs, in the U.S. District Court for the District of New Jersey (Case No. 1:14-cv-03962-JBS-KMW), moved to enjoin the Defendants from prosecuting these two IPRs and oral argument on this motion was held on October 3, 2014. A decision on this motion is pending.
	General Civil Actions
	Afexa Class Action
	On March 9, 2012, a Notice of Civil Claim was filed in the Supreme Court of British Columbia which seeks an order certifying a proposed class proceeding against the Company and a predecessor, Afexa (Case No. NEW-S-S-140954). The proposed claim asserts that Afexa and the Company made false representations respecting Cold-FX® to residents of British Columbia who purchased the product during the applicable period and that the proposed class has suffered damages as a result. The Company filed its certification materials on February 6, 2013 and a hearing on certification was held on September 3 to 6, 2013.  An additional hearing day was scheduled for January 16, 2014. On November 8, 2013, the Plaintiff served an amended notice of civil claim which seeks to re-characterize the representation claims and broaden them from what was originally claimed.  As a result, the hearing date scheduled for January 16, 2014 was cancelled and, at the request of the Court, the parties made submissions to address the impact of the amendments. The Court rendered a decision on March 27, 2014 denying costs orders for both parties and directing the parties to obtain a revised certification hearing schedule for the continuation of the certification hearing at an agreeable time. The Company denies the allegations being made and is vigorously defending this matter.
	Legacy Medicis Litigation
	Civil Investigative Demand from the U.S. Federal Trade Commission
	On May 2, 2012, Medicis received a civil investigative demand from the FTC requiring that Medicis provide to the FTC information and documents relating to various settlement and other agreements with makers of generic SOLODYN® products following patent infringement claims and litigation, each of which was previously filed with the FTC and the Antitrust Division of the Department of Justice, and other efforts principally relating to SOLODYN®. On June 7, 2013, Medicis received an additional civil investigative demand relating to such settlements, agreements and efforts. Medicis is cooperating with this investigative process. If, at the conclusion of this process, the FTC believes that any of the agreements or efforts violates antitrust laws, it could challenge Medicis through a civil administrative or judicial proceeding. If the FTC ultimately challenges the agreements, we would expect to vigorously defend in any such action.
	Employment Matter
	In September, 2011, Medicis received a demand letter from counsel purporting to represent a class of female sales employees alleging gender discrimination in, among others things, compensation and promotion as well as claims that the former management group maintained a work environment that was hostile and offensive to female sales employees. Related charges of discrimination were filed prior to the end of 2011 by six former female sales employees with the Equal Employment Opportunity Commission (the “EEOC”). Three of those charges have been dismissed by the EEOC and the EEOC has made no findings of discrimination. Medicis engaged in mediation with such former employees. On March 19, 2013, Medicis and counsel for the former employees signed an MOU to settle this matter on a class-wide basis and resolve all claims with respect thereto. In connection with the agreed-upon settlement, Medicis would pay a specified sum and would pay the costs of the claims administration up to an agreed-upon fixed amount. Medicis would also implement certain specified programmatic relief. The parties have signed a definitive settlement agreement in this matter. On September 5, 2013, a putative class action was filed in U.S. District Court for the District of Columbia in the matter of Brown et al. v. Medicis Pharmaceutical Corporation (No. 1:13-cv-01345-RJL) based on the allegations described above. Simultaneously with the filing of the Complaint, the parties filed a motion for preliminary approval of the class action settlement.  Among other things, the settlement agreement, if approved, will resolve all of the remaining related EEOC charges.  A case status conference took place on June 6, 2014 and a hearing on the motion for preliminary approval of the class action settlement took place in September 2014. The motion was denied. A hearing to address the Court's concerns with the motion for preliminary approval took place on October 23, 2014 and has been continued to November 12, 2014.
	Legacy B&L Litigation
	MoistureLoc™ Product Liability Lawsuits
	Currently, B&L has been served or is aware that it has been named as a defendant in approximately 322 currently active product liability lawsuits (some with multiple plaintiffs) pending in a New York State Consolidated Proceeding described below as well as certain other U.S. state courts on behalf of individuals who claim they suffered personal injury as a result of using a contact lens solution with MoistureLoc™. Two consolidated cases were established to handle MoistureLoc™ claims. First, on August 14, 2006, the Federal Judicial Panel on Multidistrict Litigation created a coordinated proceeding in the Federal District Court for the District of South Carolina. Second, on January 2, 2007, the New York State Litigation Coordinating Panel ordered the consolidation of cases filed in New York State, and assigned the coordination responsibilities to the Supreme Court of the State of New York, New York County. There are approximately 320 currently active non-fusarium cases pending in the New York Consolidated Proceeding. On July 15, 2009, the New York State Supreme Court overseeing the New York Consolidated Proceeding granted B&L’s motion to exclude plaintiffs’ general causation testimony with regard to non-fusarium infections, which effectively excluded plaintiffs from testifying that MoistureLoc™ caused non-fusarium infections. On September 15, 2011, the New York State Appellate Division, First Department, affirmed the Trial Court’s ruling. On February 7, 2012, the New York Court of Appeals denied plaintiffs’ additional appeal. Plaintiffs subsequently filed a motion to renew the trial court’s ruling, and B&L cross-filed a motion for summary judgment to dismiss all remaining claims. On May 31, 2013, the Trial Court denied Plaintiffs’ motion to renew, and granted B&L’s motion for summary judgment, dismissing all remaining non-fusarium claims. On June 28, 2013, Plaintiffs filed a Notice of Appeal to the Trial Court’s ruling. On March 19, 2014, Plaintiffs filed an Application for an Enlargement of Time in which to perfect the within appeal to the September term. A decision was granted on May 13, 2014, pursuant to which the Court granted the requested extension to perfect the within appeal to the October term. The plaintiffs have perfected the appeal, the matter has been fully briefed by the parties and is awaiting argument before the New York Supreme Court, Appellate Division, First Department.
	All matters under jurisdiction of the coordinated proceedings in the Federal District Court for the District of South Carolina have been dismissed, including individual actions for personal injury and a class action purporting to represent a class of consumers who suffered economic claims as a result of purchasing a contact lens solution with MoistureLoc™.
	Currently B&L has settled approximately 629 cases in connection with MoistureLoc™ product liability suits. All but one U.S. based fusarium claims have now been resolved and there are less than five active fusarium claims involving claimants outside of the United States that remain pending. The parties in these active matters are involved in settlement discussions.
	Subpoenas from the New York Office of Inspector General for the U.S. Department of Health and Human Services
	On June 29, 2011, B&L received a subpoena from the New York Office of Inspector General for the U.S. Department of Health and Human Services regarding payments and communications between B&L and medical professionals related to its pharmaceutical products Lotemax® and Besivance®. The government has indicated that the subpoena was issued in connection with a civil investigation, and B&L is cooperating fully with the government’s investigation. B&L has heard of no additional activity at this time, and whether the government’s investigation is ongoing or will result in further requests for information is unknown. B&L and the Company will continue to work with the Office of Inspector General regarding the scope of the subpoena and any additional specific information that may be requested.
	ISTA Settlement with Department of Justice
	On or about May 24, 2013 (prior to the Company’s acquisition of B&L in August 2013), B&L’s subsidiary, ISTA Pharmaceuticals, Inc. (“ISTA”), reached agreement with the U.S. government to resolve and conclude civil and criminal allegations against ISTA.  The settlement involved conduct by ISTA that occurred between January 2006 and March 2011, prior to B&L’s acquisition of ISTA in June 2012. B&L was aware of the government investigation prior to its acquisition, and fully cooperated with the government to resolve the matter.  In connection with the settlement, ISTA pled guilty to certain charges and paid approximately $34 million in civil and criminal fines, including interest and attorney’s fees. In addition, B&L agreed to maintain a specified compliance and ethics program and to annually certify compliance with this requirement to the Department of Justice for a period of three years. Failure to comply with the requirements of the settlement could result in fines.
	Legal Proceedings Involving the Proposed Transaction with Allergan
	Allergan Securities Litigation
	On August 1, 2014, Allergan commenced the federal securities litigation in the U.S. District Court for the Central District of California against the Company, Valeant, Valeant’s subsidiary AGMS Inc. (“AGMS”), Pershing Square, PS Management, GP, LLC, PS Fund 1 and William A. Ackman (Allergan, Inc. et al. v. Valeant Pharmaceuticals International, Inc., et al., Case No. 14-cv-01214-DOC). The lawsuit alleges violations of Sections 13(d), 14(a), 14(e) and 20A of the Exchange Act and rules promulgated by the SEC under those Sections. The complaint seeks, among other relief, a declaration that the defendants violated Rule 14e-3 and Sections 13(d), 14(a) and 14(e); an order requiring rescission of the defendants’ purchases of Allergan securities; an order requiring the defendants to file corrective disclosures; preliminary and/or permanent injunctive relief as may be necessary to prevent the defendants from enjoying any rights or benefits from Allergan securities that were acquired unlawfully and to prevent irreparable injury to Allergan or its stockholders arising out of unlawful solicitations; damages under Section 20A of the Exchange Act; and costs and attorneys’ fees. On August 4, 2014, Allergan filed an application for an expedited schedule, which was denied on August 21, 2014. On August 19, 2014, the Company, Valeant and AGMS filed an Answer to Complaint and Affirmative Defenses. The remaining defendants filed a separate answer on August 19, 2014. Also on August 19, 2014, the Company, Valeant, AGMS, PS Fund 1 and William A. Ackman filed Counterclaims against Allergan and the members of the Allergan Board of Directors. The Counterclaims allege violations of Sections 14(a), 14(e) and 20A of the Exchange Act and rules promulgated by the SEC under those Sections, and seek, among other relief, an injunction requiring Allergan to issue corrective disclosures; an order enjoining further violations of Sections 14(a) and 14(e) of the Exchange Act and SEC Rules 14a-9 and 14a-3, and costs and attorneys’ fees. On September 2, 2014, the counterclaim-defendants filed an Answer to the Counterclaims. On September 12, 2014, the Court entered the parties’ stipulation, setting a hearing date of October 28, 2014 for Allergan’s intended motion for a preliminary injunction. On October 6, 2014, Allergan filed its motion for preliminary injunction, seeking to enjoin defendants and their officers, agents, representatives, employees, assigns, and/or anyone acting on their behalf or in concert with them from (1) exercising any of the rights or benefits attendant to any shares acquired by PS Fund 1, including voting or acting in the December 18, 2014 special meeting of Allergan stockholders; and (2) voting any proxies solicited by defendants on the basis of their September 24, 2014 proxy solicitation and the July 22, 2014 Form S-4 and from soliciting any further proxies until corrective disclosures are made. The motion also requests that defendants be ordered to make corrective disclosures to their September 24, 2014 proxy solicitation and the July 22, 2014 Form S-4, including disclosure of the facts that give rise to their alleged potential liability under Section 14(e) of the Securities Exchange Act and Rule 14e-3 promulgated thereunder.
	Bylaws Action Against Allergan and Its Board
	On August 22, 2014, the Company, Valeant, Pershing Square and PS Fund 1 filed a verified complaint in the Delaware Court of Chancery (C.A. No. 10057-CB) against Allergan and the members of the Allergan Board of Directors. The lawsuit alleges that the special meeting request submitted by PS Fund 1 complied with Allergan’s Amended and Restated Certificate of Incorporation and all valid aspects of the Amended and Restated Bylaws of Allergan (the “Allergan Bylaws”), that the Allergan Bylaws for calling a special meeting are invalid, and that Allergan’s directors breached their fiduciary duties with respect to the special meeting request. The complaint seeks, among other relief, (1) an order requiring that a special meeting be held within a reasonable period of time and before Allergan executes, consummates or reaches any binding agreement or understanding as to an alternative transaction; (2) a declaration that PS Fund 1 and supporting shareholders have validly requested a special meeting; (3) declarations that the Allergan Bylaws for calling a special meeting are invalid on their face and as applied to special meeting requests delivered to Allergan by PS Fund 1; (4) a declaration that the special meeting requests delivered to Allergan comply with all valid provisions of the Allergan Charter and Allergan Bylaws; (5) declarations that the Allergan Board breached their fiduciary duties by acting to delay the special meeting, acting to preclude Valeant’s acquisition proposal, and unreasonably interpreting the Allergan Bylaws; and (6) costs and attorneys’ fees. On August 27, 2014, the Court granted plaintiffs’ motion to expedite, setting the trial for October 6, 2014. On September 2, 2014, plaintiffs filed an Amended Verified Complaint. In addition to the relief sought in the Complaint, the Amended Complaint sought (1) an order requiring that a special meeting be held between 45 and 50 days after the Court issues its post-trial order, and before Allergan executes, consummates or reaches any binding agreement or understanding as to an alternative transaction; (2) an order requiring defendants to set a reasonable and equitable record date for the special meeting; and (3) a declaration that the Allergan Board breached their fiduciary duties by setting unreasonable and inequitable special meeting and record dates. On September 9, 2014, defendants filed their Answer and Affirmative Defenses.
On September 16, 2014, the Court entered the parties’ stipulation dismissing the action without prejudice. The stipulation provides that (1) Allergan will hold the Allergan special meeting on December 18, 2014; (2) October 30, 2014 shall be the record date; (3) defendants will not alter the foregoing dates, seek to delay or not hold the Allergan special meeting, or seek to invalidate any special meeting requests; and (4) defendants will not adjourn the Allergan special meeting unless adjournment is approved by holders of a majority of Allergan common stock present in person or by proxy at the Allergan special meeting.

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	SEGMENT INFORMATION
	Reportable Segments
	The Company has two operating and reportable segments: (i) Developed Markets, and (ii) Emerging Markets. The following is a brief description of the Company’s segments:
	•	Developed Markets consists of (i) sales in the U.S. of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics, and dentistry, (ii) sales in the U.S. of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products we developed or acquired, and (iii) pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe and Japan.
	•	Emerging Markets consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products. Products are sold primarily in Central and Eastern Europe (primarily Poland and Russia), Asia, Latin America (Mexico, Brazil, and Argentina and exports out of Mexico to other Latin American markets), Africa and the Middle East.
	Segment profit (loss) is based on operating income after the elimination of intercompany transactions. Certain costs, such as restructuring and acquisition-related costs, other (income) expense, and in-process research and development impairments and other charges, are not included in the measure of segment profit (loss), as management excludes these items in assessing financial performance.
	Corporate includes the finance, treasury, tax and legal operations of the Company’s businesses and maintains and/or incurs certain assets, liabilities, expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In addition, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on Company-wide performance rather than the operating performance of any single segment.
	Segment Revenues and Profit (Loss)
	Segment revenues and profit (loss) for the three-month and nine-month periods ended September 30, 2014 and 2013 were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Revenues:
	Developed Markets(1)	$	1,507.90		$	1,142.70		$	4,409.40		$	2,722.80
	Emerging Markets(2)	548.3			399			1,574.10			983
	Total revenues	2,056.20			1,541.70			5,983.50			3,705.80
	Segment profit (loss):
	Developed Markets(3)	478			(328.6		)	1,375.30			106.3
	Emerging Markets(4)	104			19.5			268.1			63.9
	Total segment profit (loss)	582			(309.1		)	1,643.40			170.2
	Corporate(5)	(42.9		)	(39.3		)	(127.3		)	(129.8		)
	Restructuring, integration and other costs	(61.7		)	(243.1		)	(337.4		)	(345.7		)
	In-process research and development impairments and other charges	(19.9		)	(124.0		)	(40.3		)	(128.8		)
	Acquisition-related costs	(1.6		)	(8.6		)	(3.7		)	(24.4		)
	Acquisition-related contingent consideration	(4.0		)	35			(14.8		)	33.5
	Other income (expense)	232			(202.4		)	275.7			(208.0		)
	Operating income (loss)	683.9			(891.5		)	1,395.60			(633.0		)
	Interest income	0.8			2.8			3.8			5.4
	Interest expense	(258.4		)	(249.3		)	(746.1		)	(581.4		)
	Loss on extinguishment of debt	—			(8.2		)	(93.7		)	(29.6		)
	Foreign exchange and other	(53.0		)	5.1			(63.0		)	(3.5		)
	Gain on investments, net	3.4			—			5.9			5.8
	Income (loss) before provision for (recovery of) income taxes	$	376.7		$	(1,141.1	)	$	502.5		$	(1,236.3	)
	____________________________________
	-1	Developed Markets segment revenues reflect incremental product sales revenue of $254.2 million and $1,628.6 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from the B&L, Solta Medical and PreCision acquisitions.
	-2	Emerging Markets segment revenues reflect incremental product sales revenue of $89.3 million and $556.3 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from the B&L and Solta Medical acquisitions.
	-3	Developed Markets segment profit (loss) reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $223.9 million and $665.3 million, in the aggregate, in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from B&L and Medicis operations. Developed Markets segment profit (loss) in the three-month and nine-month periods ended September 30, 2013 reflects an impairment charge of $551.6 million related to ezogabine/retigabine.
	-4	Emerging Markets segment profit reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $89.5 million, and $243.2 million in the aggregate, in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from B&L operations.
	-5	Corporate reflects non-restructuring-related share-based compensation expense of $11.0 million and $32.1 million in the three-month and nine-month periods ended September 30, 2014, respectively, compared with $16.0 million and $32.5 million in the corresponding periods of 2013.
	Segment Assets
	Total assets by segment as of September 30, 2014 and December 31, 2013 were as follows:
		As of			As of
		September 30,			December 31,
		2014			2013
	Assets(1):
	Developed Markets(2)	$	19,450.20		$	20,007.20
	Emerging Markets(3)	6,298.80			6,907.80
		25,749.00			26,915.00
	Corporate	1,310.60			1,055.80
	Total assets	$	27,059.60		$	27,970.80
	____________________________________
	-1	The segment assets as of December 31, 2013 contain reclassifications between segments to conform to the current period presentation.
	-2	Developed Markets segment assets as of September 30, 2014 reflect (i) the divestiture of filler and toxin assets in July 2014 with the carrying values of the related assets of $1.0 billion, in the aggregate, (see note 4 titled “DIVESTITURES” for further information), (ii) the provisional amounts of identifiable intangible assets and goodwill of the PreCision acquisition of $261.2 million and $181.3 million, respectively, and (iii) the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $103.5 million and $64.4 million, respectively.
	-3	Emerging Markets segment assets as of September 30, 2014 reflect the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $69.4 million and $42.9 million, respectively.

PROPOSED_TRANSACTIONS

PROPOSED TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
PROPOSED TRANSACTIONS	'
	PROPOSED TRANSACTIONS
	Proposed Merger - Allergan, Inc.
	On April 22, 2014, the Company announced that it had submitted a merger proposal to the Board of Directors of Allergan. Since making its initial public proposal on April 22, 2014, the Company has continued to publicly express a desire to enter into a negotiated business combination with Allergan and has announced the proposals that the Company has submitted to the Allergan Board of Directors (the “Allergan Board”). The most recent of these proposals was submitted by the Company to the Allergan Board on May 30, 2014 and contemplates a merger with Allergan, in which each share of Allergan common stock would be exchanged for (i) $72.00 in cash and (ii) 0.83 shares of the Company’s common shares, subject to election and proration. Further, the Company has indicated that it is willing to include, as part of the consideration in a negotiated transaction to acquire all issued and outstanding shares of Allergan common stock, a contingent value right related to DARPin® sales.
	In connection with the proposal to merge with Allergan, the Company and Pershing Square Capital Management, L.P. (“Pershing Square”) entered into an agreement pursuant to which, among other things, Valeant and Pershing Square became members of a newly formed jointly owned entity, PS Fund 1, LLC (the “PS Fund 1”). In April 2014, the Company contributed $75.9 million to PS Fund 1, which was used by PS Fund 1, together with funds contributed by funds managed by Pershing Square, to purchase shares of Allergan common stock and derivative instruments referencing Allergan common stock. The investment in Allergan shares is considered an available-for-sale security. Currently, 597,431 of the 28,878,538 shares of Allergan common stock held for PS Fund 1 are allocable to the Company. Based on the Company’s degree of influence over such entity, the Company's investment in PS Fund 1 is accounted for under the equity method of accounting (the investment is included within the Prepaid expenses and other current assets line on the consolidated balance sheet as of September 30, 2014). Accordingly, the Company recognizes its share of any unrealized gains or losses on the Allergan shares held by PS Fund 1 as part of other comprehensive (loss) income. For the three and nine months ended September 30, 2014, an unrealized pre-tax gain of $5.4 million and $30.6 million, respectively, related to this investment was recorded in other comprehensive (loss) income.
	On May 30, 2014, in connection with the proposal to merge with Allergan described above, the Company separately agreed with Pershing Square, Allergan's largest stockholder, to exchange 28,281,107 shares of Allergan common stock allocated to funds managed by Pershing Square for the Company's common shares at an exchange rate of 1.22659 of the Company's common shares for each share of Allergan common stock, which exchange would close immediately after the consummation of the proposed merger with Allergan.
	On June 18, 2014, the Company commenced an exchange offer currently scheduled to expire on December 31, 2014, subject to extension for the shares of Allergan common stock. Under the terms of the offer, Allergan stockholders would be able to elect to exchange each of their shares of Allergan common stock for $72.00 in cash and 0.83 the Company’s common shares, or a to-be-specified amount of cash, or a to-be-specified number of the Company’s common shares, in each case subject to proration. The shares of Allergan common stock held by Pershing Square would be subject to the May 30, 2014 agreement with Pershing Square. The offer is also subject to certain conditions, including removal of various anti-takeover obstacles that the Allergan Board has the unilateral ability to remove, the tender of a majority of the total number of outstanding Allergan shares on a fully diluted basis and expiration or termination of the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other applicable antitrust laws and regulations. The exchange offer is also conditioned on the affirmative vote at a special meeting of the shareholders of the Company to approve the issuance of the Company’s common shares in the acquisition. The Company has filed a preliminary proxy statement with respect to this special meeting.
	In connection with the proposed combination with Allergan, the Company has received a commitment letter to provide, on customary terms, subject to certain conditions, $20.35 billion that, together with cash on hand, will be used for the purpose of financing the cash component of the consideration to be paid in the exchange offer. At this time, no merger agreement or other agreement relating to the merger proposal has been entered into between the Company and Allergan, and the Company cannot provide any assurance as to whether or when any such agreement will be executed or whether or when the proposed merger will be consummated or the terms thereof when and if agreed.
	In connection with the settlement of certain litigation involving the Company, Valeant, Pershing Square, PS Fund 1 and Allergan in the Delaware Court of Chancery (as further described in note 18), Allergan has agreed to call and hold a special meeting of its shareholders on December 18, 2014 to, among other things, consider proposals respecting the removal of six incumbent members of the Allergan Board, a request that the Allergan Board elect or appoint six nominees proposed by Pershing Square, amendments to Allergan’s bylaws to eliminate onerous restrictions on the calling of a special meeting and a request that Allergan promptly engage in good faith negotiations with Valeant regarding Valeant’s offer to merge with Allergan, without in any way precluding discussions the Allergan Board may choose to engage in with other parties potentially offering higher value.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to prior year amounts to conform with the current year presentation. Such amounts include a reclassification of $52.8 million recognized in the third quarter of 2013 related to B&L's previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees from Restructuring, integration and other costs to Other (income) expense on the consolidated statement of income (loss) for the three-month and nine-month periods ended September 30, 2013. This reclassification had no effect on the Company’s previously reported results of operations, financial position or cash flow.
Use of Estimates	'
	Use of Estimates
	In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.
	On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.
Adoption of New Accounting Standards	'
	Adoption of New Accounting Standards
	In July 2013, the Financial Accounting Standard Board (“FASB”) issued guidance to eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits are netted against all available same-jurisdiction loss or other tax carryforward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. The guidance was effective for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance did not have a material impact on the Company’s financial position or results of operations.
	In April 2014, the FASB issued guidance which changes the criteria for reporting a discontinued operation while enhancing disclosures in this area. Under the new guidance, a disposal of a component of an entity or group of components of an entity that represents a strategic shift that has, or will have, a major effect on operations and financial results is a discontinued operation when any of the following occurs: (i) it meets the criteria to be classified as held for sale, (ii) it is disposed of by sale, or (iii) it is disposed of other than by sale. Also, a business that, on acquisition, meets the criteria to be classified as held for sale is reported in discontinued operations. Additionally, the new guidance requires expanded disclosures about discontinued operations, as well as disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation. The Company early adopted this guidance in the second quarter of 2014, and the Company applied this guidance to the divestitures described in note 4 titled “DIVESTITURES”.
	Patient Protection and Affordable Care Act - Annual Pharmaceutical Fee
	In July 2014, the Internal Revenue Service issued final regulations related to the branded pharmaceutical drug annual fee pursuant to the Patient Protection and Affordable Care Act. Under the final regulations, an entity’s obligation to pay the annual fee is triggered by qualifying sales in the current year, rather than the liability being triggered upon the first qualifying sale of the following year. The Company adopted this guidance in the third quarter of 2014, and it did not have a material impact on the Company’s financial position or results of operations.
	Recently Issued Accounting Standards, Not Adopted as of September 30, 2014
	In May 2014, the FASB and the International Accounting Standards Board issued converged guidance on recognizing revenue from contracts with customers. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue model to contracts within its scope, an entity will: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition to these provisions, the new standard provides implementation guidance on several other topics, including the accounting for certain revenue-related costs, as well as enhanced disclosure requirements. The new guidance requires entities to disclose both quantitative and qualitative information that enables users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early application is not permitted. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In August 2014, the FASB issued guidance which requires management to assess an entity’s ability to continue as a going concern and to provide related disclosures in certain circumstances. Under the new guidance, disclosures are required when conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year from the financial statement issuance date. The guidance is effective for annual periods ending after December 15, 2016, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance will not have any impact on the Company’s financial position and results of operations and, as this time, the Company does not expect any impact on its disclosures.

BUSINESS_COMBINATIONS_Tables

BUSINESS COMBINATIONS (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations	'
Schedule of pro forma impact of merger and acquisition	'
	The following table presents unaudited pro forma consolidated results of operations for the three-month and nine-month periods ended September 30, 2014 and 2013, as if the 2014 acquisitions had occurred as of January 1, 2013 and the 2013 acquisitions had occurred as of January 1, 2012.
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
	Revenues	$	2,060.20			$	1,867.30			$	6,039.60			$	5,794.90
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	279.8				(907.8		)		376.1				(1,023.9		)
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.83			$	(2.72	)		$	1.12			$	(3.07	)
	Diluted	$	0.82			$	(2.72	)		$	1.1			$	(3.07	)
Business Combinations in 2014	'
Business Combinations	'
Summary of amounts and useful lives assigned to identifiable intangible assets	'
	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				30-Sep-14
			(Years)										(as adjusted)
	Product brands		10		$	468.4			$	14.2			$	482.6
	Product rights		8		95.2				(0.9		)		94.3
	Corporate brand		15		25.2				1.6				26.8
	In-licensed products		8		1.5				0.1				1.6
	Total identifiable intangible assets acquired		10		$	590.3			$	15			$	605.3
Schedule of acquisitions	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates. Due to the timing of the PreCision acquisition, all such amounts are provisional and subject to change. The following recognized amounts related to the Solta Medical acquisition, as well as certain smaller acquisitions, are provisional and subject to change:
	•	amounts for intangible assets, property and equipment, inventories, receivables and other working capital adjustments pending finalization of the valuation;
	•	amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and
	•	amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.
	The Company will finalize these amounts as it obtains the information necessary to complete the measurement processes. Any changes resulting from facts and circumstances that existed as of the acquisition dates may result in retrospective adjustments to the provisional amounts recognized at the acquisition dates. These changes could be significant. The Company will finalize these amounts no later than one year from the respective acquisition dates.
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Dates				Adjustments(a)				30-Sep-14
											(as adjusted)
	Cash and cash equivalents		$	18.3			$	—			$	18.3
	Accounts receivable(b)		57.1				0.2				57.3
	Assets held for sale(c)		125.7				—				125.7
	Inventories		87				(10.0		)		77
	Other current assets		17				(0.8		)		16.2
	Property, plant and equipment, net		37.3				(0.7		)		36.6
	Identifiable intangible assets, excluding acquired IPR&D(d)		590.3				15				605.3
	Acquired IPR&D(e)		65.8				0.8				66.6
	Other non-current assets		3.4				—				3.4
	Current liabilities		(129.3		)		(10.5		)		(139.8		)
	Long-term debt, including current portion		(8.5		)		—				(8.5		)
	Deferred income taxes, net		(112.0		)		(4.7		)		(116.7		)
	Other non-current liabilities		(12.8		)		(3.1		)		(15.9		)
	Total identifiable net assets		739.3				(13.8		)		725.5
	Goodwill(f)		315				6.1				321.1
	Total fair value of consideration transferred		$	1,054.30			$	(7.7	)		$	1,046.60
	________________________
	(a)	The measurement period adjustments primarily relate to the Solta Medical acquisition and reflect: (i) increases in the estimated fair value of intangible assets, (ii) reductions in the estimated fair value of inventory, and (iii) the tax impact of pre-tax measurement period adjustments. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
	(b)	The fair value of trade accounts receivable acquired was $57.3 million, with the gross contractual amount being $61.7 million, of which the Company expects that $4.4 million will be uncollectible.
	(c)	Assets held for sale relate to the divestitures of the Tretin-X® product rights and the product rights for the generic tretinoin gel and cream products acquired in the PreCision acquisition. See note 4 titled “DIVESTITURES” for further information.
	(d)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				30-Sep-14
			(Years)										(as adjusted)
	Product brands		10		$	468.4			$	14.2			$	482.6
	Product rights		8		95.2				(0.9		)		94.3
	Corporate brand		15		25.2				1.6				26.8
	In-licensed products		8		1.5				0.1				1.6
	Total identifiable intangible assets acquired		10		$	590.3			$	15			$	605.3
	(e)	The acquired in-process research and development (“IPR&D”) assets primarily relate to programs from smaller acquisitions. In addition, the Solta Medical acquisition includes a program for the development of a next generation Thermage® product.
	(f)	The goodwill relates primarily to the PreCision and Solta Medical acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is not expected to be deductible for tax purposes. The goodwill recorded from the PreCision and Solta Medical acquisitions represents the following:
	•	cost savings, operating synergies and other benefits expected to result from combining the operations of PreCision and Solta Medical with those of the Company;
	•	the Company’s expectation to develop and market new products and technology; and
	•	intangible assets that do not qualify for separate recognition (for instance, Precision’s and Solta Medical’s assembled workforce).
	The provisional amount of goodwill from the PreCision acquisition has been allocated to the Company’s Developed Markets segment ($181.3 million). The provisional amount of goodwill from the Solta Medical acquisition has been allocated to both the Company’s Developed Markets segment ($64.4 million) and Emerging Markets segment ($42.9 million).
B&L	'
Business Combinations	'
Fair Value of Consideration Transferred	'
	The following table indicates the consideration transferred to effect the B&L Acquisition:
			Fair Value
	Enterprise value		$	8,700.00
	Adjusted for the following:
	B&L’s outstanding debt, including accrued interest		(4,248.3		)
	B&L’s company expenses		(6.4		)
	Payment in B&L’s performance-based option(a)		(48.5		)
	Payment for B&L’s cash balance(b)		149
	Additional cash payment(b)		75
	Other		(3.2		)
	Equity purchase price		4,617.60
	Less: Cash consideration paid for B&L’s unvested stock options(c)		(4.3		)
	Total fair value of consideration transferred		$	4,613.30
	___________________________________
	(a)	The cash consideration paid for previously cancelled B&L’s performance-based options was recognized as a post-combination expense within Other (income) expense in the third quarter of 2013.
	(b)	As defined in the Merger Agreement.
	(c)	The cash consideration paid for B&L stock options and restricted stock attributable to pre-combination services has been included as a component of purchase price. The remaining $4.3 million balance related to the acceleration of unvested stock options for B&L employees was recognized as a post-combination expense within Other (income) expense in the third quarter of 2013.
Summary of amounts and useful lives assigned to property, plant and equipment	'
	The following table summarizes the amounts and useful lives assigned to property, plant and equipment:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Date				Adjustments				30-Sep-14
			(Years)		(as previously								(as adjusted)
					reported)
	Land		NA		$	47.4			$	(12.6	)		$	34.8
	Buildings		24		273.1				(23.8		)		249.3
	Machinery and equipment		5		273.5				76.3				349.8
	Leasehold improvements		5		22.5				(0.3		)		22.2
	Equipment on operating lease		3		13.8				(0.2		)		13.6
	Construction in progress		NA		131.1				(6.2		)		124.9
	Total property, plant and equipment acquired				$	761.4			$	33.2			$	794.6
Summary of amounts and useful lives assigned to identifiable intangible assets	'
	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Date				Adjustments				September 30, 2014
			(Years)		(as previously								(as adjusted)
					reported)
	Product brands		10		$	1,770.20			$	4.6			$	1,774.80
	Product rights		8		855.4				5.7				861.1
	Corporate brand		Indefinite		1,690.50				7				1,697.50
	Total identifiable intangible assets acquired		9		$	4,316.10			$	17.3			$	4,333.40
Summary of fair value of long-term debt assumed	'
	The following table summarizes the fair value of long-term debt assumed as of the acquisition date:
			Amounts
			Recognized as of
			Acquisition Date
	Holdco unsecured term loan(1)		$	707
	U.S. dollar-denominated senior secured term loan(1)		1,915.80
	Euro-denominated senior secured term loan(1)		604
	U.S. dollar-denominated delayed draw term loan(1)		398
	U.S. dollar-denominated revolver loan(1)		170
	9.875% senior notes(1)		350
	Multi-currency denominated revolver loan(1)		15
	Japanese revolving credit facility(2)		33.8
	Debentures		11.8
	Other(1)		4.5
	Total long-term debt assumed		$	4,209.90
	___________________________________
	-1	The Company subsequently repaid these amounts in full in the third quarter of 2013. In connection with the redemption of the 9.875% senior notes, the Company recognized a loss on extinguishment of debt of $8.2 million in the third quarter of 2013.
	-2	In the fourth quarter of 2013, the Company repaid in full the amounts outstanding. In January 2014, the Company terminated this facility.
Schedule of acquisitions	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of acquisition date.
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Date				Adjustments(b)				30-Sep-14
			(as previously								(as adjusted)
			reported)(a)
	Cash and cash equivalents		$	209.5			$	(31.4	)		$	178.1
	Accounts receivable(c)		547.9				(7.2		)		540.7
	Inventories(d)		675.8				(34.0		)		641.8
	Other current assets(e)		146.6				0.3				146.9
	Property, plant and equipment, net(f)		761.4				33.2				794.6
	Identifiable intangible assets, excluding acquired IPR&D(g)		4,316.10				17.3				4,333.40
	Acquired IPR&D(h)		398.1				17				415.1
	Other non-current assets		58.8				(1.9		)		56.9
	Current liabilities(i)		(885.6		)		2.1				(883.5		)
	Long-term debt, including current portion(j)		(4,209.9		)		—				(4,209.9		)
	Deferred income taxes, net(k)		(1,410.9		)		36				(1,374.9		)
	Other non-current liabilities(l)		(280.2		)		(1.0		)		(281.2		)
	Total identifiable net assets		327.6				30.4				358
	Noncontrolling interest(m)		(102.3		)		(0.4		)		(102.7		)
	Goodwill(n)		4,388.00				(30.0		)		4,358.00
	Total fair value of consideration transferred		$	4,613.30			$	—			$	4,613.30
	________________________
	(a)	As previously reported in the 2013 Form 10-K.
	(b)	The measurement period adjustments primarily reflect: (i) a decrease in the net deferred tax liability, (ii) a reduction in the estimated fair value of inventory, (iii) an increase in the estimated fair value of property, plant and equipment mainly related to certain machinery and equipment in Western Europe and the U.S., partially offset by a reduction in the estimated fair value related to certain manufacturing facilities and an office building, (iv) an adjustment between cash and accounts payable, and (v) increases in the estimated fair value of intangible assets, which included a net increase to IPR&D assets driven by a higher fair value for the next generation silicone hydrogel lens (Bausch + Lomb Ultra®). The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
	(c)	The fair value of trade accounts receivable acquired was $540.7 million, with the gross contractual amount being $555.6 million, of which the Company expects that $14.9 million will be uncollectible.
	(d)	Includes an estimated fair value adjustment to inventory of $269.1 million.
	(e)	Includes primarily prepaid expenses.
	(f)	The following table summarizes the amounts and useful lives assigned to property, plant and equipment:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Date				Adjustments				30-Sep-14
			(Years)		(as previously								(as adjusted)
					reported)
	Land		NA		$	47.4			$	(12.6	)		$	34.8
	Buildings		24		273.1				(23.8		)		249.3
	Machinery and equipment		5		273.5				76.3				349.8
	Leasehold improvements		5		22.5				(0.3		)		22.2
	Equipment on operating lease		3		13.8				(0.2		)		13.6
	Construction in progress		NA		131.1				(6.2		)		124.9
	Total property, plant and equipment acquired				$	761.4			$	33.2			$	794.6
	The Company sold an office building in Rochester, New York, with an adjusted carrying amount of $14.2 million, in the third quarter of 2014. There was no gain or loss associated with the sale.
	(g)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Date				Adjustments				September 30, 2014
			(Years)		(as previously								(as adjusted)
					reported)
	Product brands		10		$	1,770.20			$	4.6			$	1,774.80
	Product rights		8		855.4				5.7				861.1
	Corporate brand		Indefinite		1,690.50				7				1,697.50
	Total identifiable intangible assets acquired		9		$	4,316.10			$	17.3			$	4,333.40
	The corporate brand represents the B&L corporate trademark and has an indefinite useful life as there are no legal, regulatory, contractual, competitive, economic, or other factors that limit the useful life of this intangible asset. The estimated fair value was determined using the relief from royalty method.
	(h)	The significant components of the acquired IPR&D assets primarily relate to the development of (i) various vision care products ($223.4 million in the aggregate), such as the next generation silicone hydrogel lens (Bausch + Lomb Ultra®), (ii) various pharmaceutical products ($170.9 million, in the aggregate), such as latanoprostene bunod, a nitric oxide-donating prostaglandin for reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, and (iii) various surgical products ($20.8 million, in the aggregate). A multi-period excess earnings methodology (income approach) was used to determine the estimated fair values of the acquired IPR&D assets from market participant perspective. The projected cash flows from these assets were adjusted for the probabilities of successful development and commercialization of each project. A risk-adjusted discount rate of 10% was used to present value the projected cash flows. The next generation silicone hydrogel lens (Bausch + Lomb Ultra®) was launched in February 2014.
	(i)	Includes accrued liabilities, including reserves for sales returns, rebates and managed care, accounts payable and accrued compensation-related liabilities.
	(j)	The following table summarizes the fair value of long-term debt assumed as of the acquisition date:
			Amounts
			Recognized as of
			Acquisition Date
	Holdco unsecured term loan(1)		$	707
	U.S. dollar-denominated senior secured term loan(1)		1,915.80
	Euro-denominated senior secured term loan(1)		604
	U.S. dollar-denominated delayed draw term loan(1)		398
U.S. dollar-denominated revolver loan(1)		170
9.875% senior notes(1)		350
Multi-currency denominated revolver loan(1)		15
Japanese revolving credit facility(2)		33.8
Debentures		11.8
Other(1)		4.5
Total long-term debt assumed		$	4,209.90
___________________________________
-1	The Company subsequently repaid these amounts in full in the third quarter of 2013. In connection with the redemption of the 9.875% senior notes, the Company recognized a loss on extinguishment of debt of $8.2 million in the third quarter of 2013.
-2	In the fourth quarter of 2013, the Company repaid in full the amounts outstanding. In January 2014, the Company terminated this facility.
(k)	Comprises current net deferred tax assets ($61.6 million) and non-current net deferred tax liabilities ($1,436.5 million).
(l)	Includes $224.2 million related to the estimated fair value of pension and other benefits liabilities.
(m)	Represents the estimated fair value of B&L’s noncontrolling interest related primarily to Chinese joint ventures. A discounted cash flow methodology was used to determine the estimated fair values as of the acquisition date.
(n)	Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents the following:
•	the Company’s expectation to develop and market new product brands, product lines and technology;
•	cost savings and operating synergies expected to result from combining the operations of B&L with those of the Company;
•	the value of the continuing operations of B&L’s existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately); and
•	intangible assets that do not qualify for separate recognition (for instance, B&L’s assembled workforce).
The amount of goodwill has been allocated to the Company’s Developed Markets segment ($3.3 billion) and Emerging Markets segment ($1.1 billion).
Other Business Combinations	'
Business Combinations	'
Summary of amounts and useful lives assigned to identifiable intangible assets	'
	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				September 30, 2014
			(Years)										(as adjusted)
	Product brands		7		$	517.2			$	3.1			$	520.3
	Corporate brand		13		86.1				0.8				86.9
	Patents		3		71.7				—				71.7
	Royalty Agreement		5		26.5				—				26.5
	Partner relationships		5		16				—				16
	Technology		10		5.4				—				5.4
	Total identifiable intangible assets acquired		8		$	722.9			$	3.9			$	726.8
Schedule of acquisitions	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates.
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Dates				Adjustments(a)				September 30, 2014
											(as adjusted)
	Cash		$	43.1			$	—			$	43.1
	Accounts receivable(b)		64				0.5				64.5
	Inventories		33.6				1.9				35.5
	Other current assets		14				—				14
	Property, plant and equipment		13.9				(3.3		)		10.6
	Identifiable intangible assets, excluding acquired IPR&D(c)		722.9				3.9				726.8
	Acquired IPR&D(d)		18.7				0.2				18.9
	Indemnification assets		3.2				(0.7		)		2.5
	Other non-current assets		0.2				3.7				3.9
	Current liabilities		(36.2		)		(0.4		)		(36.6		)
	Short-term borrowings(e)		(33.3		)		0.5				(32.8		)
	Long-term debt(e)		(24.0		)		—				(24.0		)
	Deferred tax liability, net		(147.8		)		(1.1		)		(148.9		)
	Other non-current liabilities		(1.5		)		—				(1.5		)
	Total identifiable net assets		670.8				5.2				676
	Noncontrolling interest(f)		(11.2		)		—				(11.2		)
	Goodwill(g)		224.3				9				233.3
	Total fair value of consideration transferred		$	883.9			$	14.2			$	898.1
	________________________
	(a)	The measurement period adjustments primarily reflect an increase in the total fair value of consideration transferred with respect to the Natur Produkt acquisition pursuant to a purchase price adjustment. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
	(b)	The fair value of trade accounts receivable acquired was $64.5 million, with the gross contractual amount being $68.2 million, of which the Company expects that $3.7 million will be uncollectible.
	(c)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				September 30, 2014
			(Years)										(as adjusted)
	Product brands		7		$	517.2			$	3.1			$	520.3
	Corporate brand		13		86.1				0.8				86.9
	Patents		3		71.7				—				71.7
	Royalty Agreement		5		26.5				—				26.5
	Partner relationships		5		16				—				16
	Technology		10		5.4				—				5.4
	Total identifiable intangible assets acquired		8		$	722.9			$	3.9			$	726.8
	(d)	The acquired IPR&D assets relate to the Obagi and Natur Produkt acquisitions. Obagi’s acquired IPR&D assets primarily relate to the development of dermatology products for anti-aging and suncare. Natur Produkt’s acquired IPR&D assets include a product indicated for the prevention of viral diseases, specifically cold and flu, and a product indicated for the treatment of inflammation and muscular disorders.
	(e)	Short-term borrowings and long-term debt primarily relate to the Natur Produkt acquisition. In March 2013, the Company settled all of Natur Produkt’s outstanding third party short-term borrowings and long-term debt.
	(f)	Represents the estimated fair value of noncontrolling interest related to a smaller acquisition completed in the third quarter of 2013.
	(g)	The goodwill relates primarily to the Obagi and Natur Produkt acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of Obagi’s and Natur Produkt’s goodwill is expected to be deductible for tax purposes. The goodwill recorded from the Obagi and the Natur Produkt acquisitions represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations with those of the Company.
	The amount of goodwill from the Eisai acquisition has been allocated to the Company’s Developed Markets segment. The amount of goodwill from the Natur Produkt acquisition has been allocated to the Company’s Emerging Markets segment. The amount of goodwill from the Obagi acquisition has been allocated primarily to the Company’s Developed Markets segment.

RESTRUCTURING_INTEGRATION_AND_1

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Tables)	9 Months Ended
	Sep. 30, 2014
B&L	'
Restructuring costs	'
Schedule of major components of restructuring costs incurred in connection with acquisition-related initiatives	'
	The following table summarizes the major components of the restructuring costs incurred in connection with the B&L Acquisition since the acquisition date through September 30, 2014:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2013		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		155.7			52.8			—		25.6			234.1
	Cash payments		(77.8		)	(52.8		)	—		(7.8		)	(138.4		)
	Non-cash adjustments		11.4			—			—		(6.8		)	4.6
	Balance, December 31, 2013		89.3			—			—		11			100.3
	Costs incurred and/or charged to expense		22.5			—			—		6.6			29.1
	Cash payments		(50.9		)	—			—		(3.2		)	(54.1		)
	Non-cash adjustments		(2.3		)	—			—		(3.1		)	(5.4		)
	Balance, March 31, 2014		58.6			—			—		11.3			69.9
	Costs incurred and charged to expense		12.3			—			—		10.1			22.4
	Cash payments		(25.7		)	—			—		(1.8		)	(27.5		)
	Non-cash adjustments		(0.5		)	—			—		(0.4		)	(0.9		)
	Balance, June 30, 2014		44.7			—			—		19.2			63.9
	Costs incurred and charged to expense		8.2			—			—		4.5			12.7
	Cash payments		(22.2		)	—			—		(18.7		)	(40.9		)
	Non-cash adjustments		(1.7		)	—			—		(0.2		)	(1.9		)
	Balance, September 30, 2014		$	29		$	—		$	—	$	4.8		$	33.8
	___________________________________
	-1	Relates to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition. These charges were reclassified to Other (income) expense to conform to the current year presentation.
Medicis	'
Restructuring costs	'
Schedule of major components of restructuring costs incurred in connection with acquisition-related initiatives	'
	The following table summarizes the major components of the $109.2 million of restructuring costs incurred in connection with the Medicis acquisition since the acquisition date through September 30, 2014:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2012		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		85.3			77.3			—		0.4			163
	Cash payments		(78.0		)	(77.3		)	—		—			(155.3		)
	Non-cash adjustments		4.1			—			—		(0.2		)	3.9
	Balance, December 31, 2012		11.4			—			—		0.2			11.6
	Costs incurred and/or charged to expense		20			—			—		3.5			23.5
	Cash payments		(31.4		)	—			—		(3.6		)	(35.0		)
	Non-cash adjustments		0.3			—			—		(0.1		)	0.2
	Balance, December 31, 2013(2)		$	0.3		$	—		$	—	$	—		$	0.3
	____________________________________
	-1	Relates to the acceleration of unvested stock options, restricted stock awards, and share appreciation rights for Medicis employees that was triggered by the change in control. These charges were reclassified to Other (income) expense to conform to the current year presentation.
	-2	The Company has not recognized any restructuring charges, and made a payment of $0.1 million, in the nine-month period ended September 30, 2014 with respect to the Medicis acquisition-related initiatives. In the nine-month period ended September 30, 2013, the Company recognized $23.1 million of restructuring charges and made payments of $34.4 million.

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of components and classification of financial assets and liabilities measured at fair value	'
	The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value as of September 30, 2014 and December 31, 2013:
			As of September 30, 2014														As of December 31, 2013
			Carrying				Quoted			Significant			Significant				Carrying				Quoted			Significant			Significant
			Value				Prices			Other			Unobservable				Value				Prices			Other			Unobservable
							in Active			Observable			Inputs								in Active			Observable			Inputs
							Markets for			Inputs			(Level 3)								Markets for			Inputs			(Level 3)
							Identical			(Level 2)											Identical			(Level 2)
							Assets														Assets
							(Level 1)														(Level 1)
	Assets:
	Cash equivalents(1)		$	395.9			$	389.5		$	6.4		$	—			$	171.3			$	171.3		$	—		$	—
	Liabilities:
	Acquisition-related contingent consideration		$	(327.8	)		$	—		$	—		$	(327.8	)		$	(355.8	)		$	—		$	—		$	(355.8	)
	___________________________________
	-1	Cash equivalents include highly liquid investments with an original maturity of three months or less at acquisition, primarily including money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)	'
	The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the nine-month period ended September 30, 2014:
		Balance,				Issuances(a)			Payments(b)			Net				Foreign				Transfers			Transfers			Balance,
		January 1,										Unrealized				Exchange(d)				Into			Out of			September 30,
		2014										Loss(c)								Level 3			Level 3			2014
	Acquisition-related contingent consideration	$	(355.8	)		$	(65.1	)	$	106.1		$	(14.8	)		$	1.8			$	—		$	—		$	(327.8	)
	____________________________________
	(a)	Primarily relates to a contingent consideration liability assumed in the Solta Medical acquisition, as well as contingent consideration with respect to other smaller acquisitions, as described in note 3.
	(b)	Relates primarily to payments of acquisition-related contingent consideration related to the OraPharma Topco Holdings, Inc. and Eisai (Targretin®) acquisitions and the Elidel®/Xerese®/Zovirax® agreement entered into with Meda Pharma SARL (“Meda”) in June 2011 (the “Elidel®/Xerese®/Zovirax® agreement”).
	(c)	For the nine months ended September 30, 2014, a net loss of $14.8 million was recognized as Acquisition-related contingent consideration in the consolidated statements of income (loss). The acquisition-related contingent consideration net loss was primarily driven by fair value adjustments to reflect accretion for the time value of money related to the Elidel®/Xerese®/Zovirax® agreement.
	(d)	Included in other comprehensive (loss) income.

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of the components of inventories	'
	The components of inventories as of September 30, 2014 and December 31, 2013 were as follows:
		As of			As of
		September 30,			December 31,
		2014			2013
	Raw materials	$	241.1		$	221.8
	Work in process	108.1			104.7
	Finished goods	697.3			656.3
		1,046.50			982.8
	Less allowance for obsolescence	(113.8		)	(99.8		)
		$	932.7		$	883

INTANGIBLE_ASSETS_AND_GOODWILL1

INTANGIBLE ASSETS AND GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of components of intangible assets	'
	The major components of intangible assets as of September 30, 2014 and December 31, 2013 were as follows:
			As of September 30, 2014									As of December 31, 2013
			Gross			Accumulated			Net			Gross		Accumulated			Net
			Carrying			Amortization,			Carrying			Carrying		Amortization,			Carrying
			Amount			Including			Amount			Amount		Including			Amount
						Impairments								Impairments
	Finite-lived intangible assets:
	Product brands		$	10,378.00		$	(3,384.1	)	$	6,993.90		$	10,554.20	$	(2,729.1	)	$	7,825.10
	Corporate brands		379			(67.3		)	311.7			365.6		(44.4		)	321.2
	Product rights		3,193.10			(1,101.3		)	2,091.80			3,021.00		(876.9		)	2,144.10
	Partner relationships		195.9			(104.2		)	91.7			194		(83.2		)	110.8
	Out-licensed technology and other		250.8			(111.9		)	138.9			264		(93.8		)	170.2
	Total finite-lived intangible assets		14,396.80			(4,768.8		)	9,628.00			14,398.80		(3,827.4		)	10,571.40
	Indefinite-lived intangible assets:
	Acquired IPR&D(1)		294.9			—			294.9			579.3		—			579.3
	Corporate brand(2)		1,697.50			—			1,697.50			1,697.50		—			1,697.50
			$	16,389.20		$	(4,768.8	)	$	11,620.40		$	16,675.60	$	(3,827.4	)	$	12,848.20
	____________________________________
	-1	In the third quarter of 2014, the Company wrote-off IPR&D assets of $19.9 million primarily related to analysis of Phase 2 study data for a dermatological product candidate acquired in the December 2012 Medicis acquisition.
	In the third quarter of 2013, the Company wrote-off an IPR&D asset of $93.8 million related to a modified-release formulation of ezogabine/retigabine.
	The write-offs of the IPR&D assets were recorded in In-process research and development impairments and other charges in the consolidated statements of income (loss).
	-2	Represents the B&L corporate trademark, which has an indefinite useful life and is not amortizable. See note 3 “BUSINESS COMBINATIONS” for further information.
Schedule of estimated aggregate amortization expense for each of the five succeeding years	'
	Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows:
			2014			2015			2016			2017		2018
	Amortization expense(1)		$	1,421.70		$	1,379.90		$	1,289.20		$	1,231.10	$	1,108.60
	____________________________________
	-1	Estimated amortization expense shown in the table above does not include potential future impairments of finite-lived intangible assets, if any.
Schedule of changes in the carrying amount of goodwill	'
	The changes in the carrying amount of goodwill in the nine-month period ended September 30, 2014 were as follows:
			Developed			Emerging			Total
			Markets			Markets
	Balance, January 1, 2014		$	7,428.70		$	2,323.40		$	9,752.10
	Additions(a)		259.5			61.6			321.1
	Adjustments(b)		10.3			(4.3		)	6
	Divestitures(c)		(428.9		)	—			(428.9		)
	Foreign exchange and other		(111.8		)	(70.7		)	(182.5		)
	Balance, September 30, 2014		$	7,157.80		$	2,310.00		$	9,467.80
	____________________________________
	(a)	Primarily relates to the PreCision and Solta Medical acquisitions (as described in note 3).
	(b)	Primarily reflects the impact of measurement period adjustments related to the B&L Acquisition (as described in note 3).
	(c)	See note 4, titled “DIVESTITURES” for additional information.

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of long-term debt	'
	A summary of the Company’s consolidated long-term debt as of September 30, 2014 and December 31, 2013, respectively, is outlined in the table below:
			Maturity	As of			As of
			Date	September 30,			December 31,
				2014			2013
	Revolving Credit Facility(1)		April 2018	$	—		$	—
	Series A-1 Tranche A Term Loan Facility(1)		April 2016	182.3			259
	Series A-2 Tranche A Term Loan Facility(1)		Apr-16	166.3			228.1
	Series A-3 Tranche A Term Loan Facility(1)		Oct-18	1,813.90			1,935.70
	Series D-2 Tranche B Term Loan Facility(1)		Feb-19	1,088.60			1,256.70
	Series C-2 Tranche B Term Loan Facility(1)		Dec-19	837.5			966.8
	Series E-1 Tranche B Term Loan Facility(1)		Aug-20	2,544.80			3,090.50
	Senior Notes:
	6.75%(2)		October 2017	498.9			498.7
	6.88%		December 2018	940.9			940.2
	7.00%		October 2020	687.4			687.1
	6.75%		August 2021	650			650
	7.25%		July 2022	542.9			542.2
	6.38%		Oct-20	2,224.50			2,221.40
	6.75%		Aug-18	1,584.80			1,581.90
	7.50%		Jul-21	1,607.80			1,605.90
	5.63%		Dec-21	892.3			891.5
	Other(3)		Various	12			12
				16,274.90			17,367.70
	Less current portion			(690.6		)	(204.8		)
	Total long-term debt			$	15,584.30		$	17,162.90
	____________________________________
	-1	Together, the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Credit Agreement”).
	-2	On October 15, 2014, Valeant redeemed all of the outstanding $500.0 million aggregate principal amount of its 6.75% senior notes due 2017 (the “2017 Notes”) for $518.2 million, including a call premium of $16.9 million, plus accrued and unpaid interest, and satisfied and discharged the 2017 Notes indenture, solely with respect to the 2017 Notes (the 7.00% senior notes due 2020, issued under the same indenture, remain outstanding at this time). The balance of the 2017 Notes was reclassified to Current portion of long-term debt as of September 30, 2014.
	-3	Relates primarily to the debentures from B&L.

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of the components and classification of share-based compensation expense	'
	The following table summarizes the components and classification of share-based compensation expense related to stock options and restricted share units (“RSUs”) for the three-month and nine-month periods ended September 30, 2014 and 2013:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Stock options	$	5.4	$	4.6	$	14.7	$	12.8
	RSUs	14.8		11.4		45.9		19.7
	Share-based compensation expense	$	20.2	$	16	$	60.6	$	32.5
	Research and development expenses	$	1.4	$	—	$	4.2	$	—
	Selling, general and administrative expenses	18.8		16		56.4		32.5
	Share-based compensation expense	$	20.2	$	16	$	60.6	$	32.5

PENSION_AND_POSTRETIREMENT_EMP1

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Components of net periodic benefit cost	'
	The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the three-month and nine-month periods ended September 30, 2014 and 2013:
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Three Months Ended September 30,
		2014			2013			2014			2013			2014			2013
	Service cost	$	0.1		$	0.1		$	1		$	0.7		$	0.4		$	0.4
	Interest cost	2.7			1.8			2.1			1.4			0.6			0.6
	Expected return on plan assets	(3.7		)	(2.4		)	(2.0		)	(1.2		)	(0.1		)	(0.1		)
	Amortization of prior service credit	—			—			—			—			(0.6		)	—
	Net periodic (benefit) cost	$	(0.9	)	$	(0.5	)	$	1.1		$	0.9		$	0.3		$	0.9
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Nine Months Ended September 30,
		2014			2013			2014			2013			2014			2013
	Service cost	$	0.3		$	0.1		$	3		$	1.2		$	1.2		$	0.4
	Interest cost	8.1			1.8			6.4			1.6			1.8			0.6
	Expected return on plan assets	(11.1		)	(2.4		)	(6.0		)	(1.2		)	(0.3		)	(0.1		)
	Amortization of prior service credit	—			—			—			—			(1.8		)	—
	Net periodic (benefit) cost	$	(2.7	)	$	(0.5	)	$	3.4		$	1.6		$	0.9		$	0.9

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Shareholders' equity	'
		Valeant Pharmaceuticals International, Inc. Shareholders
		Common Shares					Additional			Accumulated			Accumulated			Valeant			Noncontrolling			Total
							Paid-In			Deficit			Other			Pharmaceuticals			Interest			Equity
							Capital						Comprehensive			International, Inc.
													Loss			Shareholders’
		Shares		Amount												Equity
	Balance, January 1, 2013	303.9		$	5,940.70		$	267.1		$	(2,371.0	)	$	(119.4	)	$	3,717.40		$	—		$	3,717.40
	Issuance of common stock(1)	27.1		2,269.30			—			—			—			2,269.30			—			2,269.30
	Common shares issued under share-based compensation plans(2)	2.5		64.2			(60.6		)	—			—			3.6			—			3.6
	Repurchase of common shares(2)	(0.7	)	(14.2		)	—			(41.4		)	—			(55.6		)	—			(55.6		)
	Share-based compensation	—		—			32.5			—			—			32.5			—			32.5
	Employee withholding taxes related to share-based awards	—		—			(35.9		)	—			—			(35.9		)	—			(35.9		)
	Tax benefits from stock options exercised	—		—			48.6			—			—			48.6			—			48.6
	Noncontrolling interest from business combinations	—		—			—			—			—			—			113.5			113.5
	Noncontrolling interest distributions	—		—			—			—			—			—			(2.1		)	(2.1		)
		332.8		8,260.00			251.7			(2,412.4		)	(119.4		)	5,979.90			111.4			6,091.30
	Comprehensive loss:
	Net loss (income)	—		—			—			(989.9		)	—			(989.9		)	1.3			(988.6		)
	Other comprehensive loss	—		—			—			—			(40.9		)	(40.9		)	(0.6		)	(41.5		)
	Total comprehensive loss															(1,030.8		)	0.7			(1,030.1		)
	Balance, September 30, 2013	332.8		$	8,260.00		$	251.7		$	(3,402.3	)	$	(160.3	)	$	4,949.10		$	112.1		$	5,061.20
	Balance, January 1, 2014	333		$	8,301.20		$	228.8		$	(3,278.5	)	$	(132.8	)	$	5,118.70		$	114.6		$	5,233.30
	Common shares issued under share-based compensation plans	1		33.2			(23.6		)	—			—			9.6			—			9.6
	Settlement of stock options	—		—			(3.1		)	—			—			(3.1		)	—			(3.1		)
	Share-based compensation	—		—			60.6			—			—			60.6			—			60.6
	Employee withholding taxes related to share-based awards	—		—			(38.5		)	—			—			(38.5		)	—			(38.5		)
	Tax benefits from stock options exercised	—		—			17.1			—			—			17.1			—			17.1
	Acquisition of noncontrolling interest	—		—			(1.1		)	—			—			(1.1		)	(2.2		)	(3.3		)
	Noncontrolling interest distributions	—		—			—			—			—			—			(0.5		)	(0.5		)
		334		8,334.40			240.2			(3,278.5		)	(132.8		)	5,163.30			111.9			5,275.20
	Comprehensive loss:
	Net income (loss)	—		—			—			378.6			—			378.6			(0.5		)	378.1
	Other comprehensive loss	—		—			—			—			(419.2		)	(419.2		)	(0.5		)	(419.7		)
	Total comprehensive loss															(40.6		)	(1.0		)	(41.6		)
	Balance, September 30, 2014	334		$	8,334.40		$	240.2		$	(2,899.9	)	$	(552.0	)	$	5,122.70		$	110.9		$	5,233.60
	____________________________________
	-1	On June 24, 2013, the Company completed, pursuant to an Underwriting Agreement with Goldman Sachs & Co. and Goldman Sachs Canada, Inc., a public offering of 27,058,824 of its common shares, no par value, at a price of $85.00 per share, or aggregate gross proceeds of approximately $2.3 billion. In connection with the issuance of these new common shares, the Company incurred approximately $30.7 million of issuance costs, which has been reflected as reduction to the gross proceeds from the equity issuance.
	-2	During the second quarter of 2013, 225,000 common shares were repurchased by the Company pursuant to a purchase agreement with Goldman, Sachs & Co. Under this purchase program, the repurchases were made by Goldman, Sachs & Co. in compliance with Rule 10b5-1(c)(1)(i) of the Securities Exchange Act of 1934. 217,294 of these common shares were repurchased on behalf of certain members of the Company’s Board of Directors, and were subsequently transferred to such directors, in connection with the share settlement of certain deferred stock units and restricted stock units held by such directors following the termination of the applicable equity program. The remaining 7,706 common shares were repurchased on behalf of the Company pursuant to the 2012 Securities Repurchase Program (and therefore these shares are included in the 507,957 of total common shares repurchased under the 2012 Securities Repurchase Program as of September 30, 2013) and were subsequently cancelled (see note 11 titled “SECURITIES REPURCHASE PROGRAM” for further information).

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	9 Months Ended
	Sep. 30, 2014
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
Schedule of the components of accumulated other comprehensive loss	'
	The components of accumulated other comprehensive loss as of September 30, 2014 and 2013, were as follows:
			Foreign			Unrealized		Net			Pension			Total
			Currency			Gain on		Unrealized			Adjustment
			Translation			Equity Investment		Holding
			Adjustment					Gain
								on Available-
								For-Sale
								Equity
								Securities
	Balance, January 1, 2013		$	(119.5	)	$	—	$	0.4		$	(0.3	)	$	(119.4	)
	Foreign currency translation adjustment		(40.5		)	—		—			—			(40.5		)
	Reclassification to net income (loss)(1)		—			—		(4.0		)	—			(4.0		)
	Net unrealized holding gain on available-for-sale equity securities		—			—		3.6			—			3.6
	Balance, September 30, 2013		$	(160.0	)	$	—	$	—		$	(0.3	)	$	(160.3	)
	Balance, January 1, 2014		$	(170.3	)	$	—	$	—		$	37.5		$	(132.8	)
	Foreign currency translation adjustment		(439.9		)	—		—			—			(439.9		)
	Unrealized gain on equity method investment, net of tax		—			22.5		—			—			22.5
	Net unrealized holding gain on available-for-sale equity securities, net of tax		—			—		1.8			—			1.8
	Reclassification to net income (loss)(1)		—			—		(1.8		)	—			(1.8		)
	Pension adjustment(2)		—			—		—			(1.8		)	(1.8		)
	Balance, September 30, 2014		$	(610.2	)	$	22.5	$	—		$	35.7		$	(552.0	)
	____________________________________
	-1	Included in gain on investments, net.
	-2	Reflects changes in defined benefit obligations and related plan assets of the Company’s defined benefit pension plans and the U.S. postretirement benefit plan (as described in note 13).

EARNINGS_LOSS_PER_SHARE_Tables

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of calculation of earnings per share	'
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and nine-month periods ended September 30, 2014 and 2013 were calculated as follows:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014		2013
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$	275.4	$	(973.2	)	$	378.6	$	(989.9	)
	Basic weighted-average number of common shares outstanding	335.4		333.6			335.2		316.5
	Diluted effect of stock options and RSUs(a)	5.9		—			6.2		—
	Diluted weighted-average number of common shares outstanding	341.3		333.6			341.4		316.5
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.82	$	(2.92	)	$	1.13	$	(3.13	)
	Diluted	$	0.81	$	(2.92	)	$	1.11	$	(3.13	)
	____________________________________
	(a)	In the three-month and nine-month periods ended September 30, 2013, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months	Nine Months
			Ended	Ended
			September 30,	September 30,
			2013	2013
	Basic weighted-average number of common shares outstanding		333.6	316.5
	Dilutive effect of stock options and RSUs		6.6	6.4
	Diluted weighted-average number of common shares outstanding		340.2	322.9
Schedule of dilutive effect of stock options, RSUs and Convertible Notes on weighted-average number of common shares outstanding	'
	The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months	Nine Months
			Ended	Ended
			September 30,	September 30,
			2013	2013
	Basic weighted-average number of common shares outstanding		333.6	316.5
	Dilutive effect of stock options and RSUs		6.6	6.4
	Diluted weighted-average number of common shares outstanding		340.2	322.9

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of segment revenues and profit	'
	Segment revenues and profit (loss) for the three-month and nine-month periods ended September 30, 2014 and 2013 were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Revenues:
	Developed Markets(1)	$	1,507.90		$	1,142.70		$	4,409.40		$	2,722.80
	Emerging Markets(2)	548.3			399			1,574.10			983
	Total revenues	2,056.20			1,541.70			5,983.50			3,705.80
	Segment profit (loss):
	Developed Markets(3)	478			(328.6		)	1,375.30			106.3
	Emerging Markets(4)	104			19.5			268.1			63.9
	Total segment profit (loss)	582			(309.1		)	1,643.40			170.2
	Corporate(5)	(42.9		)	(39.3		)	(127.3		)	(129.8		)
	Restructuring, integration and other costs	(61.7		)	(243.1		)	(337.4		)	(345.7		)
	In-process research and development impairments and other charges	(19.9		)	(124.0		)	(40.3		)	(128.8		)
	Acquisition-related costs	(1.6		)	(8.6		)	(3.7		)	(24.4		)
	Acquisition-related contingent consideration	(4.0		)	35			(14.8		)	33.5
	Other income (expense)	232			(202.4		)	275.7			(208.0		)
	Operating income (loss)	683.9			(891.5		)	1,395.60			(633.0		)
	Interest income	0.8			2.8			3.8			5.4
	Interest expense	(258.4		)	(249.3		)	(746.1		)	(581.4		)
	Loss on extinguishment of debt	—			(8.2		)	(93.7		)	(29.6		)
	Foreign exchange and other	(53.0		)	5.1			(63.0		)	(3.5		)
	Gain on investments, net	3.4			—			5.9			5.8
	Income (loss) before provision for (recovery of) income taxes	$	376.7		$	(1,141.1	)	$	502.5		$	(1,236.3	)
	____________________________________
	-1	Developed Markets segment revenues reflect incremental product sales revenue of $254.2 million and $1,628.6 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from the B&L, Solta Medical and PreCision acquisitions.
	-2	Emerging Markets segment revenues reflect incremental product sales revenue of $89.3 million and $556.3 million, in the aggregate, from all 2013 acquisitions and all 2014 acquisitions in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from the B&L and Solta Medical acquisitions.
	-3	Developed Markets segment profit (loss) reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $223.9 million and $665.3 million, in the aggregate, in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from B&L and Medicis operations. Developed Markets segment profit (loss) in the three-month and nine-month periods ended September 30, 2013 reflects an impairment charge of $551.6 million related to ezogabine/retigabine.
	-4	Emerging Markets segment profit reflects the addition of operations from all 2013 acquisitions and all 2014 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $89.5 million, and $243.2 million in the aggregate, in the three-month and nine-month periods ended September 30, 2014, respectively, primarily from B&L operations.
	-5	Corporate reflects non-restructuring-related share-based compensation expense of $11.0 million and $32.1 million in the three-month and nine-month periods ended September 30, 2014, respectively, compared with $16.0 million and $32.5 million in the corresponding periods of 2013.
Schedule of total assets by segment	'
	Total assets by segment as of September 30, 2014 and December 31, 2013 were as follows:
		As of			As of
		September 30,			December 31,
		2014			2013
	Assets(1):
	Developed Markets(2)	$	19,450.20		$	20,007.20
	Emerging Markets(3)	6,298.80			6,907.80
		25,749.00			26,915.00
	Corporate	1,310.60			1,055.80
	Total assets	$	27,059.60		$	27,970.80
	____________________________________
	-1	The segment assets as of December 31, 2013 contain reclassifications between segments to conform to the current period presentation.
	-2	Developed Markets segment assets as of September 30, 2014 reflect (i) the divestiture of filler and toxin assets in July 2014 with the carrying values of the related assets of $1.0 billion, in the aggregate, (see note 4 titled “DIVESTITURES” for further information), (ii) the provisional amounts of identifiable intangible assets and goodwill of the PreCision acquisition of $261.2 million and $181.3 million, respectively, and (iii) the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $103.5 million and $64.4 million, respectively.
	-3	Emerging Markets segment assets as of September 30, 2014 reflect the provisional amounts of identifiable intangible assets and goodwill of the Solta Medical acquisition of $69.4 million and $42.9 million, respectively.

DESCRIPTION_OF_BUSINESS_Detail

DESCRIPTION OF BUSINESS (Details)	Sep. 30, 2014
	country
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of Countries in which Entity Operates (over 100 countries)	100

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Details) (Other (Income) Expense, USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Other (Income) Expense	'
Summary of Significant Accounting Policies [Line Items]	'
Reclassification recognized	$52.80

BUSINESS_COMBINATIONS_Narrativ

BUSINESS COMBINATIONS - Narrative (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

14 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

In Millions, except Per Share data, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Jul. 07, 2014

Dec. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Jan. 23, 2014

Jan. 23, 2014

Sep. 30, 2014

Sep. 30, 2014

Jan. 23, 2014

Aug. 05, 2013

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2013

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Apr. 25, 2013

Apr. 25, 2013

Apr. 30, 2014

Feb. 20, 2013

Feb. 01, 2013

Mar. 31, 2013

Feb. 01, 2013

Sep. 30, 2014

Dec. 31, 2013

Office building

Developed Markets

Developed Markets

Emerging Markets

Emerging Markets

Business Combinations in 2014

PreCision Dermatology, Inc.

PreCision Dermatology, Inc.

PreCision Dermatology, Inc.

PreCision Dermatology, Inc.

Solta Medical, Inc.

Solta Medical, Inc.

Solta Medical, Inc.

Solta Medical, Inc.

Solta Medical, Inc.

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

Obagi Medical Products, Inc

Obagi Medical Products, Inc

Eisai

Eisai

Natur Produkt

Natur Produkt

Natur Produkt

Other Business Combinations

Other Business Combinations

Scenario, Forecast

Developed Markets

Other (Income) Expense

Developed Markets

Emerging Markets

Other (Income) Expense

9.875% Senior Notes

9.875% Senior Notes

Various Vision Care Products

Various Pharmaceutical Products

Various Surgical Products

IPR&D

Developed Markets

Emerging Markets

Restructuring, Integration and Other Costs

Business Combinations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price

'

'

'

'

'

'

'

'

'

'

'

$1,046.60

$454.50

'

'

'

'

$292.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related contingent consideration

116.5

'

'

116.5

'

114.5

'

'

'

'

'

65.1

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.8

'

'

'

'

59.1

Separately recognized post-combination expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Per share consideration (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.92

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$24

'

'

'

'

'

'

'

Repayments of long-term debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge relating to settlement of preexisting relationship

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of accounts receivable

'

'

'

'

'

'

'

'

'

'

'

57.3

'

'

'

'

'

'

'

'

'

'

540.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64.5

'

Gross contractual amount of trade accounts receivable acquired

'

'

'

'

'

'

'

'

'

'

'

61.7

'

'

'

'

'

'

'

'

'

'

555.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

68.2

'

Expected uncollectible of trade accounts receivable acquired

'

'

'

'

'

'

'

'

'

'

'

4.4

'

'

'

'

'

'

'

'

'

'

14.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.7

'

Goodwill

9,467.80

'

'

9,467.80

'

9,752.10

'

7,157.80

7,428.70

2,310

2,323.40

321.1

'

'

181.3

'

'

'

64.4

42.9

'

'

4,358

'

'

'

'

'

'

'

3,300

1,100

'

'

'

'

'

'

'

'

233.3

'

Acquisition-related costs

1.6

'

8.6

3.7

24.4

'

'

'

'

'

'

4.2

'

'

'

'

'

'

'

'

'

'

13.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues of acquiree since acquisition date

'

'

'

'

'

'

'

'

'

'

'

133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net earnings (loss), net of tax of acquiree since acquisition date

'

'

'

'

'

'

'

'

'

'

'

-44.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value per share of common stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Enterprise value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration paid for unvested options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.3

'

'

'

'

'

'

'

'

'

Estimated fair value adjustment to inventory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

269.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Carrying amount of long-lived asset held for sale

'

'

'

'

'

'

14.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired IPR&D

'

'

'

'

'

'

'

'

'

'

'

66.6

'

'

'

'

'

'

'

'

'

'

415.1

'

'

'

223.4

170.9

20.8

'

'

'

'

'

'

'

'

'

'

'

18.9

'

Risk-adjusted discount rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on debt (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.88%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (loss) on extinguishment of debt

0

-93.7

-8.2

-93.7

-29.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

61.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liability, noncurrent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,436.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148.9

'

Fair value of pension and other benefits liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

224.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price (less non-controlling interest)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,613.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

898.1

898.1

Contingent consideration payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

'

'

'

'

'

Total fair value of consideration transferred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,613.30

'

'

'

'

'

'

'

'

'

'

'

437.1

'

'

'

149.9

'

'

'

'

Upfront payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66.5

'

'

'

'

'

Potential future milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60

'

'

'

'

'

Contingent refund of purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

Refund of contingent purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20

'

'

'

BUSINESS_COMBINATIONS_Estimate

BUSINESS COMBINATIONS - Estimated fair values of the assets acquired and liabilities assumed (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Aug. 05, 2013	Aug. 05, 2013	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
In Millions, unless otherwise specified			Business Combinations in 2014	Business Combinations in 2014	Business Combinations in 2014	B&L	B&L	B&L	B&L	Other Business Combinations	Other Business Combinations	Other Business Combinations	Other Business Combinations
				Amounts Recognized as of Acquisition Date (as previously reported)	Measurement Period Adjustments			Amounts Recognized as of Acquisition Date (as previously reported)	Measurement Period Adjustments			Amounts Recognized as of Acquisition Date (as previously reported)	Measurement Period Adjustments
Assets acquired and liabilities assumed	'	'	'	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents	'	'	$18.30	$18.30	$0	$178.10	'	$209.50	($31.40)	$43.10	'	$43.10	$0
Accounts receivable	'	'	57.3	57.1	0.2	540.7	'	547.9	-7.2	64.5	'	64	0.5
Assets held for sale	'	'	125.7	125.7	0	'	'	'	'	'	'	'	'
Inventories	'	'	77	87	-10	641.8	'	675.8	-34	35.5	'	33.6	1.9
Other current assets	'	'	16.2	17	-0.8	146.9	'	146.6	0.3	14	'	14	0
Property, plant and equipment, net	'	'	36.6	37.3	-0.7	794.6	'	761.4	33.2	10.6	'	13.9	-3.3
Identifiable intangible assets, excluding acquired IPR&D	'	'	605.3	590.3	15	4,333.40	'	4,316.10	17.3	726.8	'	722.9	3.9
Acquired IPR&D	'	'	66.6	65.8	0.8	415.1	'	398.1	17	18.9	'	18.7	0.2
Indemnification assets	'	'	'	'	'	'	'	'	'	2.5	'	3.2	-0.7
Other non-current assets	'	'	3.4	3.4	0	56.9	'	58.8	-1.9	3.9	'	0.2	3.7
Current liabilities	'	'	-139.8	-129.3	-10.5	-883.5	'	-885.6	2.1	-36.6	'	-36.2	-0.4
Short-term borrowings	'	'	'	'	'	'	'	'	'	-32.8	'	-33.3	0.5
Long-term debt, including current portion	'	'	-8.5	-8.5	0	-4,209.90	-4,209.90	-4,209.90	0	-24	'	-24	0
Deferred income taxes, net	'	'	-116.7	-112	-4.7	-1,374.90	'	-1,410.90	36	'	'	'	'
Deferred tax liability, net	'	'	'	'	'	-1,436.50	'	'	'	-148.9	'	-147.8	-1.1
Other non-current liabilities	'	'	-15.9	-12.8	-3.1	-281.2	'	-280.2	-1	-1.5	'	-1.5	0
Total identifiable net assets	'	'	725.5	739.3	-13.8	358	'	327.6	30.4	676	'	670.8	5.2
Noncontrolling interest	'	'	'	'	'	-102.7	'	-102.3	-0.4	-11.2	'	-11.2	0
Goodwill	9,467.80	9,752.10	321.1	315	6.1	4,358	'	4,388	-30	233.3	'	224.3	9
Total fair value of consideration transferred	'	'	1,046.60	1,054.30	-7.7	'	'	'	'	'	'	'	'
Total fair value of consideration transferred	'	'	'	'	'	$4,613.30	'	$4,613.30	$0	$898.10	$898.10	$883.90	$14.20

BUSINESS_COMBINATIONS_Identifi

BUSINESS COMBINATIONS - Identifiable intangible assets (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

In Millions, unless otherwise specified

Corporate brand

Corporate brand

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

Business Combinations in 2014

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Other Business Combinations

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Product brands

Product brands

Product brands

Product rights

Product rights

Product rights

Corporate brand

Corporate brand

Corporate brand

In-licensed products

In-licensed products

In-licensed products

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Corporate brand

Corporate brand

Corporate brand

Product brands

Product brands

Product brands

Product rights

Product rights

Product rights

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Product brands

Product brands

Product brands

Corporate brand

Corporate brand

Corporate brand

Patents

Patents

Patents

Royalty Agreement

Royalty Agreement

Royalty Agreement

Partner relationships

Partner relationships

Partner relationships

Technology

Technology

Technology

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Business Combinations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted- Average Useful Lives (Years)

'

'

'10 years

'

'

'10 years

'

'

'8 years

'

'

'15 years

'

'

'8 years

'

'

'9 years

'

'

'

'

'

'10 years

'

'

'8 years

'

'

'8 years

'

'

'7 years

'

'

'13 years

'

'

'3 years

'

'

'5 years

'

'

'5 years

'

'

'10 years

'

'

Total identifiable intangible assets acquired

'

'

$605.30

$590.30

$15

$482.60

$468.40

$14.20

$94.30

$95.20

($0.90)

$26.80

$25.20

$1.60

$1.60

$1.50

$0.10

$4,333.40

$4,316.10

$17.30

'

'

'

$1,774.80

$1,770.20

$4.60

$861.10

$855.40

$5.70

$726.80

$722.90

$3.90

$520.30

$517.20

$3.10

$86.90

$86.10

$0.80

$71.70

$71.70

$0

$26.50

$26.50

$0

$16

$16

$0

$5.40

$5.40

$0

Indefinite-lived intangible assets

$1,697.50

$1,697.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,697.50

$1,690.50

$7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BUSINESS_COMBINATIONS_Consider

BUSINESS COMBINATIONS - Consideration transferred (Details) (B&L, USD $)	0 Months Ended
In Millions, unless otherwise specified	Aug. 05, 2013
B&L	'
Business Combinations	'
Enterprise value	$8,700
Adjusted for the following:	'
B&L’s outstanding debt, including accrued interest	-4,248.30
B&L’s company expenses	-6.4
Payment in B&L’s performance-based option	-48.5
Payment for B&L's cash balance	149
Additional cash payment	75
Other	-3.2
Equity purchase price	4,617.60
Less: Cash consideration paid for B&L’s unvested stock options	-4.3
Total fair value of consideration transferred	$4,613.30

BUSINESS_COMBINATIONS_Property

BUSINESS COMBINATIONS - Property, Plant and Equipment Acquired (Details) (B&L, USD $)

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2013

Sep. 30, 2014

In Millions, unless otherwise specified

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Land

Land

Land

Buildings

Buildings

Buildings

Machinery and equipment

Machinery and equipment

Machinery and equipment

Leasehold improvements

Leasehold improvements

Leasehold improvements

Equipment on operating lease

Equipment on operating lease

Equipment on operating lease

Construction in progress

Construction in progress

Construction in progress

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Amounts Recognized as of Acquisition Date (as previously reported)

Measurement Period Adjustments

Business Combinations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted- Average Useful Lives (Years)

'

'

'

'

'

'

'24 years

'

'

'5 years

'

'

'5 years

'

'

'3 years

'

'

'

'

'

Total property, plant and equipment acquired

$794.60

$761.40

$33.20

$34.80

$47.40

($12.60)

$249.30

$273.10

($23.80)

$349.80

$273.50

$76.30

$22.20

$22.50

($0.30)

$13.60

$13.80

($0.20)

$124.90

$131.10

($6.20)

BUSINESS_COMBINATIONS_Longterm

BUSINESS COMBINATIONS - Long-term debt assumed (Details) (B&L, USD $)	Sep. 30, 2014	Aug. 05, 2013
In Millions, unless otherwise specified
Business Combinations	'	'
Total long-term debt assumed	$4,209.90	$4,209.90
9.875% Senior Notes	'	'
Business Combinations	'	'
Total long-term debt assumed	'	350
Holdco unsecured term loan	'	'
Business Combinations	'	'
Total long-term debt assumed	'	707
Senior secured term loan | U.S. Dollar	'	'
Business Combinations	'	'
Total long-term debt assumed	'	1,915.80
Senior secured term loan | Euro	'	'
Business Combinations	'	'
Total long-term debt assumed	'	604
Delayed draw term loan | U.S. Dollar	'	'
Business Combinations	'	'
Total long-term debt assumed	'	398
Revolver loan	'	'
Business Combinations	'	'
Total long-term debt assumed	'	15
Revolver loan | U.S. Dollar	'	'
Business Combinations	'	'
Total long-term debt assumed	'	170
Revolving Credit Facility | Japanese	'	'
Business Combinations	'	'
Total long-term debt assumed	'	33.8
Debentures	'	'
Business Combinations	'	'
Total long-term debt assumed	'	11.8
Other	'	'
Business Combinations	'	'
Total long-term debt assumed	'	$4.50

BUSINESS_COMBINATIONS_Pro_form

BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Pro forma of consolidated results of operations	'	'	'	'
Revenues	$2,060.20	$1,867.30	$6,039.60	$5,794.90
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$279.80	($907.80)	$376.10	($1,023.90)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:	'	'	'	'
Basic (in dollars per share)	$0.83	($2.72)	$1.12	($3.07)
Diluted (in dollars per share)	$0.82	($2.72)	$1.10	($3.07)

DIVESTITURES_Details

DIVESTITURES (Details) (USD $)	0 Months Ended	3 Months Ended	0 Months Ended	3 Months Ended	1 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Jul. 10, 2014	Sep. 30, 2014	Jul. 01, 2014	Sep. 30, 2014	Jul. 31, 2014	Jul. 31, 2014	Sep. 30, 2014
	Filler and Toxin Group	Filler and Toxin Group	Metronidazole 1.3 Percent Vaginal Gel Antibiotic Development Product	Metronidazole 1.3 Percent Vaginal Gel Antibiotic Development Product	PreCision Tretin-X Cream Products	Precision Generic Tretinoin Products	Precision Generic Tretinoin Products
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'
Proceeds from divestiture of businesses	$1,400	'	$10	'	$70	$45	'
Gain (loss) on sale of business	'	323.9	'	-58.5	'	'	-8.8
Disposal group, costs to sell for divestiture	'	$43	'	'	'	'	'
Period of payment of minimum royalties from commercialization of development product	'	'	'3 years	'	'	'	'

RESTRUCTURING_INTEGRATION_AND_2

RESTRUCTURING, INTEGRATION AND OTHER COSTS - Narrative (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

14 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

22 Months Ended

9 Months Ended

22 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

B&L

Medicis

Medicis

Medicis

Medicis

Medicis

Medicis

Medicis

Medicis

Employee Termination Costs

employees

Maximum

employees

Maximum

Maximum

B&L

Cost-rationalization and integration initiatives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and acquisition-related costs since acquisition date

'

'

'

'

'

'

'

'

'

'

'

$554,600,000

$600,000,000

'

'

'

'

'

$193,100,000

'

'

'

Restructuring, integration and other costs

61,700,000

243,100,000

337,400,000

345,700,000

12,700,000

22,400,000

29,100,000

52,800,000

'

'

234,100,000

'

'

77,300,000

'

23,100,000

23,500,000

163,000,000

'

'

'

'

Restructuring costs related to employee termination

'

'

'

'

'

'

'

'

56,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring expenses related to acquisition

'

'

'

'

'

'

'

'

'

'

'

302,200,000

'

'

'

'

'

'

109,200,000

'

'

'

Integration expenses related to acquisition

'

'

'

'

'

'

'

'

123,000,000

45,800,000

'

239,000,000

'

'

11,800,000

31,200,000

'

'

51,700,000

'

'

'

Acquisition-related costs

1,600,000

8,600,000

3,700,000

24,400,000

'

'

'

'

'

'

'

13,400,000

'

24,200,000

'

'

'

'

32,200,000

'

'

'

Approximate number of employees expected to be terminated

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

750

'

'

'

Payments for integration related costs

'

'

'

'

'

'

'

'

128,500,000

40,400,000

'

'

'

'

8,400,000

28,300,000

'

'

'

'

'

17,500,000

Estimated cost related to cost-rationalization and integration initiatives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$200,000,000

$200,000,000

'

RESTRUCTURING_INTEGRATION_AND_3

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Details 2) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended				12 Months Ended	3 Months Ended			12 Months Ended	3 Months Ended			12 Months Ended	3 Months Ended			12 Months Ended	3 Months Ended			12 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
					B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	B&L	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis	Medicis
										Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Share-Based Compensation	Employee Termination Costs - Share-Based Compensation	Employee Termination Costs - Share-Based Compensation	Employee Termination Costs - Share-Based Compensation	IPR&D Termination Costs	IPR&D Termination Costs	IPR&D Termination Costs	IPR&D Termination Costs	Contract Termination, Facility Closure and Other Costs	Contract Termination, Facility Closure and Other Costs	Contract Termination, Facility Closure and Other Costs	Contract Termination, Facility Closure and Other Costs						Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Severance and Related Benefits	Employee Termination Costs - Share-Based Compensation	Employee Termination Costs - Share-Based Compensation	IPR&D Termination Costs	IPR&D Termination Costs	Contract Termination, Facility Closure and Other Costs	Contract Termination, Facility Closure and Other Costs
Restructuring reserve	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period	'	'	'	'	$63.90	$69.90	$100.30	'	$0	$44.70	$58.60	$89.30	$0	$0	$0	$0	$0	$0	$0	$0	$0	$19.20	$11.30	$11	$0	'	$0.30	$11.60	$11.60	$0	$11.40	$0	$0	$0	$0	$0	$0.20	$0
Costs incurred and/or charged to expense	61.7	243.1	337.4	345.7	12.7	22.4	29.1	52.8	234.1	8.2	12.3	22.5	155.7	0	0	0	52.8	0	0	0	0	4.5	10.1	6.6	25.6	77.3	'	23.1	23.5	163	20	85.3	0	77.3	0	0	3.5	0.4
Cash payments	'	'	'	'	-40.9	-27.5	-54.1	'	-138.4	-22.2	-25.7	-50.9	-77.8	0	0	0	-52.8	0	0	0	0	-18.7	-1.8	-3.2	-7.8	'	-0.1	-34.4	-35	-155.3	-31.4	-78	0	-77.3	0	0	-3.6	0
Non-cash adjustments	'	'	'	'	-1.9	-0.9	-5.4	'	4.6	-1.7	-0.5	-2.3	11.4	0	0	0	0	0	0	0	0	-0.2	-0.4	-3.1	-6.8	'	'	'	0.2	3.9	0.3	4.1	0	0	0	0	-0.1	-0.2
Balance at the end of the period	'	'	'	'	$33.80	$63.90	$69.90	'	$100.30	$29	$44.70	$58.60	$89.30	$0	$0	$0	$0	$0	$0	$0	$0	$4.80	$19.20	$11.30	$11	$11.60	'	'	$0.30	$11.60	$0.30	$11.40	$0	$0	$0	$0	$0	$0.20

RESTRUCTURING_INTEGRATION_AND_4

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Details 3) (Other Restructuring, Integration-related and Other Costs, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Other Restructuring, Integration-related and Other Costs	'	'
Cost-rationalization and integration initiatives	'	'
Other restructuring, integration-related costs incurred	$81.70	$81.10
Integration consulting, duplicate labor, transition service, and other	49.3	46.8
Severance costs	18.5	12.4
Facility closure costs	7.3	14.9
Other costs, including non-personnel manufacturing integration costs	6.6	7
Cash payment made	$78.60	$75.90

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
		Recurring basis	Recurring basis	Quoted Prices in Active Markets for Identical Assets (Level 1)	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Significant Unobservable Inputs (Level 3)
				Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis
Assets:	'	'	'	'	'	'	'	'	'
Cash equivalents	'	$395.90	$171.30	$389.50	$171.30	$6.40	$0	$0	$0
Liabilities:	'	'	'	'	'	'	'	'	'
Acquisition-related contingent consideration	'	($327.80)	($355.80)	$0	$0	$0	$0	($327.80)	($355.80)
Highly liquid investments, maturity period	'3 months	'	'	'	'	'	'	'	'

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
			Significant Other Observable Inputs (Level 2)	Significant Other Observable Inputs (Level 2)
			Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets
Assets Measured at Fair Value on a Recurring Basis	'	'	'	'
Carrying value of time deposits	'	'	$33,100,000	$25,200,000
Available-for-sale securities, gross realized gain	3,400,000	'	'	'
Fair Value, Assets Level 1 to Level 2 Transfers, Value	'	$0	'	'

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation	'	'	'	'
Acquisition-related contingent consideration	($4)	$35	($14.80)	$33.50
Acquisition-related contingent consideration	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation	'	'	'	'
Balance at the beginning of the period	'	'	-355.8	'
Issuances	'	'	-65.1	'
Payments	'	'	106.1	'
Net Unrealized Loss	'	'	-14.8	'
Foreign Exchange	'	'	1.8	'
Transfers Into Level 3	'	'	0	'
Transfers Out of Level 3	'	'	0	'
Balance at the end of the period	($327.80)	'	($327.80)	'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$241.10	$221.80
Work in process	108.1	104.7
Finished goods	697.3	656.3
Inventories, gross	1,046.50	982.8
Less allowance for obsolescence	-113.8	-99.8
Inventories, net	932.7	883
Solta Medical, Inc.	'	'
Business Combinations	'	'
Inventories	30.3	'
PreCision Dermatology, Inc.	'	'
Business Combinations	'	'
Inventories	$18.80	'

INTANGIBLE_ASSETS_AND_GOODWILL2

INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

In Millions, unless otherwise specified

Acquired IPR&D(1)

Acquired IPR&D(1)

Acquired IPR&D(1)

Corporate brand

Corporate brand

Product brands

Product brands

Corporate brand

Corporate brand

Product rights

Product rights

Partner relationships

Partner relationships

Out-licensed technology and other

Out-licensed technology and other

Ezogabine Retigabine

Finite-lived intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

$14,396.80

$14,398.80

'

'

'

'

'

$10,378

$10,554.20

$379

$365.60

$3,193.10

$3,021

$195.90

$194

$250.80

$264

Accumulated Amortization, Including Impairments

-4,768.80

-3,827.40

'

'

'

'

'

-3,384.10

-2,729.10

-67.3

-44.4

-1,101.30

-876.9

-104.2

-83.2

-111.9

-93.8

Net Carrying Amount

9,628

10,571.40

'

'

'

'

'

6,993.90

7,825.10

311.7

321.2

2,091.80

2,144.10

91.7

110.8

138.9

170.2

Indefinite-lived intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-lived intangible assets

'

'

294.9

579.3

'

1,697.50

1,697.50

'

'

'

'

'

'

'

'

'

'

Impairment charges on intangible assets

'

'

19.9

'

93.8

'

'

'

'

'

'

'

'

'

'

'

'

Total intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

16,389.20

16,675.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Carrying Amount

$11,620.40

$12,848.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

INTANGIBLE_ASSETS_AND_GOODWILL3

INTANGIBLE ASSETS AND GOODWILL (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Intangible assets	'	'	'	'
Amortization and impairment of intangible assets, finite-lived	$393.10	$910.20	$1,113.90	$1,540
Estimated aggregate amortization expense	'	'	'	'
2014	1,421.70	'	1,421.70	'
2015	1,379.90	'	1,379.90	'
2016	1,289.20	'	1,289.20	'
2017	1,231.10	'	1,231.10	'
2018	1,108.60	'	1,108.60	'
Grifulvin	'	'	'	'
Intangible assets	'	'	'	'
Impairment charges on intangible assets	'	'	32.4	'
Ezogabine Retigabine	'	'	'	'
Intangible assets	'	'	'	'
Impairment charges on intangible assets	'	$551.60	'	'

INTANGIBLE_ASSETS_AND_GOODWILL4

INTANGIBLE ASSETS AND GOODWILL (Details 3) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Change in the carrying amount of goodwill	'
Balance at the beginning of the period	$9,752.10
Additions	321.1
Adjustments	6
Divestitures(c)	-428.9
Foreign exchange and other	-182.5
Balance at the end of the period	9,467.80
Developed Markets	'
Change in the carrying amount of goodwill	'
Balance at the beginning of the period	7,428.70
Additions	259.5
Adjustments	10.3
Divestitures(c)	-428.9
Foreign exchange and other	-111.8
Balance at the end of the period	7,157.80
Emerging Markets	'
Change in the carrying amount of goodwill	'
Balance at the beginning of the period	2,323.40
Additions	61.6
Adjustments	-4.3
Divestitures(c)	0
Foreign exchange and other	-70.7
Balance at the end of the period	$2,310

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Oct. 15, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

In Millions, unless otherwise specified

Series A-1 Tranche A Term Loan Facility

Series A-1 Tranche A Term Loan Facility

Series A-2 Tranche A Term Loan Facility

Series A-2 Tranche A Term Loan Facility

Series A-3 Tranche A Term Loan Facility

Series A-3 Tranche A Term Loan Facility

Series D-2 Tranche B Term Loan Facility

Series D-2 Tranche B Term Loan Facility

Series C-2 Tranche B Term Loan Facility

Series C-2 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

6.75% Senior Notes due in October 2017

6.75% Senior Notes due in October 2017

6.75% Senior Notes due in October 2017

6.875% Senior Notes due in December 2018

6.875% Senior Notes due in December 2018

7.00% Senior Notes due in October 2020

7.00% Senior Notes due in October 2020

6.75% Senior Notes due in August 2021

6.75% Senior Notes due in August 2021

7.25% Senior Notes due in July 2022

7.25% Senior Notes due in July 2022

6.375% Senior Notes due in October 2020

6.375% Senior Notes due in October 2020

6.75% Senior Notes due in August 2018

6.75% Senior Notes due in August 2018

7.50% Senior Notes due in July 2021

7.50% Senior Notes due in July 2021

5.625% Senior Notes due in December 2021

5.625% Senior Notes due in December 2021

Other

Other

Revolving Credit Facility

Revolving Credit Facility

Subsequent Event

Long-term debt, net of unamortized debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

$16,274.90

$17,367.70

$182.30

$259

$166.30

$228.10

$1,813.90

$1,935.70

$1,088.60

$1,256.70

$837.50

$966.80

$2,544.80

$3,090.50

$498.90

$498.70

'

$940.90

$940.20

$687.40

$687.10

$650

$650

$542.90

$542.20

$2,224.50

$2,221.40

$1,584.80

$1,581.90

$1,607.80

$1,605.90

$892.30

$891.50

$12

$12

$0

$0

Less current portion

-690.6

-204.8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

15,584.30

17,162.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate, stated percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.75%

'

'

6.88%

6.88%

7.00%

7.00%

6.75%

6.75%

7.25%

7.25%

6.38%

6.38%

6.75%

6.75%

7.50%

7.50%

5.63%

5.63%

'

'

'

'

Debt instrument, redemption amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

518.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, call premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LONGTERM_DEBT_Details_2

LONG-TERM DEBT (Details 2) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Feb. 06, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Feb. 06, 2014

Sep. 30, 2014

Dec. 31, 2013

Feb. 06, 2014

Feb. 06, 2014

Revolving Credit Facility

Revolving Credit Facility

Secured Secured Credit Facilities

Series A-1 Tranche A Term Loan Facility

Series A-1 Tranche A Term Loan Facility

Series A-2 Tranche A Term Loan Facility

Series A-2 Tranche A Term Loan Facility

Series A-3 Tranche A Term Loan Facility

Series A-3 Tranche A Term Loan Facility

Series A-3 Tranche A Term Loan Facility

Series C-2 Tranche B Term Loan Facility

Series C-2 Tranche B Term Loan Facility

Series D-2 Tranche B Term Loan Facility

Series D-2 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Series E-1 Tranche B Term Loan Facility

Base Rate

London Interbank Offered Rate (LIBOR)

Long-term debt, net of unamortized debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

$16,274,900,000

'

'

$16,274,900,000

'

$17,367,700,000

$0

$0

'

$182,300,000

$259,000,000

$166,300,000

$228,100,000

'

$1,813,900,000

$1,935,700,000

$837,500,000

$966,800,000

$1,088,600,000

$1,256,700,000

'

$2,544,800,000

$3,090,500,000

'

'

Total fair value of long-term debt

16,800,000,000

'

'

16,800,000,000

'

18,400,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Secured Credit Facilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

225,600,000

'

'

'

'

'

'

2,950,000,000

'

'

'

'

Interest rate margin (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

3.00%

Variable rate floor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

0.75%

Loss on extinguishment of debt

0

93,700,000

8,200,000

93,700,000

29,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective rate (as a percent)

'

'

'

'

'

'

2.42%

'

'

2.41%

'

2.41%

'

'

2.41%

'

3.75%

'

3.75%

'

'

3.86%

'

'

'

Principal payments

1,100,000,000

'

'

'

'

'

'

'

1,000,000,000

27,500,000

'

25,400,000

'

'

274,500,000

'

127,200,000

'

165,400,000

'

'

380,000,000

'

'

'

Principal reduction

$70,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SECURITIES_REPURCHASE_PROGRAM_

SECURITIES REPURCHASE PROGRAM (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Nov. 21, 2013

Sep. 30, 2014

Nov. 15, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

2013 Securities Repurchase Program

2013 Securities Repurchase Program

2012 Securities Repurchase Program

2012 Securities Repurchase Program

2012 Securities Repurchase Program

Additional Repurchases Outside 2012 Securities Repurchase Program

Additional Repurchases Outside 2012 Securities Repurchase Program

Securities Repurchase Program

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate maximum amount authorized under the Securities Repurchase Program

'

'

'

'

'

$1,500,000,000

'

$1,500,000,000

'

'

'

'

Common shares repurchased

'

'

225,000

'

'

'

0

'

7,706

507,957

217,294

'

Aggregate repurchase price of the entity's common shares repurchased

0

0

'

0

55,600,000

'

'

'

'

35,700,000

'

19,900,000

Excess of repurchase price over carrying value of securities repurchased, charged to accumulated deficit

'

'

'

'

'

'

'

'

'

$25,800,000

'

$15,600,000

SHAREBASED_COMPENSATION_Narrat

SHARE-BASED COMPENSATION - Narrative (Details) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Stock options	'	'
Stock option activity	'	'
Granted (in shares)	261,000	912,000
Weighted average exercise price (in dollars per share)	$117.82	$84.51
Weighted average grant date fair value of stock options (in dollars per share)	$62.15	$26.10
RSUs	'	'
Stock option activity	'	'
Remaining unrecognized compensation expense related to non-vested awards	$169.60	'
Weighted average service period over which compensation cost is expected to be recognized	'3 years 4 months 28 days	'
Time-based RSUs	'	'
Stock option activity	'	'
Granted (in shares)	94,000	95,000
Weighted average grant date fair value of stock options (in dollars per share)	$135.06	$73.90
Performance-based RSUs	'	'
Stock option activity	'	'
Granted (in shares)	410,000	338,000
Weighted average grant date fair value of stock options (in dollars per share)	$209.72	$125.04
2014 Omnibus Incentive Plan	'	'
Stock option activity	'	'
Shares registered for future issuance	20,000,000	'
Shares available for grants	17,611,183	'
2014 Omnibus Incentive Plan | Maximum	'	'
Stock option activity	'	'
Shares authorized to grant	18,000,000	'

SHAREBASED_COMPENSATION_Detail

SHARE-BASED COMPENSATION (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Components and classification of share-based compensation expense	'	'	'	'
Share-based compensation expense	$20.20	$16	$60.60	$32.50
Research and development expenses	'	'	'	'
Components and classification of share-based compensation expense	'	'	'	'
Share-based compensation expense	1.4	0	4.2	0
Selling, general and administrative expenses	'	'	'	'
Components and classification of share-based compensation expense	'	'	'	'
Share-based compensation expense	18.8	16	56.4	32.5
Stock options	'	'	'	'
Components and classification of share-based compensation expense	'	'	'	'
Share-based compensation expense	5.4	4.6	14.7	12.8
RSUs	'	'	'	'
Components and classification of share-based compensation expense	'	'	'	'
Share-based compensation expense	$14.80	$11.40	$45.90	$19.70

PENSION_AND_POSTRETIREMENT_EMP2

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Aug. 05, 2013
		U.S. Pension Benefit Plans	Non-U.S. Pension Benefit Plans	B&L
				Ireland
				Non-U.S. Pension Benefit Plans
				defined_benefit_plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'
Number of defined benefit plans	'	'	'	2
Employer contribution maximum age	'65 years	'	'	'
Defined benefit plan contributions made	'	$8.50	$6.90	'
Estimated Company contributions in current fiscal year	'	$10.80	$8.50	'

PENSION_AND_POSTRETIREMENT_EMP3

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
U.S. Pension Benefit Plans	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	$0.10	$0.10	$0.30	$0.10
Interest cost	2.7	1.8	8.1	1.8
Expected return on plan assets	-3.7	-2.4	-11.1	-2.4
Amortization of prior service credit	0	0	0	0
Net periodic (benefit) cost	-0.9	-0.5	-2.7	-0.5
Non-U.S. Pension Benefit Plans	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	1	0.7	3	1.2
Interest cost	2.1	1.4	6.4	1.6
Expected return on plan assets	-2	-1.2	-6	-1.2
Amortization of prior service credit	0	0	0	0
Net periodic (benefit) cost	1.1	0.9	3.4	1.6
Postretirement Benefit Plan	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	0.4	0.4	1.2	0.4
Interest cost	0.6	0.6	1.8	0.6
Expected return on plan assets	-0.1	-0.1	-0.3	-0.1
Amortization of prior service credit	-0.6	0	-1.8	0
Net periodic (benefit) cost	$0.30	$0.90	$0.90	$0.90

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 24, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance (in shares)	'	'	'	333,036,637	'
Beginning Balance	'	'	'	$5,233.30	$3,717.40
Issuance of common stock (in shares)	27,058,824	'	'	'	'
Issuance of common stock	2,300	'	'	'	2,269.30
Common shares issued under share-based compensation plans	'	'	'	9.6	3.6
Repurchase of common shares	'	'	'	'	-55.6
Settlement of stock options	'	'	'	-3.1	'
Share-based compensation	'	'	'	60.6	32.5
Employee withholding taxes related to share-based awards	'	'	'	-38.5	-35.9
Tax benefits from stock options exercised	'	'	'	17.1	48.6
Noncontrolling interest from business combinations	'	'	'	'	113.5
Acquisition of noncontrolling interest	'	'	'	-3.3	'
Noncontrolling interest distributions	'	'	'	-0.5	-2.1
Total before comprehensive income (loss)	'	5,275.20	6,091.30	5,275.20	6,091.30
Comprehensive loss:	'	'	'	'	'
Net income (loss)	'	276.4	-971.9	378.1	-988.6
Other comprehensive loss	'	'	'	-419.7	-41.5
Comprehensive loss	'	-169.7	-788.9	-41.6	-1,030.10
Beginning Balance (in shares)	'	334,004,879	'	334,004,879	'
Ending Balance	'	5,233.60	5,061.20	5,233.60	5,061.20
Common Shares	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance (in shares)	'	'	'	333,000,000	303,900,000
Beginning Balance	'	'	'	8,301.20	5,940.70
Issuance of common stock (in shares)	'	'	'	'	27,100,000
Issuance of common stock	'	'	'	'	2,269.30
Common shares issued under share-based compensation plans (in shares)	'	'	'	1,000,000	2,500,000
Common shares issued under share-based compensation plans	'	'	'	33.2	64.2
Repurchase of common shares (in shares)	'	'	'	'	-700,000
Repurchase of common shares	'	'	'	'	-14.2
Total before comprehensive income (loss) (in shares)	'	334,000,000	332,800,000	334,000,000	332,800,000
Total before comprehensive income (loss)	'	8,334.40	8,260	8,334.40	8,260
Comprehensive loss:	'	'	'	'	'
Beginning Balance (in shares)	'	334,000,000	332,800,000	334,000,000	332,800,000
Ending Balance	'	8,334.40	8,260	8,334.40	8,260
Additional Paid-In Capital	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance	'	'	'	228.8	267.1
Common shares issued under share-based compensation plans	'	'	'	-23.6	-60.6
Settlement of stock options	'	'	'	-3.1	'
Share-based compensation	'	'	'	60.6	32.5
Employee withholding taxes related to share-based awards	'	'	'	-38.5	-35.9
Tax benefits from stock options exercised	'	'	'	17.1	48.6
Acquisition of noncontrolling interest	'	'	'	-1.1	'
Total before comprehensive income (loss)	'	240.2	251.7	240.2	251.7
Comprehensive loss:	'	'	'	'	'
Ending Balance	'	240.2	251.7	240.2	251.7
Accumulated Deficit	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance	'	'	'	-3,278.50	-2,371
Repurchase of common shares	'	'	'	'	-41.4
Total before comprehensive income (loss)	'	-3,278.50	-2,412.40	-3,278.50	-2,412.40
Comprehensive loss:	'	'	'	'	'
Net income (loss)	'	'	'	378.6	-989.9
Ending Balance	'	-2,899.90	-3,402.30	-2,899.90	-3,402.30
Accumulated Other Comprehensive Loss	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance	'	'	'	-132.8	-119.4
Total before comprehensive income (loss)	'	-132.8	-119.4	-132.8	-119.4
Comprehensive loss:	'	'	'	'	'
Other comprehensive loss	'	'	'	-419.2	-40.9
Ending Balance	'	-552	-160.3	-552	-160.3
Valeant Pharmaceuticals International, Inc. Shareholders’ Equity	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance	'	'	'	5,118.70	3,717.40
Issuance of common stock	'	'	'	'	2,269.30
Common shares issued under share-based compensation plans	'	'	'	9.6	3.6
Repurchase of common shares	'	'	'	'	-55.6
Settlement of stock options	'	'	'	-3.1	'
Share-based compensation	'	'	'	60.6	32.5
Employee withholding taxes related to share-based awards	'	'	'	-38.5	-35.9
Tax benefits from stock options exercised	'	'	'	17.1	48.6
Acquisition of noncontrolling interest	'	'	'	-1.1	'
Total before comprehensive income (loss)	'	5,163.30	5,979.90	5,163.30	5,979.90
Comprehensive loss:	'	'	'	'	'
Net income (loss)	'	'	'	378.6	-989.9
Other comprehensive loss	'	'	'	-419.2	-40.9
Comprehensive loss	'	'	'	-40.6	-1,030.80
Ending Balance	'	5,122.70	4,949.10	5,122.70	4,949.10
Noncontrolling Interest	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'
Beginning Balance	'	'	'	114.6	'
Noncontrolling interest from business combinations	'	'	'	'	113.5
Acquisition of noncontrolling interest	'	'	'	-2.2	'
Noncontrolling interest distributions	'	'	'	-0.5	-2.1
Total before comprehensive income (loss)	'	111.9	111.4	111.9	111.4
Comprehensive loss:	'	'	'	'	'
Net income (loss)	'	'	'	-0.5	1.3
Other comprehensive loss	'	'	'	-0.5	-0.6
Comprehensive loss	'	'	'	-1	0.7
Ending Balance	'	$110.90	$112.10	$110.90	$112.10

SHAREHOLDERS_EQUITY_Narrative_

SHAREHOLDERS' EQUITY - Narrative (Details) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 24, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 24, 2013
Equity, Class of Treasury Stock [Line Items]	'	'	'	'
Issuance of common stock (in shares)	27,058,824	'	'	'
Price per share (in dollars per share)	'	'	'	$85
Issuance of common stock	$2,300	'	$2,269.30	'
Issuance costs	$30.70	'	'	'
Shares repurchased	'	225,000	'	'
2012 Securities Repurchase Program	'	'	'	'
Equity, Class of Treasury Stock [Line Items]	'	'	'	'
Shares repurchased	'	7,706	507,957	'
Common shares repurchased	'	'	507,957	'
Director	'	'	'	'
Equity, Class of Treasury Stock [Line Items]	'	'	'	'
Shares repurchased	'	217,294	'	'

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Foreign Currency Translation Adjustment

Foreign Currency Translation Adjustment

Accumulated Net Unrealized Investment Gain (Loss)

Accumulated Net Unrealized Investment Gain (Loss)

Accumulated Net Unrealized Investment Gain (Loss)

Accumulated Net Unrealized Investment Gain (Loss)

Accumulated Net Unrealized Investment Gain (Loss)

Pension Adjustment

Pension Adjustment

Pension Adjustment

Unrealized Gain on Equity Investment

Unrealized Gain on Equity Investment

Unrealized Gain on Equity Investment

Net Unrealized Holding Gain on Available- For-Sale Equity Securities

Net Unrealized Holding Gain on Available- For-Sale Equity Securities

Components of accumulated other comprehensive loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

'

'

($132.80)

($119.40)

($170.30)

($119.50)

$0

$0

$0

$0

$0.40

$37.50

($0.30)

($0.30)

Foreign currency translation adjustment

'

'

-439.9

-40.5

-439.9

-40.5

'

'

'

'

'

'

'

'

Reclassification to net income (loss)

'

'

'

-4

'

0

'

'

'

'

-4

'

'

'

Unrealized gain on equity method investment, net of tax

4

0

22.5

0

'

'

22.5

'

'

'

'

'

'

'

Net unrealized holding gain on available-for-sale equity securities, net of tax

-0.9

0

1.8

3.6

'

0

'

'

'

1.8

3.6

'

'

'

Reclassification to net income (loss)

'

'

-1.8

'

'

'

'

'

'

-1.8

'

'

'

'

Pension adjustment

'

'

-1.8

'

'

'

'

'

'

'

'

-1.8

'

'

Balance at the end of the period

($552)

($160.30)

($552)

($160.30)

($610.20)

($160)

$22.50

$0

$0

$0

$0

$35.70

($0.30)

($0.30)

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Prior Period Adjustment

Galderma

Outside of Canada

Outside of Canada

Canada

Canada

Income tax Expense Benefit

'

'

'

'

'

'

'

'

'

'

'

'

Income tax expense (benefit)

$100.30

'

($169.20)

$124.40

($247.70)

'

$13.30

$97.20

$101.40

$130.70

($1.10)

($6.30)

Tax expense (benefit) related to US Federal tax return filing update

-22.2

'

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits from uncertain tax positions previously accrued

'

20.4

'

'

'

'

'

'

'

'

'

'

Adjustment to unrecognized tax benefits from uncertain tax positions previously accrued

'

15.9

'

'

'

'

'

'

'

'

'

'

Valuation allowance against deferred tax assets

487.2

'

'

487.2

'

477.6

'

'

'

'

'

'

Unrecognized tax benefits including interest and penalties

222.8

'

'

222.8

'

'

'

'

'

'

'

'

Unrecognized tax benefits related to interest and penalties

39.8

'

'

39.8

'

'

'

'

'

'

'

'

Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate

115.7

'

'

115.7

'

'

'

'

'

'

'

'

Accrued interest related to unrecognized tax benefits

4

'

'

4

'

'

'

'

'

'

'

'

Accrued penalties related to unrecognized tax benefits

$0.80

'

'

$0.80

'

'

'

'

'

'

'

'

EARNINGS_LOSS_PER_SHARE_Detail

EARNINGS (LOSS) PER SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$275.40	($973.20)	$378.60	($989.90)
Basic weighted-average number of common shares outstanding	335.4	333.6	335.2	316.5
Diluted effect of stock options and RSUs (in shares)	5.9	0	6.2	0
Diluted weighted-average number of common shares outstanding	341.3	333.6	341.4	316.5
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:	'	'	'	'
Basic (in dollars per share)	$0.82	($2.92)	$1.13	($3.13)
Diluted (in dollars per share)	$0.81	($2.92)	$1.11	($3.13)

EARNINGS_LOSS_PER_SHARE_Detail1

EARNINGS (LOSS) PER SHARE (Details 2)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Anti-dilutive shares not included in the computation of diluted earnings per share	'	'	'	'
Basic weighted-average number of common shares outstanding	335,400,000	333,600,000	335,200,000	316,500,000
Diluted weighted-average number of common shares outstanding	'	340,200,000	'	322,900,000
Dilutive effect of stock options and RSUs	'	'	'	'
Anti-dilutive shares not included in the computation of diluted earnings per share	'	'	'	'
Dilutive effect of stock options and RSUs	'	6,600,000	'	6,400,000
Dilutive effect of stock options	'	'	'	'
Anti-dilutive shares not included in the computation of diluted earnings per share	'	'	'	'
Dilutive effect of stock options and RSUs	1,130,000	401,000	896,000	415,000

LEGAL_PROCEEDINGS_Details

LEGAL PROCEEDINGS (Details) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Aug. 08, 2014

Aug. 07, 2014

Sep. 02, 2014

Sep. 02, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Dec. 04, 2013

Sep. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Nov. 15, 2013

Aug. 13, 2014

Jan. 31, 2014

Jun. 20, 2014

Jul. 22, 2014

24-May-13

16-May-08

16-May-08

Sep. 11, 2009

Mar. 27, 2013

Oct. 11, 2013

Mar. 31, 2014

Sep. 30, 2014

Dec. 31, 2011

Sep. 30, 2014

Minimum

Maximum

MoistureLoc

MoistureLoc

MoistureLoc

Natur Produkt

Natur Produkt

Natur Produkt

Natur Produkt

Perrigo

Taro

Lupin

Metrics, Inc.

Metrics, Inc.

ISTA

Written plea agreement

Non-prosecution agreement

Corporate Integrity Agreement

Obagi Shareholder Class Actions

Antitrust

Antitrust

Employment Matter

Employment Matter

Non Fusarium Cases

D

D

B&L

B&L

B&L

AntiGrippin Trademark

AntiGrippin Trademark

AntiGrippin Trademark

AntiGrippin Trademark

Acanya® Gel

Acanya® Gel

Prolensa

Prolensa

Prolensa

Biovail Pharmaceuticals, Inc.

Biovail Pharmaceuticals, Inc.

Biovail Pharmaceuticals, Inc.

complaints

cases

suits

Medicis

Medicis

MoistureLoc

cases

U.S

Outside the U.S.

suits

Other (Income) Expense

Other (Income) Expense

notice

charges

employees

B&L

suits

suits

suits

cases

Legal proceedings and other matters

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Civil Penalty

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$22.20

$2.40

'

'

'

'

'

'

'

Obligation term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Number of complaints filed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Loss Contingency, Number of Class Action Cases

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

Recent suits filed

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Damages awarded to plaintiff

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognized charge loss during period

'

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognized charge gain during period

'

'

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of stay on approval triggered on filing of suit

'30 months

'30 months

'

'

'

'

'

'

'

'

'

'30 months

'30 months

'30 months

'30 months

'

'

'

'

'

'

'

'

'

'

'

Number of patent related Notices of Filing Date Accorded papers issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Number of former employees who filed charges with the EEOC

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

Number of charges dismissed by the EEOC

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

Currently active lawsuits/claims

'

'

'

'

322

1

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

320

Number consolidated cases

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of cases settled

'

'

'

'

629

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Settlement, amount paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$34

'

'

'

'

'

'

'

'

'

Litigation settlement, required compliance and ethics period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

Special meeting period of time

'

'

45

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
				segments
Segment Reporting [Abstract]	'	'	'	'	'
Number of operating segments	'	'	'	2	'
Number of reportable segments	'	'	'	2	'
Segment reporting information	'	'	'	'	'
Total revenues	$2,056.20	'	$1,541.70	$5,983.50	$3,705.80
Total segment profit (loss)	276.4	'	-971.9	378.1	-988.6
Restructuring, integration and other costs	-61.7	'	-243.1	-337.4	-345.7
In-process research and development impairments and other charges	-19.9	'	-124	-40.3	-128.8
Acquisition-related costs	-1.6	'	-8.6	-3.7	-24.4
Acquisition-related contingent consideration	-4	'	35	-14.8	33.5
Other income (expense)	232	'	-202.4	275.7	-208
Operating income (loss)	683.9	'	-891.5	1,395.60	-633
Interest income	0.8	'	2.8	3.8	5.4
Interest expense	-258.4	'	-249.3	-746.1	-581.4
Loss on extinguishment of debt	0	-93.7	-8.2	-93.7	-29.6
Foreign exchange and other	-53	'	5.1	-63	-3.5
Gain on investments, net	3.4	'	0	5.9	5.8
Income (loss) before provision for (recovery of) income taxes	376.7	'	-1,141.10	502.5	-1,236.30
Share-based compensation expense	20.2	'	16	60.6	32.5
Ezogabine Retigabine	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Impairment charges on intangible assets	'	'	551.6	'	'
Total Segment	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total segment profit (loss)	582	'	-309.1	1,643.40	170.2
Corporate	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total segment profit (loss)	-42.9	'	-39.3	-127.3	-129.8
Share-based compensation expense	11	'	16	32.1	32.5
Developed Markets	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total revenues	1,507.90	'	1,142.70	4,409.40	2,722.80
Total segment profit (loss)	478	'	-328.6	1,375.30	106.3
Developed Markets | Ezogabine Retigabine	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Impairment charges on intangible assets	'	'	551.6	'	551.6
Developed Markets | Acquisitions 2013 and 2014	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total revenues	254.2	'	'	1,628.60	'
Developed Markets | Acquisitions 2013 and 2014 | Fair Value Adjustment to Inventory and Identifiable Intangible Assets	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total segment profit (loss)	223.9	'	'	665.3	'
Emerging Markets	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total revenues	548.3	'	399	1,574.10	983
Total segment profit (loss)	104	'	19.5	268.1	63.9
Emerging Markets | Acquisitions 2013 and 2014	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total revenues	89.3	'	'	556.3	'
Emerging Markets | Acquisitions 2013 and 2014 | Fair Value Adjustment to Inventory and Identifiable Intangible Assets	'	'	'	'	'
Segment reporting information	'	'	'	'	'
Total revenues	'	'	'	243.2	'
Total segment profit (loss)	$89.50	'	'	'	'

SEGMENT_INFORMATION_Details_2

SEGMENT INFORMATION (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	$27,059.60	$27,970.80
Identifiable intangible assets	11,620.40	12,848.20
Goodwill	9,467.80	9,752.10
Total Segment	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	25,749	26,915
Corporate	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	1,310.60	1,055.80
Developed Markets	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	19,450.20	20,007.20
Goodwill	7,157.80	7,428.70
Developed Markets | Filler and Toxin Group	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	1,000	'
Developed Markets | PreCision Dermatology, Inc.	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Identifiable intangible assets	261.2	'
Goodwill	181.3	'
Developed Markets | Solta Medical, Inc.	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Identifiable intangible assets	103.5	'
Goodwill	64.4	'
Emerging Markets	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	6,298.80	6,907.80
Goodwill	2,310	2,323.40
Emerging Markets | Solta Medical, Inc.	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Identifiable intangible assets	69.4	'
Goodwill	$42.90	'

PROPOSED_TRANSACTIONS_Details

PROPOSED TRANSACTIONS (Details) (USD $)	30-May-14	Sep. 30, 2014	Sep. 30, 2014	Apr. 30, 2014	Jun. 18, 2014	30-May-14	30-May-14	Sep. 30, 2014	Dec. 18, 2014
	Letter of Credit	PS Fund 1, LLC	PS Fund 1, LLC	PS Fund 1, LLC	Allergan	Allergan	Allergan	Allergan	Subsequent Event
							Common Stock	PS Fund 1, LLC	nominee
								Common Stock	member
Subsequent events	'	'	'	'	'	'	'	'	'
Expected per share consideration (in dollars per share)	'	'	'	'	'	$72	'	'	'
Expected shares exchanged per transaction	'	'	'	'	'	0.83	'	'	'
Equity Method Investment	'	'	'	$75,900,000	'	'	'	'	'
Exchange of common stock, number of shares allocable	'	'	'	'	'	'	'	597,431	'
Exchange of common stock, number of shares held	'	'	'	'	'	'	'	28,878,538	'
Unrealized gain on equity method investment, pre-tax	'	5,400,000	30,600,000	'	'	'	'	'	'
Exchange of common stock related to proposed merger (in shares)	'	'	'	'	'	'	28,281,107	'	'
Exchange of common stock, exchange rate	'	'	'	'	'	'	1.22659	'	'
Proposed business acquisition, per share consideration (in dollars per share)	'	'	'	'	$72	'	'	'	'
Proposed business acquisition, shares exchanged per transaction	'	'	'	'	0.83	'	'	'	'
Line of credit facility, capacity available for acquisition cash consideration	$20,350,000,000	'	'	'	'	'	'	'	'
Number of board members	'	'	'	'	'	'	'	'	6
Number of nominees	'	'	'	'	'	'	'	'	6